Document:

EX-10.17

 Exhibit 10.17 
 *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

			
	CONFIDENTIAL	  	Execution Copy

 Research Collaboration and License Agreement 

This Research Collaboration and License Agreement (this “Agreement”) is effective as of March 14, 2013 (the
“Effective Date”) and is entered into by and between UCB Pharma S.A., a Belgium corporation (“UCB”), and Five Prime Therapeutics, Inc., a Delaware corporation (“FivePrime”). UCB and FivePrime are
referred to individually as a “Party” and collectively as the “Parties.” 
 Recitals

 WHEREAS, FivePrime has developed a proprietary protein library and proprietary technologies for screening, identifying,
validating and characterizing target proteins involved in human diseases, and for the development of therapeutic candidates directed to or against such proteins or incorporating or deriving from such proteins, for treatment of human diseases;

 WHEREAS, UCB has developed certain proprietary know-how and technologies related to the discovery, validation and development
of target proteins involved in human diseases, and for the discovery and development of biologic and small molecule therapeutic products for the treatment of human diseases, and has know-how and expertise with regard to the development,
registration, manufacture and commercialization of such products; 
 WHEREAS, UCB and FivePrime desire to enter into a research
collaboration to use their respective know-how, technologies and other assets to screen for, identify, validate, characterize and advance target proteins involved in renal fibrosis, as well as *** for *** associated with CNS diseases, upon
the terms and conditions set forth herein; 
 WHEREAS, UCB desires to obtain a license under certain of FivePrime’s
intellectual property for the further research, development and commercialization of products directed to or against, or incorporating or deriving from, certain of such target proteins identified in such research collaboration, and FivePrime desires
to grant such a license, upon the terms and conditions set forth herein; 
 NOW, THEREFORE, in consideration of the foregoing
premises and the mutual covenants herein contained, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 
 1.        Definitions. Unless specifically set forth to the contrary herein, the following terms, whether used in the singular or plural, have the respective
meanings set forth below. 
 1.1        “Acquiror” means, with
respect to a Strategic Transaction, the Third Party referenced in the definition of “Strategic Transaction.” 
 1.2
        “Affiliate” means, with respect to a Party or an Acquiror, any Entity that directly or indirectly controls, is controlled by, or is under common control with, as applicable, that
Party or such Acquiror. For the purpose of this definition, “control” means direct or indirect ownership of at least 50% of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or more than 50%
of the equity interest in the case of any other type of 

 
legal entity, status as a general partner in any partnership, or any other similar arrangement whereby such Entity controls or has the right to control the board of directors or equivalent
governing body of such Entity, or such other relationship as results in actual control over the management, assets, business and affairs of an Entity. 
 1.3        “Agreement” has the meaning set forth in the preamble of this Agreement. 

1.4        “Alliance Manager” has the meaning set forth in
Section 2.1.3. 
 1.5        “Arbitration” has the meaning
set forth in Section 14.6.1. 
 1.6        “***” has the
meaning set forth in Section 8.4.1. 
 1.7        “BLA”
means a Biological License Application (as defined by the FDA) and including any amendments or supplements thereto, which is filed with the FDA to seek regulatory approval to market and sell a product in the U.S., or any corresponding foreign
equivalent applications which are filed with the relevant Regulatory Authorities in another country or region in the Territory, or any successor application having substantially the same function. 

1.8        “Business Day” means any day other than a Saturday, a Sunday
or any day on which banks in Brussels, Belgium are permitted or required to close by Law. 

1.9        “Calendar Quarter” means the respective periods of three
consecutive calendar months ending on March 31, June 30, September 30 and December 31. 

1.10    “Calendar Year” means a successive period of 12 calendar months commencing on
January 1 and ending on December 31. 
 1.11    “Chief Patent Counsels”
has the meaning set forth in Section 2.3.3. 
 1.12    “Clinical Trial” means a
Phase 1 Trial, Phase 2 Trial, or Phase 3 Trial. 
 1.13    “Claiming Date” has the
meaning set forth in Section 4.2.1. 
 1.14    “Claiming Option” has the
meaning set forth in Section 4.2.1. 
 1.15    “Claiming Option Period” has the
meaning set forth in Section 4.2.1. 
 1.16    “CNS Project” means the program
of research and development activities directed to the discovery and evaluation of Proteins linked to ***, as set forth in the relevant portions of the Research Plan. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 2 

 1.17    “Collaboration Know-How” means any and
all Know-How discovered, developed, made, generated or invented by or on behalf of: (i) FivePrime in the performance of the Research Plan (including during any applicable License Option Period), but excluding any such Know-How constituting
FivePrime Platform Technology; and/or (ii) UCB in the performance of the Research Plan, but excluding any Protein Know-How and UCB Evaluation Know-How. 
 1.18    “Collaboration Patent” means any and all Patents that claim an invention: (i) discovered by or on behalf of FivePrime in the performance of the
Research Plan (including during any applicable License Option Period), but excluding any FivePrime Platform Patents; (ii) discovered by or on behalf of UCB in the performance of the Research Plan, but excluding any Protein Patents and UCB
Evaluation Patents; or (iii) jointly invented in the performance of the Research Plan (including during any applicable License Option Period) by one or more individuals obligated to assign their rights to FivePrime or its Affiliates and one or
more individuals obligated to assign their rights to UCB or its Affiliates . 

1.19    “Combination Product” means a Licensed Product which contains at least two different
therapeutically active ingredients, at least one of which would not by itself constitute a Licensed Product. 

1.20    “Commercial License” means the licenses granted to UCB pursuant to Section 6.1.2
with respect to a given Licensed Protein and Licensed Products with respect thereto. 

1.21    “Commercial License Fee” has the meaning set forth in Section 8.2.2. 

1.22    “Commercially Reasonable Efforts” means: (a) where applied to carrying out
specific obligations under the Research Plan, deploying appropriate resources commensurate with the obligation, and carrying out such obligation in a reasonably sustained manner; and (b) where applied to the development or commercialization
activities of UCB pursuant to a Commercial License, the efforts and resources that UCB and its Affiliates would use as part of an active and continuing program of development or commercialization of its other pharmaceutical products of a commercial
potential similar to the commercial potential of the relevant Licensed Product, at a similar stage of its product life, taking into account relevant factors such as the establishment of the Licensed Product in the marketplace, the competitiveness of
the marketplace, the proprietary position of the Licensed Product, the regulatory status involved, the pricing and launching strategy and the risk/benefit profile (including relative safety and efficacy) of the Licensed Product. “Commercially
Reasonable Efforts” of a Party shall require that such Party (on its own or acting through any of its Affiliates, sublicensees or subcontractors), at a minimum: (i) promptly assign responsibility for such obligations to qualified
employees, set annual goals and objectives for carrying out such obligations, and monitor and hold employees accountable for progress with respect to such goals and objectives; 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 3 

 
(ii) set and seek to achieve specific and meaningful objectives for carrying out such obligations; and (iii) make and implement decisions and allocate resources reasonably designed to
diligently advance progress with respect to such objectives. Commercially Reasonable Efforts shall be determined on a market-by-market and indication-by-indication basis for a particular Licensed Product and it is acknowledged and understood that
the level of efforts may be significantly different for different markets and will change over time. 

1.23    “Confirmed Hit” means a Protein that is initially identified as a hit from a
Screening Assay as a result of screening all or a portion of the FivePrime Library and is confirmed by the Working Group based upon the results of follow-up activities performed under the Research Plan. 

1.24    “Confirmed Hit Data” has the meaning set forth in Section 4.1. 

1.25    “Confidential Information” has the meaning set forth in Section 9.1. 

1.26    “Contractor” has the meaning set forth in Section 3.4. 

1.27    “Controlled” means with respect to any Know-How, Patent, Material or other tangible
or intangible intellectual property, the possession of (whether by ownership or license, other than licenses granted pursuant to this Agreement) or the ability of a Party to grant to the other Party access to, or a license or sublicense of, such
Know-How, Patent, Material or other intellectual property without violating the terms of any agreement or other arrangement with any Third Party. 
 1.28    “Diagnostic” means, with respect to a particular Protein, a diagnostic product used to identify, diagnose, screen or monitor patients with a
predisposition to a human condition, disease or disorder, or to predict prognosis, safety and/or efficacy of therapeutic treatment of a human condition, disease or disorder in a patient, and in each case which product: (i) contains the Protein,
a functional fragment of such Protein, any variant of the foregoing (including splice variants), any nucleic acid sequence encoding any of the foregoing, or a complementary nucleic acid sequence to such nucleic acid sequence; and/or
(ii) primarily functions by determining the absence or presence (and/or quantity) of any molecule described in (i) that is present in a sample obtained or derived from humans, including without limitation samples of human tissue, blood,
plasma, urine or serous fluids. 
 1.29    “Diagnostic Royalties” has the meaning
set forth in Section 8.5.1. 
 1.30    “Disclosing Party” has the meaning set
forth in Section 9.1. 
 1.31    “Dollar” “dollar” or
“$” means the legal tender of the United States. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 4 

 1.32    “Effective Date” has the meaning set
forth in the preamble of this Agreement. 
 1.33    “EMA” means the European
Medicines Agency, or any successor thereof performing substantially the same functions. 

1.34    “Entity” means a partnership, limited partnership, limited liability partnership,
corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization. 
 1.35    “EU” means the European Union, as its membership may be altered from time to time, any successor thereto and any country included therein. 

1.36    “Evaluation Materials” has the meaning set forth in Section 4.3.1. 

1.37    “Excluded Claim” has the meaning set forth in Section 14.6.9. 

1.38    “Excluded Protein” means a Protein for which FivePrime has reserved rights (whether
for itself or for any Third Party) in accordance with Section 5.1. 
 1.39    “Excluded
Protein List” means the list of Excluded Proteins provided from time to time by FivePrime to UCB pursuant to Section 5.1. 
 1.40    “FDA” means the United States Food and Drug Administration, or any successor entity thereof performing substantially the same functions. 

1.41    “Fibrosis Project” means the program of research and development activities directed
to the discovery and evaluation of Proteins that modulate ***. 
 1.42    “First
Commercial Sale” means, with respect to a particular Licensed Product in a particular country, the first sale of such Licensed Product in such country following the receipt of Marketing Authorization. 

1.43    “FivePrime” has the meaning set forth in the preamble of this Agreement. 

1.44    “FivePrime Background Know-How” means any and all Know-How Controlled by FivePrime
that is related to a Protein and/or Therapeutics or Diagnostics with respect thereto (but excluding any such Know-How constituting FivePrime Platform Technology) that was or is discovered, developed, made or generated by or on behalf of FivePrime:
(i) prior to the Effective Date; or (ii) during the Research Term and other than in performance of the Research Plan. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 5 

 1.45    “FivePrime Background Patent” means any
Patent Controlled by FivePrime (but excluding any Patents included in FivePrime Platform Technology) that arose from inventions discovered by or on behalf of FivePrime: (i) prior to the Effective Date; or (ii) during the Research Term and
other than in the performance of the Research Plan. 
 1.46    “FivePrime
Indemnitee” has the meaning set forth in Section 13.2. 
 1.47    “FivePrime
IP” means FivePrime Background Know-How, FivePrime Background Patents, FivePrime’s interests in any Collaboration Patents or Collaboration Know-How, and the FivePrime Platform Technology. 

1.48    “FivePrime Library” means FivePrime’s proprietary protein library existing as of
the Effective Date (and including any modifications or improvements thereto existing at the time the applicable Screening Assay is conducted), comprising (a) ***; and (b) ***. 

1.49    “FivePrime Losses” has the meaning set forth in Section 13.2. 

1.50    “FivePrime Platform Patent” means any Patent included in the FivePrime Platform
Technology. 
 1.51    “FivePrime Platform Technology” means any and all Patents,
Materials and Know-How Controlled by FivePrime pertaining to: (a) the FivePrime Library; (b) the design, composition, and methods of generating or screening the FivePrime Library; (c) FivePrime’s protein expression technology;
(d) FivePrime’s in vivo or in vitro screening technology, including the Rapid In Vivo Protein Production System (RIPPSSM) technology; and (e) any bioinformatics software applications used in connection with the foregoing, but
excluding in each case any Patents, Materials and Know-How specifically and directly related to a specific Protein and/or its biological activity, function and/or utility. 
 1.52    “GLP Toxicology Study” means a toxicology study of a Licensed Product conducted pursuant to good laboratory practices (GLP) and applicable ICH
Guidelines for the purpose of submitting an IND for a Licensed Product. 

1.53    “IFRS” means current International Financial Reporting Standards as established by
the International Accounting Standards Board. 
 1.54    “IND” means any
investigational new drug application filed with the FDA pursuant to Part 312 of Title 21 of the U.S. Code of Federal Regulations, including any amendments thereto. References herein to IND shall include, to the extent applicable, any comparable
filing(s) outside of the U.S. (such as a CTA in the European Union). 
 1.55    “Independent
Assay” means an assay or other specific research activity that is or has been performed independently and outside of the scope of this Agreement by FivePrime for or on behalf of a Third Party, and without any use of Collaboration Know-How,
Collaboration Patents, Protein Patents, Protein Know-How or UCB IP, pursuant to which FivePrime and/or such Third Party had the option to obtain rights, has rights to, or may obtain rights to Proteins as Excluded Proteins. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 6 

 1.56    “Initiation” means (a) with respect
to a Clinical Trial, the (i) ***; or (ii) ***; or (b) with respect to a GLP Toxicology Study, ***. 
 1.57    “JPC” has the meaning set forth in Section 2.3.1. 
 1.58    “JSC” has the meaning set forth in Section 2.2. 
 1.59    “Know-How” means any tangible and intangible information, data, results (including pharmacological, research and development data, reports and batch
records), and materials, discoveries, improvements, inventions, compositions of matter, cell lines, assays, sequences, processes, methods, knowledge, protocols, formulas, utility, formulations, inventions (whether patentable or not), strategy,
know-how and trade secrets, and all other scientific, pre-clinical, clinical, regulatory, manufacturing, marketing, financial and commercial information or data, in each case that either Party has treated as confidential or proprietary information
and that is not generally known by the public, but excluding any of the foregoing to the extent claimed in any Patents. 

1.60    “Law” means any federal, state, local, foreign or multinational law, statute,
ordinance, code, rule, regulation, resolution, or order of any government authority in the Territory, or any similar provision having the force or effect of law. 
 1.61    “License Effective Date” has the meaning set forth in Section 4.3.2. 
 1.62    “License Option” has the meaning set forth in Section 4.3.2. 
 1.63    “License Option Period” means with respect to each UCB Reserved Protein, the period commencing on the date on which UCB receives all of the Evaluation
Materials for such UCB Reserved Protein, and continuing for *** thereafter, as such period may be extended pursuant to Section 4.3.2. 
 1.64    “Licensed Product” means any and all Therapeutics and Diagnostics with respect to a particular Licensed Protein. 

1.65    “Licensed Protein” means a UCB Reserved Protein for which UCB has exercised its
License Option pursuant to Section 4.3. 
 1.66    “Major Markets” means the
***. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 7 

 1.67    “Marketing Authorizations” means all
approvals necessary from the relevant Regulatory Authority to permit a Party or its sublicense(s) to market and sell a Licensed Product in a particular country, including approval of an NDA or BLA and any Pricing Approvals. 

1.68    “Materials” means any proprietary compounds, cell lines, animals, biological
materials, research tools, or other tangible materials (including without limitation any such materials which constitute or are directly related to a Protein) which are Controlled by a Party or its Affiliates and that are used in connection with the
performance of the Research Plan under this Agreement. 
 1.69    “Materials Receiving
Party” has the meaning set forth in Section 3.5.1. 
 1.70    “Materials
Transferring Party” has the meaning set forth in Section 3.5.1. 

1.71    “NDA” means a New Drug Application or similar application or submission in any
country for approval to market a Licensed Product. 
 1.72    “Net Sales” means the
actual gross amount invoiced by UCB, or its Affiliate or sublicensee, for sales or other commercial disposition of a Licensed Product, in a bona fide, arms-length transaction to a Third Party purchaser (including distributors), less the following
accrual based deductions to the extent directly applicable to such sales and which are not already reflected in such gross amount invoiced: 
  

	 	•	 	 normal and customary rebates, quantity, trade and cash discounts to customers actually allowed and properly taken; 

 

	 	•	 	 governmental and other rebates, chargebacks or administrative fees (or equivalents thereof) granted to managed health care organizations, pharmacy
benefit managers (or equivalents thereof) or to national, federal, state, provincial, local and other governments, their respective agencies, purchasers and reimbursers or to trade customers actually allowed and properly taken;

  

	 	•	 	 retroactive price reductions, credits or allowances actually granted upon rejections, destruction or returns of such Licensed Product, including for
recalls or damaged goods; 

  

	 	•	 	 freight, postage, shipping and insurance charges actually allowed or paid for delivery of such Licensed Product, to the extent included in the gross
sales price; wholesalers’ distribution fees actually paid, and fees actually paid for services or commissions to Third Party distributors, brokers or agents, other than sales personnel, sales representatives and sales agents employed by or on
behalf of UCB, its Affiliates or sublicensees; 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 8 

	 	•	 	 sales taxes, excise taxes, use taxes, import/export duties or other governmental charges actually due or incurred with respect to such sales, including
value-added taxes, to the extent applicable; and 

  

	 	•	 	 amounts actually written off as uncollectible to the extent consistent with UCB’s, its Affiliate’s or sublicensee’s business practices
for its other products; provided that such amounts shall be added back to Net Sales if and when actually collected. 

Any of the above deductions shall be permitted if incurred in the ordinary course of business in type and amount consistent with good industry practice
and determined in accordance with IFRS as applied by UCB on a consistent basis. 
 Any Licensed Product used for clinical study or other
research purposes, or used or distributed in the Territory free of charge *** shall not be included in Net Sales. Net Sales will not include transfers among UCB, its Affiliates, or sublicensees, but in such cases the royalty shall be due and
calculated on UCB’s or its Affiliates or sublicensee’s Net Sales to the first independent Third Party. 
 If a Licensed Product is
sold as part of a Combination Product, the Net Sales of such Licensed Product for the purpose of calculating royalties owed under this Agreement for sales of such Licensed Product, shall be determined as follows: first, UCB shall determine the
actual Net Sales of such Combination Product (using the above provisions) and then such amount shall be multiplied by the fraction A/(A+B), where A is the average gross selling price in the applicable country of such Licensed Product sold
separately, if sold separately, in the same formulation and dosage, and B is the sum of the average gross selling prices in the applicable country of each other active ingredient, drug, device, test, kit or biological product in the Combination
Product sold separately, if sold separately, in the same formulation, dosage or unit quantity. If any active ingredient, drug, device, test, kit or biological product in the Combination Product is not sold separately in the relevant formulation,
dosage or unit quantity, Net Sales shall be calculated by multiplying actual Net Sales of such Combination Product by the fraction A/C where A is the average gross selling price in the applicable country of such Licensed Product sold separately in
the same formulation and dosage and C is the average gross selling price in the applicable country of such Combination Product. If neither the Licensed Product nor any other active ingredient, drug, device, test, kit or biological product in the
Combination Product is sold separately in the relevant formulation, dosage or unit quantity, the adjustment to Net Sales shall be determined by the Parties in good faith to reasonably reflect the fair market value of the contribution of such
Licensed Product in the Combination Product to the total fair market value of such Combination Product. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 9 

 The average gross selling price for such other therapeutically active ingredient(s) contained in the
Combination Product shall be calculated for each calendar year by dividing the sales amount by the units of such other product(s), as published by IMS or another independent source agreed upon by the Parties. 

In the case of any other sale or other disposal for value, such as barter or counter trade, of any Licensed Product, or part thereof, other than in an
arm’s length transaction exclusively for money, Net Sales shall be calculated as above on the fair market value of the consideration given. 
 1.73    “Non-Selected Protein” means (a) a Confirmed Hit that is not selected as a UCB Reserved Protein pursuant to Section 4.2; or (b) a UCB
Reserved Protein that does not become a Licensed Protein pursuant to Section 4.3. 

1.74    “Option Extension Fee” has the meaning set forth in Section 8.2.1. 

1.75    “Optioning Fee” has the meaning set forth in Section 8.2.1. 

1.76    “Outside Counsel” has the meaning set forth in Section 2.3.2. 

1.77    “Party” or “Parties” has the meaning set forth in the preamble of
this Agreement. 
 1.78    “Patent” means (a) an issued patent or pending
patent application and any patent issuing therefrom, including any certificate of invention, application for certificate of invention, utility model, or application for utility model, provisional, converted provisional, non-provisional, divisional,
continuation, continuation-in-part, and continued prosecution application; and (b) any substitution, reissue, reexamination, renewal, confirmation, revalidation, extension and supplementary protection certificate with respect to any of the
foregoing. 
 1.79    “Person” means any individual, unincorporated organization or
association, governmental authority or agency, Entity or other entity not specifically listed herein. 

1.80    “Phase 1 Trial” means a human clinical trial of a Licensed Product in any country
that would satisfy the requirements of 21 C.F.R. § 312.21(a). 
 1.81    “Phase 2
Trial” means a human clinical trial of a Licensed Product in any country that is consistent with the requirements of 21 C.F.R. § 312.21(b). 
 1.82    “Phase 3 Trial” means a pivotal study in human patients with a defined dose or a set of defined doses of a Licensed Product which is designed to
(i) demonstrate the efficacy and safety of such Licensed Product for one or more specific indications, and (ii) enable the preparation and submission of an NDA, BLA or other similar applications for regulatory approval in the Territory.
For clarity, a Phase 3 Trial will be consistent with the requirements of 21 C.F.R. § 312.21(c). 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 10 

 1.83    “Pricing Approval” means, in those
countries in the Territory where Regulatory Authorities approve, determine or otherwise directly control the pricing or pricing reimbursement for pharmaceutical products sold in such country, such approval or determination. 

1.84    “Protein Know-How” means, with respect to a UCB Reserved Protein, any and all
Know-How specifically and directly related to such UCB Reserved Protein and/or its biological activity, function or uses, and that is discovered, developed, made or generated solely by or on behalf of UCB during the applicable License Option Period
and in the performance of activities under the Research Plan with respect to such UCB Reserved Protein. For clarity, any activities, work or services performed by FivePrime for UCB with respect to a UCB Reserved Protein (including during the License
Option Period) for such UCB Reserved Protein shall not be deemed to be “on behalf of UCB” as such phrase is used in the foregoing sentence. 
 1.85    “Protein Patent” means, with respect to a UCB Reserved Protein, any Patent claiming such UCB Reserved Protein, the use of such UCB Reserved Protein for
a particular purpose and/or the use of any Therapeutic with respect to such UCB Reserved Protein for a particular purpose, and which Patent claims an invention discovered solely by or on behalf of UCB during the applicable License Option Period and
in the performance of activities under the Research Plan with respect to such UCB Reserved Protein. For clarity, any activities, work or services performed by FivePrime for UCB with respect to a UCB Reserved Protein (including during the License
Option Period) for such UCB Reserved Protein shall not be deemed to be “on behalf of UCB” as such phrase is used in the foregoing sentence. 
 1.86    “Product Infringement” has the meaning set forth in Section 10.3.1. 
 1.87    “Project Leader” has the meaning set forth in Section 2.1.2. 
 1.88    “Protein” means: (a) a protein that is contained in or otherwise represented in and directly and specifically identifiable through screening of the
FivePrime Library, including without limitation through the use of one or more Screening Assays, or (b) if the protein described in subsection (a) is not of human origin, the human homologue of such protein having essentially the same
biological function. 
 1.89    “Receiving Party” has the meaning set forth in
Section 9.1. 
 1.90    “Regulatory Authority” means any applicable
governmental regulatory authority involved in granting approvals for the marketing and sale of a Licensed Product, including the FDA and the EMA. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 11 

 1.91    “Research License” has the meaning set
forth in Section 6.1.1. 
 1.92    “Research Plan” means the research plan
attached to this Agreement as Exhibit A, which sets forth the activities to be undertaken by the Parties as part of the Fibrosis Project and the CNS Project. 
 1.93    “Research Term” means the period starting as of the Effective Date and ending on the fifth (5th) anniversary of the Effective Date, or such later date as may be agreed in writing by the Parties in the event
the Screening Assays contemplated under the Research Plan are not completed by the third (3rd) anniversary of the Effective Date. 

1.94    “RIPPS Assay” means an in vivo Screening Assay designed and conducted using
FivePrime’s proprietary RIPPS technology. 
 1.95    “Royalty Term” has the
meaning set forth in Section 8.4.2. 
 1.96    “Screening Assay” means an assay
(including without limitation a UCB Assay which is modified to be compatible with the FivePrime Platform Technology) that is utilized pursuant to the Research Plan to screen the FivePrime Library (or any portion thereof) to identify Proteins as
Confirmed Hits. 
 1.97    *** has the meaning set forth in Section 8.4.1. 

1.98    “Strategic Transaction” means, with respect to a Party, the occurrence of any of the
following events: (i) the direct or indirect acquisition by any Third Party of more than fifty percent (50%) of the combined voting power of the then outstanding voting securities of such Party normally entitled to vote in elections of
directors; (ii) the sale, transfer, conveyance or other disposition of all or substantially all of such Party’s assets to a Third Party, or (iii) the consummation of a merger, acquisition, consolidation or other similar transaction
between or involving a Third Party and such Party (or the ultimate parent Entity which, immediately prior to the Strategic Transaction, directly or indirectly controls such Party.) 

1.99    “Term” has the meaning set forth in Section 12.1. 

1.100    “Terminated Protein” means a Licensed Protein for which the licenses granted to UCB
under Section 6.1 are terminated pursuant to Section 12.2 or Section 12.3. 

1.101    “Termination Date” has the meaning set forth in Section 12.6.1. 

1.102    “Territory” means worldwide. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 12 

 1.103    “Therapeutic” means, with respect to a
particular Protein, any pharmaceutical product that contains: (a) such Protein, a functional fragment of such Protein, or any variants of the foregoing (including splice variants) that are either naturally occurring or engineered using the
sequence of such Protein; and (b) a protein, antibody (or antibody-like molecule) or other compound (including small molecules) that binds to and inhibits, activates or otherwise modulates the activity of any molecule described in subsection
(a). 
 1.104    “Third Fibrosis Screen” has the meaning set forth in
Section 3.1.1. 
 1.105    “Third Party” means any Person other than UCB,
FivePrime and their respective Affiliates. 
 1.106    “UCB” has the meaning set
forth in the preamble of this Agreement. 
 1.107    “UCB Assay” means any
proprietary in vitro assay developed by or on behalf of UCB or its Affiliates (together with any Materials and/or Know-How with respect thereto) and that is made available to FivePrime for adaptation and use as a Screening Assay. 

1.108    “UCB Background Know-How” means any and all Know-How Controlled by UCB or its
Affiliates that is related to the UCB Assays, a Protein and/or any Therapeutics or Diagnostics with respect thereto, which was or is discovered, developed, made or generated by or on behalf of UCB: (i) prior to the Effective Date; or
(ii) during the Research Term and (except in the case of Know-How specifically and directly related to the UCB Assays) other than in performance of the Research Plan. 
 1.109    “UCB Background Patent” means any Patent Controlled by UCB that arose or arise from inventions discovered by or on behalf of UCB: (i) prior to the
Effective Date; or (ii) during the Research Term and other than in performance of the Research Plan. 

1.110    “UCB Evaluation Know-How” means, with respect to a UCB Reserved Protein, any and all
Know-How (excluding Protein Know-How) that is discovered, developed, made or generated solely by or on behalf of UCB during the applicable License Option Period in the performance of activities under the Research Plan with respect to such UCB
Reserved Protein, including uses thereof. For clarity, any activities, work or services performed by FivePrime for UCB with respect to a UCB Reserved Protein during the License Option Period for such UCB Reserved Protein shall not be deemed to be
“on behalf of UCB” as such phrase is used in the foregoing sentence. 

1.111    “UCB Evaluation Patent” means, with respect to a UCB Reserved Protein, any Patent
(other than a Protein Patent) arising from an application filed by or on behalf of UCB that claims an invention discovered solely by or on behalf of UCB during the applicable License 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 13 

 
Option Period and in the performance of activities under the Research Plan with respect to such UCB Reserved Protein, including uses thereof. For clarity, any activities, work or services
performed by FivePrime for UCB with respect to a UCB Reserved Protein during the License Option Period for such UCB Reserved Protein shall not be deemed to be “on behalf of UCB” as such phrase is used in the foregoing sentence. 

1.112    “UCB Indemnitee” has the meaning set forth in Section 13.1. 

1.113    “UCB Independent Research” has the meaning set forth in Section 5.3.

 1.114    “UCB IP” means UCB Background Know-How, UCB Background IP, UCB Assays,
UCB Product Know-How and UCB Product Patents. 
 1.115    “UCB Losses” has the
meaning set forth in Section 13.1. 
 1.116    “UCB Product Know-How” means,
with respect to a Licensed Protein and any corresponding Licensed Product, any and all Know-How discovered, developed, made or generated by or on behalf of UCB on or after the applicable License Effective Date in connection with the research,
development, manufacture, or commercialization of such Licensed Protein or Licensed Product, as applicable. 

1.117    “UCB Product Patent” means, with respect to a Licensed Protein and any corresponding
Licensed Products, any Patent having the earliest priority date on or after the applicable License Effective Date and filed by or on behalf of UCB that claims an invention discovered on or after the applicable License Effective Date in the research,
development, manufacture or commercialization of such Licensed Protein or Licensed Product, as applicable. 

1.118    “UCB Reserved Protein” means a Confirmed Hit for which UCB has exercised its
Claiming Option pursuant to Section 4.2.1. 
 1.119    “US” or “United
States” means the United States of America and all of its territories and possessions. 

1.120    “Valid Claim” means claim of any issued and unexpired Patent (as may be extended
through supplementary protection certificate or patent term extension or the like) that has not been revoked, abandoned, held invalid, or unenforceable by a patent office, court or other governmental agency of competent jurisdiction in a final and
non-appealable judgment (or judgment from which no appeal was taken within the allowable time period) and which claim has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination, opposition or
disclaimer or otherwise. 
 1.121    “Working Group” has the meaning set forth in
Section 2.1.1. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 14 

 2.        Governance. 

   2.1        Working Group; Project Leaders; Alliance Managers.

         2.1.1.    The Parties shall establish a joint
working group (the “Working Group”) that is responsible for coordinating the day-to-day performance of the Research Plan under the oversight of the JSC. Each Party’s representatives to the Working Group shall be members of such
Party’s internal project team having responsibility for aspects of the day-to-day performance of the Research Plan. The Parties acknowledge that the Fibrosis Project and the CNS Project constitute separate and distinct projects that are being
coordinated together under the Research Plan, and that a Party may therefore choose to allocate responsibilities and appoint different representatives to the Working Group with respect to each such project. 

        2.1.2.    UCB and FivePrime shall each appoint one of its
representatives to the Working Group who shall be responsible as the primary point of contact for coordinating the performance of the Research Plan (each, a “Project Leader”); provided that a Party may choose to separately
assign the Project Leader responsibilities for the Fibrosis Project and those for the CNS Project to two different representatives, in which case each such individual shall be considered a Project Leader. Each Party shall notify the other within
*** days after the Effective Date of the appointment of its Project Leader(s) and thereafter shall notify the other Party in writing prior to changing any such appointment. The Working Group shall make decisions on day-to-day operational
matters, including which hits from a Screening Assay shall be subject to further assays or other follow-up activities necessary to confirm selection of such hits as Confirmed Hits, and otherwise coordinate the conduct of activities related to assay
development and screening under the Research Plan. The Working Group will also establish the criteria to be used for evaluating the results of Screening Assays and other follow-up activities and shall be responsible for the selection of Confirmed
Hits. The Working Group shall also serve as a forum through which the Parties will routinely share operational information regarding performance of the Research Plan, all in accordance with the terms of this Agreement. 

        2.1.3.    During the Research Term each Party may also choose
to appoint one of its employees to act as alliance manager for such Party under this Agreement (each, an “Alliance Manager”). The Alliance Managers will assist the JSC in performing its oversight responsibilities, including
monitoring whether activities are being conducted in accordance with the Research Plan and preparing and finalizing the minutes from meetings of the JSC. Each Party shall promptly provide to the other Party the name and contact information of the
Alliance Manager such Party may choose, in its sole discretion, to appoint from time to time. 

   2.2        Joint Steering Committee. The Parties shall establish a joint
steering committee to oversee the Research Plan activities during the Research Term (the “JSC”). 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 15 

        2.2.1.    Composition of the JSC. The JSC shall consist of
*** FivePrime representatives and *** UCB representatives. Each Party shall designate its JSC representatives within *** days after the Effective Date. A Party may change one or more of its JSC representatives from time to time
in its sole discretion, effective upon written notice to the other Party of such change. A Party’s representatives to the JSC shall have appropriate technical credentials, experience and knowledge, and ongoing familiarity with the Research
Plan, and shall have supervisory responsibilities within such Party’s organization with respect to performance of the Research Plan. The Parties respective Project Leaders and Alliance Managers may also attend all JSC meetings as a non-voting
observers. 
         2.2.2.    Decision-Making. The Parties
anticipate that the Working Group will make most day-to-day decisions regarding the Research Plan, except for those that are within the purview of the JSC. If the Working Group disagrees on any matters within the purview of the Working Group, the
Project Leaders will first try to reach agreement on such matter. If the Project Leaders do not reach agreement with respect to a matter within *** Business Days after first attempting to resolve such matter, it will be elevated to the JSC,
which shall meet as soon as possible thereafter for discussion and resolution of the matter. At the JSC, each Party shall have collectively one vote in all decisions within the JSC’s purview, and the JSC shall make all decisions by unanimous
vote, except as set forth below: 
 (a)    Elevation to Senior Executives. In the
event that the JSC cannot reach a unanimous vote with respect to a decision within its purview, the JSC shall refer such dispute to ***. If such senior executives cannot agree on a matter within *** Business Days after their first
discussion regarding such matter, then *** shall, in good faith and taking into consideration the comments of ***, have the final decision-making authority, provided that such final decision of *** shall not result in:
(i) any additional cost or obligation to *** under the Research Plan beyond those set forth in the then-current Research Plan; (ii) a material reduction of efforts by either Party in the Research Plan unless otherwise expressly
permitted under this Agreement; or (iii) ***. 

(b)        Exclusion of Licensed Proteins from JSC Oversight. Effective
as of the applicable License Effective Date, and notwithstanding that the Research Term may not have ended, the Working Group and JSC will thereafter have no oversight over any aspect of the research, development, progression, regulatory activities,
manufacturing, distribution, marketing, sales or commercialization of a Licensed Protein or any Licensed Products with respect thereto. UCB will have sole and final decision-making authority with respect to all decisions regarding such Licensed
Protein and any corresponding Licensed Product(s) in accordance with the terms and conditions of this Agreement, and UCB will, in its sole discretion, control the research, development, progression, regulatory activities, manufacturing, marketing,
sales and other commercialization of any such Licensed Product, unless and until such time (if any) that the Licensed Protein becomes a Terminated Protein. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 16 

         2.2.3.    JSC
Meetings. The JSC shall meet at least *** during the Research Term in accordance with a schedule agreed to by the Parties. The JSC may meet in person or by means of teleconference, Internet conference, videoconference or other similar
communications equipment. However, at least *** during the Research Term such meetings will be conducted in person with the location for such in-person meetings generally alternating between FivePrime’s and UCB’s facilities in the
United States and Europe, respectively, or such other location as the JSC may determine. Each Party shall bear its own travel, lodging and telecommunication expenses related to participation in and attendance at such meetings by its JSC
representatives. 
 (a)        Each Party may invite non-voting
observers to attend any JSC meeting, provided that any such observers who are not employees of either Party or its Affiliates may only attend with the prior written consent of the other Party, which consent shall not be unreasonably withheld.
All such observers shall be bound by confidentiality and non-use obligations similar to those contained in Section 9, or which are otherwise mutually acceptable to the Parties. 

(b)        Meeting Minutes. FivePrime shall prepare written minutes of
the meetings of the JSC and provide a draft of such minutes to the JSC members for review. The Parties shall limit the content of such minutes to factual statements regarding the status and results of work under the Research Plan and of any
decisions made by JSC. The Parties shall refrain from including any opinions or other extraneous content in such minutes. The JSC minutes shall become official when approved by the JSC at the next regularly scheduled JSC meeting. FivePrime shall
consider in good faith any comments to the draft minutes that are provided by UCB’s JSC members. Any discrepancies or disputes with respect to the content of JSC minutes shall be resolved by the Parties prior to being presented at a JSC meeting
for approval. 
         2.2.4.    Scope of JSC Oversight.
Except as otherwise provided herein, the responsibility of the JSC shall be to: 

(a)        provide oversight of the Working Group; 

(b)        prioritize Research Plan experiments for the Working Group;

 (c)        resolve disputes arising at the Working Group;

 (d)        confer regarding the status of the Research Plan;

 (e)        review data generated in the course of the
Research Plan by the Parties, including with respect to assay development and results of screening, and to consider and advise on any technical issues that arise in the course of the Research Plan; 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 17 

 (f)        review and
approve any proposed amendments to the Research Plan; 

(g)        review written updates submitted to the JSC pursuant to
Section 3.2.3; 
 (h)        monitor the Parties’
progress under the Research Plan; and 
 (i)        perform such
other obligations as are necessary for the conduct of the Research Plan. 
 For clarity, the JSC shall not have any authority beyond the
specific matters set forth in this Section 2.2.4, including not having the authority to: (i) obligate UCB to exercise the Claiming Option or License Option with respect to any Protein; (ii) amend this Agreement, waive any breach of
either Party under this Agreement, or terminate this Agreement; (iii) make decisions or take any actions that are inconsistent with the terms of this Agreement; or (iv) approve any amendment to the Research Plan that is inconsistent with
the terms of this Agreement. 
 2.3        Joint Patent Committee. 

    2.3.1.    Formation. Within *** days after the Effective Date, the Parties
shall establish a joint patent committee under this Agreement (the “JPC”), which shall consist of at least *** from each of FivePrime and UCB. 
     2.3.2.    Role. The JPC shall be responsible for developing patent strategy for Collaboration Patents, including making key decisions on drafting,
filing, prosecution and maintenance of the Collaboration Patents, as well as providing a forum for the Parties to discuss material issues and provide input to each other regarding Collaboration Patents. The JPC will also be responsible for selecting
and working with outside patent counsel that is mutually acceptable to the Parties to handle drafting, filing, prosecution and maintenance of the Collaboration Patents on behalf of the Parties (the “Outside Counsel”) and in
accordance with the terms of Sections 10.2. The Outside Counsel will be retained to represent and act on behalf of the Parties jointly, and will work in a manner consistent with the best interests of both Parties. Periodically during the Research
Term, or upon request, the JPC shall report its activities and the status of such to the JSC. 

    2.3.3.    Decisions. The JPC shall make all decisions unanimously with each Party
collectively having one vote in each decision of the JPC. In the event that the JPC is unable to reach a unanimous decision within *** Business Days after it has met and attempted to reach such decision, then either Party may, by written
notice to the other, have such issue submitted to 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 18 

 
the respective chief patent counsels of UCB and FivePrime (“Chief Patent Counsels”), or such other person holding a similar position designated by UCB or FivePrime from time to
time, for resolution. The Chief Patent Counsels shall meet or confer promptly to discuss the matter submitted and to determine a resolution. If the Chief Patent Counsels are unable to determine a resolution within *** Business Days after the
matter was referred to them, then Outside Counsel shall make the final decision with respect to such matter based upon the facts and respective recommendations provided to Outside Counsel by the Parties. For clarity, any and all decisions regarding
Patents directed to an Excluded Protein, Terminated Protein, Non-Selected Protein, Licensed Protein or Licensed Product shall be outside of the scope of the JPC. 
         2.3.4.    Meetings. The JPC shall meet at least ***, either in person, by teleconference or by video conference, on such
dates and at such places and times as are agreed to by the Parties. Each Party shall bear its own travel and lodging expenses related to participation in and attendance at such meetings by its JPC representatives. 

    2.4        Oversight Periods of Committees. The activities to be
performed by the JSC and JPC shall solely relate to governance under this Agreement, and shall not involve the delivery of services. The JSC shall continue to exist until the expiration of the Research Term, whereupon it shall be disbanded.
Following the expiration of the Research Term, the JPC will be disbanded in the event that there are no Collaboration Patents either filed or anticipated to be filed, or as the Parties may otherwise agree in writing. Notwithstanding the foregoing,
FivePrime shall have the right to resign from the JSC and/or JPC at any time by providing written notice to UCB. 

3.        Research Plan. 
     3.1        Overview. The Research Plan shall govern the Parties’ activities under the CNS Project and the Fibrosis Project
during the Research Term. Neither Party shall be obligated to conduct activities that are not described in the Research Plan. The Research Plan in effect as of the Effective Date is attached hereto as Exhibit A. The goal of the Research Plan
is: (i) to design and develop Screening Assays, and to conduct screening of the FivePrime Library (or a portion thereof as determined by the unanimous agreement of the Working Group) using such Screening Assays and perform such other activities
as may be agreed to by the Parties to generate Confirmed Hits; (ii) for UCB to evaluate the Confirmed Hits and determine whether it desires to exercise the Claiming Option on such Confirmed Hits; and (iii) for UCB to evaluate UCB Reserved
Proteins and determine whether or not to exercise the License Option for any such UCB Reserved Proteins. The Research Plan will include, among other things, a description of the Screening Assays intended to be performed and any agreed upon criteria
to be applied for the determination as to whether a preliminary hit is a Confirmed Hit. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 19 

 3.1.1. Provisions Regarding the Fibrosis Project. The Parties acknowledge that UCB
intends to conduct assay development work in respect of *** different in vitro cell-based UCB Assays for possible use as Screening Assays for the Fibrosis Project. FivePrime will conduct the further assay development work under the
Research Plan which is necessary to utilize the UCB Assays with the FivePrime Platform Technology. In addition, FivePrime will initiate assay development work for and commence the conduct of the RIPPS Assay for the Fibrosis Project as soon as
practicable after the Effective Date. The Working Group and JSC will monitor the progress of assay development work. In addition to the RIPPS Assay, at least *** and at most *** (subject to UCB’s right to substitute in
Section 3.2.4) in vitro Screening Assays based upon the UCB Assays will be selected by UCB, with input from FivePrime, for screening under the Research Plan. UCB shall have sole discretion in deciding whether or not to proceed with
screening using the Third Fibrosis Assay; provided that such decision must be made and communicated to FivePrime prior to ***. 
 3.1.2.    Provisions Regarding the CNS Project. The Parties acknowledge that the primary objective of the CNS Project is to *** which are the focus of the Screening
Assays to be used for the CNS Project. In the event that either Party becomes aware of any Third Party publication or other public disclosure of data and information that identifies such ***, it shall promptly notify the JSC to that effect.
In such event, and if FivePrime has not yet initiated screening of the FivePrime Library using the Screening Assays for the CNS Project, then the JSC will promptly meet to discuss in good faith the merits of and thereafter decide whether or not to
proceed with such screening. If the JSC decides not to proceed with the planned Screening Assays for the CNS Project, then UCB (through the relevant Working Group) shall have the right to select a substitute Screening Assay to be conducted for the
CNS Project or Fibrosis Project that is of similar scope and requires no more resource commitment (including FTE, time, materials, equipment and funding) by FivePrime than the originally planned Screening Assay. 

3.1.3.    Validation Phase of Projects. Following the selection of each UCB Reserved Protein, UCB will be
responsible for performance of the activities under the Research Plan to evaluate and validate the UCB Reserved Protein. This may include activities necessary to generate samples of the native Protein corresponding to such UCB Reserved Protein that
are needed for UCB to perform such activities. In the case of the CNS Project, FivePrime will, upon request, inform UCB via the Working Group if FivePrime is willing and able to assist UCB in the generation of native Protein. However, FivePrime will
not be obligated to undertake any such work unless the Parties agree in writing on a specific work plan and related compensation to be paid to FivePrime for such efforts. 
 3.2        Resource Commitment. Each Party shall use Commercially Reasonable Efforts to conduct, in accordance with the terms of this Agreement, the work
allocated to such Party in the Research Plan. During the Research Term, FivePrime and UCB shall each commit sufficient resources, staffing, equipment, facilities, materials and other resources to timely perform all the activities allocated to it
under the Research Plan. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 20 

     3.2.1.    During the Research Term
FivePrime shall determine and maintain appropriate FivePrime staffing levels as are necessary from time to time to resource and timely perform its activities under the Research Plan. Except for the payments to be made by UCB as expressly set forth
in Section 8, FivePrime shall be fully responsible for its research efforts and shall bear all corresponding costs and expenses. 
     3.2.2.    During the Research Term UCB shall determine and maintain appropriate UCB staffing levels as are necessary from time to time to resource and
timely perform its activities under the Research Plan. UCB shall be fully responsible for its research efforts and shall bear all corresponding costs and expenses. 
     3.2.3.    During the Research Term, each Party shall provide the JSC with a written update summarizing the status of its respective activities under the
Research Plan, in advance of each scheduled JSC meeting. If there are any UCB Reserved Proteins, the update shall describe the status of research conducted with regard to such UCB Reserved Proteins. 

    3.2.4.    To the extent that the Parties agree that any un-performed Screening Assay
under the Research Plan would not be scientifically feasible to perform, then the JSC may, during the Research Term, amend the Research Plan to substitute such un-performed Screening Assay with a new Screening Assay(s) that is of similar scope and
require similar efforts and expenditures, provided that such substitution(s) shall not cause either UCB or FivePrime to incur any additional costs. In addition, if, before ***, the Parties determine jointly to forego all of the planned
in vitro Screening Assays in the Fibrosis Project, then the JSC may, during the Research Term, amend the Research Plan to substitute these planned and un-performed in vitro Screening Assays in the Fibrosis Project with alternative Screening Assays
and/or other research activities to be agreed upon by the Parties at such time. Any such alternative activities may be within the scope of the Fibrosis Project and/or the CNS Project, and shall in the aggregate require similar efforts and
expenditures from FivePrime to that reasonably contemplated for the previously planned and un-performed activities. 

    3.2.5.    *** 

3.3        Sharing of Data. The Parties shall share the results of all research performed
by or on behalf of either Party under the Research Plan that constitutes Collaboration Know-How or Collaboration Patents. In addition, UCB shall from time-to-time during the Research Term also provide FivePrime with information or results of
activities conducted under the Research Plan with respect to UCB Reserved Proteins. Nothing in this Agreement shall be interpreted as obligating FivePrime to disclose to UCB, and FivePrime hereby agrees that it shall not disclose to UCB:
(a) any data obtained by FivePrime through testing the FivePrime Library and/or any Protein in any Independent Assays; or (b) the identity of or any data regarding any Protein that is an Excluded Protein. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 21 

 3.4        Third Party Contractors. UCB shall
be entitled to utilize the service of Third Party contractors (each, a “Contractor”) in connection with the performance of its obligations under the Research Plan. Any proposed use of Contractors by FivePrime to perform its
obligations under the Research Plan shall be subject to the prior written approval of UCB, not to be unreasonably withheld, except that FivePrime shall have the right to engage Contractor(s) without such prior written approval from UCB if the
engagement of Contractor(s) for a particular activity has been contemplated by the Research Plan. Each Party shall remain at all times fully responsible for the activities allocated to it under the Research Plan and shall be responsible and liable
hereunder with respect to the performance of any such activities by its Contractors. 

3.5        Use of Materials. The Parties acknowledge and agree that any Materials
Controlled by a Party that are used in connection with the performance of the Research Plan, together with all progeny and/or derivatives thereof, are and shall remain the property of such Party. The Parties further acknowledge and agree that the
use by or on behalf of a Party of any of its Materials in connection with performance of the Research Plan shall not result in such Materials (or any progeny and/or derivatives thereof) being considered Collaboration Know-How (or in the case of
UCB’s Materials, Protein Know-How), except in each case to the extent that such Materials were, prior to such use, Collaboration Know-How (or Protein Know-How, as applicable). 

    3.5.1.    Transfer of Materials. During the course of the Research Plan, each Party
may transfer (the “Materials Transferring Party”) to the other Party (the “Materials Receiving Party”) samples of Materials for use in connection with the Research Plan. All Materials supplied by a Materials
Transferring Party, and any progeny and/or derivatives thereof that are generated by or on behalf of the Materials Receiving Party, are and shall remain the sole and exclusive property of the Materials Transferring Party. For clarity, neither Party
shall be obligated to provide the other Party with any samples of its Materials except to the extent expressly set forth in the Research Plan and/or this Agreement. 
     3.5.2.    Warranty Disclaimer Regarding Materials. The Materials Transferring Party hereby represents that it Controls and has the rights and authority
to provide the relevant Materials to the Materials Receiving Party for use in accordance with the terms of this Section 3.5. THE MATERIALS SUPPLIED BY THE MATERIALS TRANSFERRING PARTY PURSUANT TO THIS SECTION 3.5 ARE OTHERWISE SUPPLIED IN
“AS IS” CONDITION WITH NO WARRANTY, EXPRESS, IMPLIED OR STATUTORY, INCLUDING WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT, EXCLUSIVITY, OR FITNESS FOR A PARTICULAR PURPOSE. ANY MATERIAL DELIVERED PURSUANT TO THIS AGREEMENT IS UNDERSTOOD
TO BE EXPERIMENTAL IN NATURE AND MAY HAVE HAZARDOUS PROPERTIES. THE MATERIALS RECEIVING PARTY WILL HANDLE THE MATERIAL ACCORDINGLY. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 22 

 3.5.3.    Restrictive Covenants on Materials. The Materials
Receiving Party agrees that it will: 

    (a)        Use the received Materials solely for,
and in compliance with, the Research Plan; 

    (b)        Use the received Materials in
compliance with applicable Laws; 

    (c)        Not use the received Materials in
human subjects; 
     (d)        Use the
received Materials only in the Materials Receiving Party’s laboratories by personnel of the Materials Receiving Party; 
     (e)        Not transfer the received Materials to any Third Party without the prior written consent of the Materials Transferring
Party; and 
     (f)        Not reverse
engineer or chemically analyze the received Materials, except as expressly agreed in writing by the Materials Transferring Party. 
 The
Materials Receiving Party further agrees that all of the foregoing restrictions shall also apply to all progeny and/or derivatives of Materials it receives from the Materials Transferring Party that are generated by or on behalf of the Materials
Receiving Party. 
 3.5.4.    Exceptions. In the specific case of Materials provided to UCB by
FivePrime that are specifically related to a Licensed Protein, the restrictions set forth in Section 3.5.3 shall not, as of the applicable License Effective Date, apply to such Materials for so long as such Licensed Protein remains a Licensed
Protein. In the event that FivePrime receives any Materials from UCB which are Protein Know-How and are specifically related to a Non-Selected Protein, the foregoing restrictions shall not, as of the date such Protein becomes a Non-Selected Protein
apply to FivePrime with respect to such Materials. 
 3.5.5.    Allocation of Liability. The
Materials Receiving Party assumes all liability for damages which may arise from its handling, use, storage or disposal of the Materials. The Materials Transferring Party shall not be liable to the Materials Receiving Party for any loss, claim or
demand made by the Materials Receiving Party, or made against the Materials Receiving Party by any Third Party, due to or arising from the handling, use, storage or disposal of the Materials as permitted hereunder, except to the extent caused by the
gross negligence or willful misconduct of the Materials Transferring Party. 
 3.5.6.    Disposition of
Materials After the Research Term. Except as expressly provided below, upon expiration or the earlier termination of the Research Term, the Materials Receiving Party shall discontinue its use of any Materials pursuant to this Agreement and
shall, 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 23 

 
upon direction of the Materials Transferring Party, return or destroy (and certify destruction of) any remaining Material (and all progeny and/or derivatives thereof) in its possession. The
foregoing notwithstanding, UCB shall have the right: (i) during the applicable License Option Period to retain any and all Materials related to a UCB Reserved Protein that were provided to it by or on behalf of FivePrime pursuant to
Section 4.3.1; and (ii) thereafter to retain any and all such Materials which are related to any such UCB Reserved Protein that becomes a Licensed Protein, unless and until such time (if any) that it becomes a Terminated Protein.
Similarly, in the event that FivePrime receives any Materials from UCB which are Protein Know-How and are specifically related to a Non-Selected Protein, FivePrime shall have the right to retain such Materials. 

4.        Confirmed Hits; UCB Reserved Proteins; Licensed Proteins. 

  4.1        Confirmed Hits. FivePrime will disclose to UCB in writing the
identity of all Confirmed Hits as soon as practicable through the Working Group but in any event at the next JSC meeting. FivePrime will at such time or promptly thereafter deliver to UCB all available Collaboration Know-How with respect to each
such Confirmed Hit and any other data and information Controlled by FivePrime with respect to such Confirmed Hit (the “Confirmed Hit Data”); provided, however, that the Confirmed Hit Data for Confirmed Hits first
identified from (as opposed to confirmed in) a RIPPS Assay will be delivered to UCB in batches based upon completed first round of screening in RIPPS Assays of *** Proteins (or the remainder of Proteins with respect to the last such batch).
The Confirmed Hit Data shall in each case include a sample of the cDNA encoding the relevant Protein which cDNA sample shall constitute Materials of FivePrime and be subject to the terms of Section 3.5. UCB shall have the right to use any and
all Confirmed Hit Data solely for the purpose of evaluating the relevant Confirmed Hit so as to determine whether or not UCB will exercise its Claiming Option with respect to such Confirmed Hit. For clarity, this will include the use of the relevant
cDNA sample(s) by UCB to perform apoptosis testing and other activities as described in the Research Plan with respect to each such Confirmed Hit. 
   4.2        Conversion of Confirmed Hits to UCB Reserved Proteins. 
       4.2.1.    Claiming Option. During the applicable Claiming Option Period (as defined in Section 4.2.3), UCB shall have an exclusive
option (even as to FivePrime) to select a Confirmed Hit for evaluation and further development as a UCB Reserved Protein (each such option, a “Claiming Option”). UCB shall have the right to exercise its Claiming Option at any time
prior to the expiration of the applicable Claiming Option Period by providing written notice to FivePrime to that effect and thereafter paying FivePrime the Optioning Fee pursuant to Section 8.2.1. The term “Claiming Option
Period” with respect to a Confirmed Hit means the ***-day period following the date on which FivePrime delivers to UCB the Confirmed Hit Data with respect to such Confirmed Hit. Effective as of the date on which FivePrime receives
such written notice (the “Claiming Date”), such Confirmed Hit shall cease to be a Confirmed Hit and shall thereafter be considered a UCB Reserved Protein, subject to timely payment of such Optioning Fee. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 24 

     4.2.2.    If UCB fails to notify
FivePrime of its exercise of the Claiming Option with respect to a particular Confirmed Hit during the applicable Claiming Option Period, then effective upon the expiration of such Claiming Option Period the Claiming Option shall irrevocably expire
with respect to such Confirmed Hit which shall cease to be a Confirmed Hit and shall thereafter be a Non-Selected Protein. 

    4.2.3.    In the case of a UCB Reserved Protein which was a Confirmed Hit first
identified from (as opposed to confirmed in) a RIPPS Assay, if UCB fails to timely pay the second installment of the Optioning Fee pursuant to Section 8.2.1, then effective upon the expiration of the *** day period after the relevant
Claiming Date such UCB Reserved Protein shall immediately cease to be a UCB Reserved Protein and shall thereafter be a Non-Selected Protein, and the License Option Period and License Option with respect thereto shall be irrevocably terminated.

 4.3        Conversion of UCB Reserved Proteins to Licensed Proteins.

     4.3.1.    Access to Evaluation Materials. Within *** Business
Days after UCB selects a Confirmed Hit as a UCB Reserved Protein, and subject to Section 3.5, FivePrime shall transfer to UCB, at no additional cost to UCB, all of the Materials, FivePrime Background Know-How and Collaboration Know-How that the
Parties agree are necessary to enable UCB to evaluate such UCB Reserved Protein as a potential Licensed Protein (the “Evaluation Materials”). For clarity, in the case of any UCB Reserved Protein which was subjected to a RIPPS Assay,
the Evaluation Materials shall include any liver and lung tissues the Parties agree to collect from relevant mice pursuant to the Research Plan. UCB shall bear all costs associated with its evaluation of any UCB Reserved Protein. 

    4.3.2.    License Option. During the License Option Period (including as it may be
extended) with respect to a particular UCB Reserved Protein, UCB shall have the right to evaluate such UCB Reserved Protein, and FivePrime shall reasonably cooperate with UCB in such evaluation at UCB’s request and expense. During the relevant
License Option Period, UCB shall have an exclusive option with respect to such UCB Reserved Protein, exercisable as set forth below, to select such UCB Reserved Protein as a Licensed Protein (each such option, a “License Option”).
UCB shall have the right, exercisable at any time prior to the expiration of the License Option Period, to effect a one-time extension of the License Option Period for *** by providing FivePrime with written notification of such extension and
paying to FivePrime an Option Extension Fee pursuant to Section 8.2.1. UCB shall have the right, prior to the expiration of the License Option Period, to exercise the License Option by providing FivePrime with

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 25 

 
written notice and paying FivePrime the Commercial License Fee pursuant to Section 8.2.2. Effective as of the date of FivePrime’s receipt of such written notice (the “License
Effective Date”), such UCB Reserved Protein shall cease to be a UCB Reserved Protein and shall thereafter be a Licensed Protein, subject to timely payment of such Commercial License Fee. 

    4.3.3.    If UCB fails to notify FivePrime of its exercise of the License Option with
respect to a particular UCB Reserved Protein during the applicable License Option Period, then effective upon the expiration of such License Option Period the License Option shall irrevocably expire with respect to such UCB Reserved Protein which
shall cease to be a UCB Reserved Protein and shall thereafter be a Non-Selected Protein. 

    4.3.4.    As soon as reasonably practicable, but in any event within ***
Business Days after the relevant License Effective Date, FivePrime shall transfer to UCB, to the extent not previously provided, all Collaboration Know-How with respect to the Licensed Protein, and any and all additional information and data
Controlled by FivePrime related to such Licensed Protein. 
 4.4        Provisions
Regarding Non-Selected Proteins. 
     4.4.1.    Termination of Research
License. Effective as of the date on which any Confirmed Hit or UCB Reserved Protein becomes a Non-Selected Protein, the Research License granted by FivePrime to UCB with respect to such Non-Selected Protein shall terminate and all such rights
will revert to FivePrime. For clarity, the termination of such Research License shall not affect UCB’s ownership interests and related rights in and to any related Collaboration Patents or Collaboration Know-How. 

    4.4.2.    Transfer of Collaboration Know-How. UCB shall promptly thereafter, upon
request and to the extent not previously provided or otherwise made available to FivePrime, deliver to FivePrime a copy of any Collaboration Know-How that was generated by or on behalf of UCB with respect to such Non-Selected Protein. The foregoing
notwithstanding, UCB will not be obligated to deliver to FivePrime and shall promptly destroy any and all transfected cell lines generated by UCB using the cDNA with respect to such Non-Selected Protein that was provided to UCB pursuant to
Section 4.1. 
     4.4.3.    License to Protein Patents. Effective upon
the date on which a UCB Reserved Protein becomes a Non-Selected Protein, UCB hereby grants to FivePrime a fully-paid, royalty-free, perpetual, irrevocable, non-exclusive license, with the right to sublicense, under all Protein Patents Controlled by
UCB with respect to such Non-Selected Protein to make, have made, use, offer for sale, sell and import such Non-Selected Protein and/or Therapeutics and/or Diagnostics with respect thereto. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 26 

     4.4.4.    Related Protein Know-How. In
the event that a UCB Reserved Protein becomes a Non-Selected Protein, FivePrime shall have the option to request a license from UCB to the Protein Know-How related to such Non-Selected Protein. Such option shall be exercisable by FivePrime, in its
sole discretion, by providing UCB with written notice to that effect at any time during a period of *** days after the expiration of the relevant License Option Period. Following receipt of such notice, the Parties will promptly meet to
discuss in good faith and negotiate over a period of *** days the terms of a possible license to FivePrime to use the relevant Protein Know-How to develop, manufacture and commercialize Therapeutics related to such Non-Selected Protein.
Nothing herein shall be construed as obligating either Party to enter into any such agreement on terms and conditions which are not acceptable to it, and each Party shall have the right to unilaterally discontinue all discussions and negotiations
with respect to such a transaction at any time after the end of such *** day negotiation period and without obligation or liability to the other Party. 
 5.        Excluded Proteins. 

  5.1      Excluded Protein List. 

    5.1.1.    During the Research Term, FivePrime shall maintain an accurate and complete
Excluded Protein List that clearly identifies each Excluded Protein by its unique FivePrime internal tracking number. The Excluded Protein List of all Excluded Proteins existing as of the Effective Date is attached hereto as Exhibit B. From
time to time during the Research Term, FivePrime shall have the right to add or remove Excluded Proteins from the Excluded Protein List to reflect changes in the status of existing Excluded Proteins or to add additional Excluded Proteins discovered
and designated by FivePrime outside of the Research Plan and without use of Collaboration Know-How or UCB IP. The foregoing notwithstanding, FivePrime’s right to discover and designate additional Proteins as Excluded Proteins (whether for
itself or on behalf of Third Parties) shall be subject to the terms of Section 6.4.3, and FivePrime shall not have the right to add any Excluded Protein to the Excluded Protein List (or to otherwise select or designate as an Excluded Protein)
if such Protein is a Confirmed Hit, UCB Reserved Protein or Licensed Protein, unless and until such time (if any) that the Protein becomes, as applicable, a Non-Selected Protein or a Terminated Protein. In addition, FivePrime shall not remove any
Excluded Protein from the Excluded Proteins List unless and until such time as FivePrime Controls and has the right to grant both a Research License and a Commercial License under all Patents and Know-How related to such Excluded Protein that was
generated by or on behalf of FivePrime and/or any Third Party which previously held the rights to such Excluded Protein. During the Research Term FivePrime shall promptly notify UCB in writing of any modifications to the Excluded Protein List.

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 27 

     5.1.2.    Any additional information to
be contained in the Excluded Protein Lists provided to UCB pursuant to Section 5.1.1 shall be determined by FivePrime in its sole discretion; provided that FivePrime shall not inform UCB of the identity or structure of any of the
Excluded Proteins, the indication for which any of the Excluded Proteins are being evaluated or developed, or provide UCB with any other non-public data or information associated with such Excluded Proteins, or the development stage of any of the
Excluded Proteins. 
 5.2        Excluded Protein Hits. In the event that a
Protein identified from any Screening Assay performed by FivePrime pursuant to the Research Plan (including as a preliminary hit) is already an Excluded Protein, then FivePrime will not undertake any additional screening or other activities to
determine whether or not such Excluded Protein would qualify as a Confirmed Hit. In such event, FivePrime will inform UCB of the total number of Excluded Proteins that were so identified using the Relevant Screening Assay. FivePrime shall not
identify such Protein to UCB or disclose to UCB any data or results pertaining to such Protein; (ii) under no circumstances will such Excluded Protein be deemed a Confirmed Hit; (iii) FivePrime and/or its Third Party licensee shall retain
all rights under the FivePrime IP with respect to such Excluded Protein; and (iv) UCB shall have no rights under the FivePrime IP with respect to such Excluded Protein. The Parties will not further evaluate such Excluded Protein under the
Research Plan and UCB will not have the right to exercise any Claiming Option or License Option with respect to such Excluded Protein. 
 5.3        Independent Research by UCB. The Parties acknowledge that UCB and its Affiliates are engaged in various independent research and development
programs with respect to the identification of novel biological targets and/or the discovery, development and commercialization of bio-pharmaceutical products with respect thereto, which programs are separate and distinct from the activities being
undertaken by the Parties pursuant to this Agreement (the “UCB Independent Research”). Such UCB Independent Research may include programs and related activities undertaken on or before the Effective Date and/or during or after the
Term of this Agreement. For clarity, nothing herein shall be construed as limiting or restricting UCB’s or its Affiliates’ ability to independently discover, develop and/or commercialize pharmaceutical products through UCB Independent
Research which may correspond to or otherwise compete with Therapeutics in respect of a Non-Selected Protein or Excluded Protein; provided that UCB and its Affiliates shall not have any rights to utilize: (i) any of the FivePrime IP in
connection with any UCB Independent Research; and/or (ii) any Collaboration Patents, non-public Collaboration Know-How or non-public Protein Know-How in connection with any UCB Independent Research. For clarity, in the event of any dispute
between the Parties with respect to UCB Independent Research, UCB shall bear the initial burden of proof that it has complied with the foregoing restrictions on utilization of FivePrime IP, Collaboration Patents, Collaboration Know-How and Protein
Know-How. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 28 

 6.        Licenses; Negative Covenants; Exclusivity.

   6.1      License Grants to UCB. 

    6.1.1.    Research License. FivePrime hereby grants to UCB a fully-paid,
royalty-free, non-exclusive license, with the right to grant sublicenses as provided below, under the FivePrime Background Patents and FivePrime Background Know-How solely to the extent necessary for UCB to: (i) conduct its obligations and
responsibilities under the Research Plan during the Research Term; and (ii) thereafter to complete its evaluation and determination of whether to exercise any remaining Claiming Options and/or License Options during the remainder of, as
applicable, any unexpired Claiming Option Periods and/or License Option Periods. FivePrime further hereby grants to UCB during the applicable License Option Period a fully-paid, royalty-free, exclusive license, with the right to grant sublicenses as
provided below, under FivePrime’s interest in Collaboration Patents and Collaboration Know-How with respect to a UCB Reserved Protein solely to the extent necessary for UCB to complete its evaluation and determination of whether to exercise the
License Option with respect thereto. (The licenses granted by FivePrime to UCB under this Section 6.1.1 are referred to herein as the “Research License”). UCB may sublicense its rights under the Research License solely to its
Affiliates and Contractors for the sole purpose of conducting UCB’s obligations and responsibilities under this Agreement on UCB’s behalf. 
     (a)        The licenses granted in Section 6.1.1 shall not be construed as granting to UCB (either expressly or by implication)
any rights for UCB or its Affiliates to practice the FivePrime Platform Technology or requiring FivePrime to transfer any portion of the FivePrime Platform Technology to UCB. Instead, as between the Parties, FivePrime shall be the Party conducting
activities that requires the practice of FivePrime Platform Technology under the Research Plan. 

    6.1.2.    Commercial License. Effective as of the applicable License Effective Date,
FivePrime hereby grants to UCB an exclusive, royalty-bearing (as set forth in Section 8) license in the Territory, with the right to grant sublicenses pursuant to Section 6.1.3, under the FivePrime Background Patents, FivePrime Background
Know-How, and FivePrime’s interest in the Collaboration Patents and Collaboration Know-How, to research, develop, make, have made, import, export, distribute, market, promote, use, sell, offer for sale and otherwise commercialize Licensed
Products with respect to such Licensed Protein for any and all purposes. The foregoing notwithstanding, the licenses granted to UCB under this Section 6.1.2 to offer for sale, sell and otherwise commercialize Diagnostics with respect to a
Licensed Protein shall be subject to the terms of Sections 6.4.4(c) and 8.5.1. The licenses granted in this Section 6.1.2 shall not be construed as granting to UCB (either expressly or by implication) any rights with respect to FivePrime
Platform Technology. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 29 

 6.1.3.    Right to Sublicense. UCB may grant sublicenses
(including the right to grant further sublicenses) of rights under any Commercial License to any of its Affiliates or any Third Party without the prior written consent of FivePrime, provided that the agreement between UCB and such sublicensee
shall be consistent with the terms and conditions of this Agreement. UCB shall remain responsible for its obligations, including payment obligations pursuant to Section 8, under this Agreement that have been delegated, subcontracted or
sublicensed to any of its Affiliates or to Third Parties. UCB shall ensure that any Third Party sublicense includes appropriate audit rights exercisable by UCB to ensure compliance by such sublicensee and which are comparable in scope to those set
forth in Section 8.7. UCB shall notify FivePrime in the event that UCB sublicenses to a Third Party the rights to commercialize a Licensed Product in the U.S., Japan and/or any of the Major Markets, which notice shall identify the Third Party
sublicensee. 
 6.1.4.    Retained Rights. FivePrime retains all rights under the FivePrime IP that
are not expressly granted herein to UCB. 

    (a)        Right to Maintain Library. The Parties
acknowledge and agree that FivePrime shall retain the limited right to maintain any and all Confirmed Hits, UCB Reserved Proteins and Licensed Proteins in the FivePrime Library, and, subject to the licenses granted to UCB under Section 6.1 and
the restrictions set forth in Sections 6.4.3, to use the FivePrime Library for any purpose (including conducting screening and/or collaborations with Third Parties). The incidental use of Confirmed Hits, UCB Reserved Proteins and/or Licensed
Proteins in connection with the use of the FivePrime Library shall not constitute a breach of this Agreement; provided, however, that FivePrime shall not, for so long as a particular Protein remains a Confirmed Hit, UCB Reserved
Protein and/or Licensed Protein: (i) disclose the identity or structure of such Protein to any Third Party; (ii) publish or disclose to any Third Party, or use for any purpose, any data or results pertaining to such Protein that are
generated through such use of the FivePrime Library; or (iii) grant any rights or license to any Third Party with respect to such Protein. During the Research Term, FivePrime agrees that it will not use in any RIPPS screening assay other than a
Screening Assay conducted under the Research Plan, any Protein that is a UCB Reserved Protein or Licensed Protein. 
     (b)        Rights to Excluded Proteins. Notwithstanding anything to the contrary herein, FivePrime shall retain all rights under the
FivePrime IP to research, develop, manufacture and commercialize Therapeutics with respect to any Excluded Protein, for all uses at all times, either by itself, in collaboration with a Third Party or indirectly through a Third Party licensee.

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 30 

 6.1.5.    Non-Selected Proteins and Terminated Proteins.
Promptly after a Protein becomes a Non-Selected Protein or a Terminated Protein, UCB shall return or destroy, at FivePrime’s election, any and all FivePrime Background Know-How in its possession or control with respect to such Non-Selected
Protein or Terminated Protein and shall immediately cease to use such FivePrime Background Know-How, except in each case to the extent such FivePrime Background Know-How is also related to one or more remaining UCB Reserved Proteins and/or Licensed
Proteins. 
 6.2      Research License Grant to FivePrime. UCB hereby grants to FivePrime a
fully-paid, royalty-free, non-exclusive license, effective only during the Research Term, under UCB Background Patents, UCB Background Know-How solely to the extent necessary for FivePrime to conduct its obligations and responsibilities under the
Research Plan. FivePrime may grant sublicenses under the foregoing license solely to those of its Affiliates and Contractors that are responsible for and solely to conduct such obligations and responsibilities on its behalf. 

6.3      No Implied Licenses. Except as specifically set forth in this Agreement, neither Party
shall acquire any license, intellectual property interest or other rights, by implication or otherwise, in any Know-How disclosed to it under this Agreement or under any Patents Controlled by the other Party or its Affiliates. 

6.4      Negative Covenants. 

  6.4.1.    Covenants by UCB. UCB hereby covenants that it shall not use any FivePrime Background
Know-How, FivePrime Background Patents, Collaboration Know-How or Collaboration Patents for any purposes other than those purposes expressly permitted in Section 6.1 or as may otherwise expressly be permitted in this Agreement. 

  6.4.2.    Covenant by FivePrime. FivePrime hereby covenants that it shall not use any UCB
Background Know-How, UCB Background Patents, Collaboration Patents, or Collaboration Know-How for any purposes other than those purposes expressly permitted in Section 6.2, or in the case of Collaboration Patents and Collaboration Know-How as
may otherwise expressly be permitted in this Agreement. 
   6.4.3.    Further Covenants by
FivePrime. FivePrime hereby covenants that FivePrime and its Affiliates shall not: 

    (a)        during and after the Research Term,
use the UCB Assays (or any of UCB’s Materials, UCB Evaluation Know-How or UCB Background Know-How with respect thereto) for any purpose other than in performance of the Research Plan; 

    (b)        during the Research Term, conduct (or
grant licenses to Third Parties to conduct) any screening of all or any portion of the FivePrime Library using any Screening Assay developed from a UCB Assay, or any other assay having *** as such UCB Assay, either for itself or on behalf of
any Third Party; 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 31 

    (c)        commencing on the Effective Date and
until ***, undertake any screening of the FivePrime Library primarily intended to identify Proteins that modulate *** in humans outside the Research Plan; 

    (d)        commencing on the Effective Date and
until ***, undertake any screening of the FivePrime Library primarily intended to identify Proteins that modulate *** in humans outside the Research Plan; 

    (e)        undertake any activities on its own or
with a Third Party to discover or develop any Therapeutic or Diagnostic with respect to any Protein that is a Confirmed Hit, UCB Reserved Protein or Licensed Protein; or 

    (f)        disclose to any Third Party the
structure or identity of a Licensed Protein, the behavior of such Licensed Protein in other screening assays, or any other data or information in the possession of FivePrime or its Affiliates with respect to such Licensed Protein. 

For clarity, in the event that FivePrime experiences a Strategic Transaction at any time during the Term, the foregoing covenants in sub-sections
(e) and (f) shall not apply with respect to the relevant Acquiror or any of the Acquiror’s Affiliates which exist as of the time immediately prior to the closing of such Strategic Transaction. 

6.4.4.    Further Covenants by UCB. UCB hereby covenants that UCB and its Affiliates shall not: 

    (a)        other than as part of the Research
Plan, perform, or have performed on its behalf, any research studies, testing or development involving any Confirmed Hit prior to the Claiming Date (if any) on which such Protein becomes a UCB Reserved Protein provided, however, that
this restriction shall not apply to or otherwise limit the scope of any activities within the UCB Independent Research; 
     (b)        perform, or have performed on its behalf, any development or commercial activities for Therapeutics or Diagnostics with
respect to any UCB Reserved Protein prior to the License Effective Date (if any) on which such UCB Reserved Protein becomes a Licensed Protein; provided, however, that this restriction shall not apply to or otherwise limit the scope of
any activities within the UCB Independent Research; or 

    (c)        directly or indirectly (whether
through Sublicensees or otherwise) offer for sale of sell any Diagnostics with respect to a Licensed Protein prior to the date on which the Parties agree in writing on the Diagnostic Royalties to be paid to FivePrime

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 32 

 
in respect to sales of such Diagnostic; provided, however, that this restriction shall not apply to or otherwise affect the sale or commercialization of any diagnostic products
resulting from UCB Independent Research. 
 6.4.5.    Covenant Regarding Non-Selected Proteins. UCB
hereby covenants that UCB and its Affiliates shall not perform, or have performed on its behalf, any research, development or commercial activities for Therapeutics or Diagnostics with respect to any Non-Selected Protein; provided,
however, that this restriction shall not apply to or otherwise limit the scope of any activities within the UCB Independent Research. In the event that UCB successfully develops through the performance of UCB Independent Research and
thereafter commercializes a Therapeutic with respect to a Non-Selected Protein, then UCB shall pay royalties to FivePrime pursuant to Section 8.5.2 on sales of such Therapeutic in such countries (if any) in which there is a Protein Patent
and/or a Collaboration Patent having a Valid Claim which covers the sale of such Therapeutic in such country. 

7.      Development, Commercialization and Manufacturing of Licensed Products. 

7.1      Responsibilities of UCB. Effective as of the License Effective Date, UCB will be solely
responsible, at its own expense, and will control and have sole and final decision-making authority with respect to the conduct of any and all research, development (including pre-clinical and clinical studies), regulatory activities, manufacturing,
marketing, distribution, sales and other commercialization activities for Licensed Products with respect to such Licensed Protein. 
 7.2      Diligence and Reporting. UCB shall use Commercially Reasonable Efforts to develop and commercialize at least one Licensed Product for each Licensed Protein in
the Territory. After the Research Term, UCB shall within *** days after the end of each *** provide FivePrime with a written report summarizing the status of its research, development and commercialization efforts with respect to each
Licensed Protein and its related Licensed Product(s) in such ***. UCB’s reporting obligations under this Section 7.2 with respect to Licensed Products related to a given Licensed Protein shall terminate upon the date of First
Commercial Sale of a Licensed Product with respect to such Licensed Protein in the U.S. or one of the Major Markets. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 33 

 8.        Payments; Royalties and Reports. 

  8.1      Research, Technology Access and Related Payments. 

    8.1.1.    Research License Fee. UCB shall pay to FivePrime a one-time, non-refundable
upfront payment and license fee of six million dollars ($6,000,000) within *** Business Days after the Effective Date. 

    8.1.2.    Technology Access Fees. In further consideration for the Research License
and for the access to the FivePrime Background Know-How during the Research Term, UCB shall pay to FivePrime non-refundable technology access fees. The technology access fees will be payable as three (3) equal payments of two million two
hundred thousand dollars ($2,200,000) each, to be due and payable as follows: (a) within *** Business Days after the Effective Date; (b) on the first anniversary of the Effective Date; and (c) on the second anniversary of the
Effective Date. 
     8.1.3.    Quarterly Research Funding. UCB shall provide
research funding to FivePrime during the Research Term, such funding to be paid in *** non-refundable quarterly payments in the amount of *** dollars ($***) per quarter during *** of the Research Term. The first such
payment shall be due on the first Business Day of the *** Calendar Quarter during the Research Term and the remaining payments will be due on the first Business Day of each of the *** consecutive Calendar Quarters which occur
thereafter during the Research Term. 
     8.1.4.    Reimbursement of Reagent
Costs. UCB shall reimburse FivePrime for the documented, reasonable out-of-pocket costs actually incurred by FivePrime for ***; provided, that the aggregate total for which UCB is responsible for reimbursing FivePrime shall not
exceed $***. UCB will also reimburse FivePrime for the documented, reasonable out-of-pocket costs actually incurred by FivePrime for ***; provided that the aggregate total for which UCB is responsible for reimbursing FivePrime
shall in each not exceed the relevant cap set forth in the Research Plan with respect to such Screening Assay. Reimbursement payments to FivePrime under this Section 8.1.4 shall be made pursuant to detailed itemized invoices to be provided to
UCB by FivePrime, which shall be due and payable within *** days of UCB’s receipt of each such invoice. 

    8.1.5.    Optional Third Fibrosis Screen. In the event that FivePrime undertakes
performance of a third in vitro Screening Assay for the Fibrosis Project (the “Third Fibrosis Screen”) pursuant to Section 3.1.1, UCB shall make the non-refundable milestone payments set forth below to FivePrime within
*** days after the first occurrence of the milestone event set forth below: 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 34 

 
					
	 Milestone Events for Third Fibrosis
Screen
	  	 	Amount	  

	 Upon
*** of the Third Fibrosis Screen
	  	 	$	*** 
	 Upon
*** in the Third Fibrosis Screen
	  	 	$	*** 

 8.2        Optioning and Commercial License Fees.

     8.2.1.    Optioning Fee. UCB shall pay to FivePrime a non-refundable
payment of *** dollars ($***) with respect to each Confirmed Hit selected by UCB as a UCB Reserved Protein (the “Optioning Fee”). Each such Optioning Fee shall be due within *** days after the relevant Claiming
Date; *** dollars ($***) ***. If UCB extends the applicable License Option Period for a given UCB Reserved Protein under Section 4.2.1, UCB shall pay to FivePrime a non-refundable payment of *** dollars ($***)
concurrent with notice of such election (the “Option Extension Fee”). 

    8.2.2.    Commercial License Fee. UCB shall pay to FivePrime a non-refundable payment
of *** dollars ($***) with respect to each UCB Reserved Protein for which UCB exercises a License Option pursuant to Section 4.3.2 (the “Commercial License Fee”). Each such Commercial License Fee shall be due
within *** days after the relevant License Effective Date 

8.3        Milestone Payments. UCB shall pay to FivePrime each of the following
non-refundable milestone payments upon the first occurrence of the indicated milestone event with respect to Licensed Products which are Therapeutics related to a given Licensed Protein, and no additional payments will be due FivePrime under this
Section 8.3 in the event of a subsequent repeated occurrence of the same milestone event with respect to the same or any other Licensed Product related to the same Licensed Protein. Each such milestone payment shall be due and payable to
FivePrime within *** days after the achievement of the relevant milestone event. 
  

					
	 Milestone Event
	  	 	Amount	  

	
Initiation of the first GLP Toxicology Study
	  	 	$	*** 
	
Initiation of the first Phase 1 Trial
	  	 	$	*** 
	
Initiation of the first Phase 2 Trial
	  	 	$	*** 
	
Initiation of the first Phase 3 Trial
	  	 	$	*** 
	 Filing
and acceptance of first BLA or NDA in the United States
	  	 	$	*** 
	 Filing
and acceptance of first BLA or NDA in European Union
	  	 	$	*** 
	 Filing
and acceptance of first BLA or NDA in Japan
	  	 	$	*** 
	 First
Commercial Sale in United States
	  	 	$	*** 
	 First
Commercial Sale in European Union (any ***)
	  	 	$	*** 
	 First
Commercial Sale in Japan
	  	 	$	*** 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 35 

 
					
	 Milestone Event
	  	 	Amount	  

	Upon the first occurrence of aggregate annual Net Sales of
Licensed Product in the Territory in a Calendar Year exceeding $***	  	 	$	*** 
	Upon the first occurrence of aggregate annual Net Sales of
Licensed Product in the Territory in a Calendar Year exceeding $***	  	 	$	*** 
	Upon the first occurrence of aggregate annual Net Sales of a
Licensed Product in the Territory in a Calendar Year exceeding $***	  	 	$	*** 

 The Parties acknowledge that the design of the clinical development program for a Licensed Product related to a
Licensed Protein is not intended to result in one of milestones in respect of initiating Clinical Trials being skipped over. For example, it is possible that the first Phase 2 Trial undertaken by UCB in such program is a hybrid study design, i.e.
that begins as a Phase 2 Trial but at an interim evaluation and decision point could be continued as a Phase 3 Trial. In such event, the milestone for initiation of the first Phase 2 Trial would be triggered at the start of the study and the
milestone for initiation of the first Phase 3 Trial would be triggered by a decision at such interim decision point to continue the trial as a Phase 3 Trial. 
 8.4        Royalties. 

    8.4.1.    Royalties for Licensed Products. UCB shall pay FivePrime royalties on a
Calendar Quarterly basis with respect to Net Sales in the Territory of Licensed Products which are Therapeutics during such Calendar Quarter, calculated on a Licensed Product-by-Licensed Product and country-by-country basis, as set forth in this
Section 8.4. 
  

			
	 Net Sales for the Relevant Calendar
Year
	  	Royalty Rate for 
such
 Portion of Net Sales

	Portion of aggregate worldwide Net Sales for
such
Licensed Product that is less than *** dollars ($***)	  	***%
	Portion of aggregate worldwide Net Sales for
such
Licensed Product that is equal to or greater than ***
dollars ($***) and less than *** dollars ($***)	  	***%
	Portion of aggregate worldwide Net Sales for
such
Licensed Product that is equal to or greater than ***
dollars ($***)	  	***%

 Notwithstanding the foregoing, in each country in which no Valid Claim of a FivePrime Background Patent,
Collaboration Patent or Protein Patent exists which covers the sale of a particular Licensed Product by UCB, its Affiliates or sublicensees, the applicable royalty rates for such Licensed Product in such country shall be reduced by ***
percent (***%) for so long as no such Valid Claim exists with respect to such Licensed Product in such country. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 36 

 For the aggregation of Net Sales for the purpose of determining the applicable royalty rate
under Section 8.4, all Combination Products and single-agent Licensed Products directed to or against or that incorporate or are derived from or that inhibit, activate or otherwise modulate the activity of the same Licensed Protein shall be
considered the same Licensed Products, regardless of the formulation, dosage strength, route of administration, packaging or product indication thereof or any other active ingredient(s) contained therein. *** 

8.4.2.    Royalty Term. UCB’s royalty payment obligations shall expire, on a Licensed
Product-by-Licensed Product and country-by-country basis, on the later of: (a) the tenth (10th) anniversary of the First Commercial Sale of such Licensed Product in such country; or (b) the expiration of the last-to-expire Valid Claim of any FivePrime Background Patents, Collaboration Patents
or Protein Patents which Valid Claim covers the sale of such Licensed Product in such country by UCB, its Affiliate or sublicensee (the “Royalty Term”). For the purpose of determining the applicable Royalty Term under this
Section 8.4.2, all Combination Products and single-agent Licensed Products directed to or against or that incorporate or are derived from or that inhibit, activate or otherwise modulate the activity of the same Licensed Protein shall be
considered the same Licensed Products, regardless of the formulation, dosage strength, route of administration, packaging or product indication thereof or any other active ingredient(s) contained therein. *** 

8.4.3.    Third Party Obligations. 

    (a)        Licenses Related to FivePrime IP.
FivePrime shall be solely responsible for paying any amounts due under any intellectual property licenses required from Third Parties to the extent required for: (i) either Party to practice the subject matter of the FivePrime Background
Patents or use FivePrime Background Know-How to perform its respective obligations under the Research Plan; or (ii) FivePrime to use the FivePrime Platform Technology to perform its obligations under the Research Plan. 

    (b)        Other Third Party Licenses. On a
country-by-country and Licensed Product-by-Licensed Product basis, in the event it is necessary for UCB to obtain a license under a Valid Claim of a Patent owned or controlled by a Third Party that covers a Licensed Protein in connection with the
development and commercialization of a Licensed Product related to such Licensed Protein, such that the sale of such Licensed Product in such country absent such license would otherwise infringe such Valid Claim of such Third Party Patent, then UCB
shall be solely responsible for obtaining such license and shall be responsible for payment of all the costs incurred in connection with obtaining such license. UCB shall have the right to credit and deduct *** percent (***%) of any
royalties actually paid by UCB to such Third Party under such license with respect to sales of Licensed Product in a given country against the royalty payments due to 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 37 

 
FivePrime under Sections 8.4.1 and 8.4.2; provided that the royalty payment to FivePrime on Net Sales of same Licensed Product in a given Calendar Quarter shall not be reduced below
*** percent (***%) of the royalties that would otherwise be due under this Section 8.4. 

    8.4.4.    Reports; Payment of Royalty. UCB shall keep, and shall cause its Affiliates
and Sublicensees to keep, complete and accurate books and records in sufficient detail to enable the royalties payable hereunder to be determined. During the Term, and following the First Commercial Sale of any Licensed Product, UCB shall within
*** days after the end of each Calendar Quarter furnish to FivePrime a written report for such Calendar Quarter based upon the data then available to UCB showing on a Licensed Product-by-Licensed Product basis: (i) for the U.S. and each
of the Major Markets, the gross sales of such Licensed Product(s) during such Calendar Quarter, the reconciliation of gross sales to Net Sales (including the deductions and adjustments), and the royalties due FivePrime for such Calendar Quarter, and
(ii) for sales in all other countries the gross sales of such Licensed Product(s) during such Calendar Quarter, the reconciliation of such gross sales to Net Sales during such Calendar Quarter, and the royalties due FivePrime for such Calendar
Quarter. UCB shall pay all royalties due under this Agreement with respect to a Calendar Quarter within *** days after the end of each Calendar Quarter. 
 8.5        Special Royalty Provisions. 
     8.5.1.    Commercial Terms for Diagnostics. The Parties acknowledge and agree that the milestone payment and royalty obligations set forth in Sections
8.3 and 8.4 shall not apply to the development or commercialization of Licensed Products which are Diagnostics. In the event that UCB (and/or its Affiliates or Sublicensees) intends to initiate commercialization and sales in the Territory of any
Licensed Product which is a Diagnostic, it shall notify FivePrime in writing to that effect at least *** prior to the planned launch of such Diagnostic in the Territory. The Parties shall promptly thereafter meet to negotiate in good faith
and agree in writing upon mutually acceptable royalty rates that will be used to determine the royalties that will be paid to FivePrime on Net Sales of such Diagnostic Licensed Product in the Territory (the “Diagnostic Royalties”).
The Parties acknowledge and agree that the Diagnostic Royalties will be generally consistent with benchmark royalty rates for similar licensing arrangements in the diagnostic industry***. 

    8.5.2.    Royalties on Certain Other Products. The terms of this Section 8.5.2
shall apply in the event that UCB (and/or its Affiliates or Sublicensees), resulting from UCB Independent Research, commercializes a Therapeutic with respect to a Non-Selected Protein or Terminated Protein in one or more countries in the Territory
in which the sales of such Therapeutic are covered by a Valid Claim of a Protein Patent and/or a Collaboration Patent. In such event, UCB shall pay royalties to FivePrime on sales of such Therapeutic in such country during the term of such Protein
Patent or Collaboration Patent, whichever is longer. The 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 38 

 
applicable royalty payments shall be determined based upon the relevant sales of such Therapeutic, where such relevant sales shall be determined in the same manner as Net Sales of Licensed
Products. The applicable royalty rate to be applied in calculating such royalty payments shall be *** percent (***%) of the corresponding royalty rate set forth in the table in Section 8.4.1 that would apply with respect to
Licensed Products. Any royalty payments due under this Section 8.5.2 shall be paid quarterly in a manner consistent with the terms of Section 8.4.4 and in accordance with the terms of Section 8.6, 8.7, 8.8 and 8.9. Such royalty
obligations will expire in each country upon expiration of the relevant Protein Patent or Collaboration Patent. 

8.6        Payment Date. If UCB fails to timely pay any undisputed fees, milestone
payments, royalties or any other payments due according to this Agreement, interest on such undisputed amount shall accrue at an annual rate of interest equal to ***% above the average rate of the *** months LIBOR as published in the
Wall Street Journal, Eastern U.S. Edition, effective for the applicable days of the period of default. 

8.7        Financial Audits. Upon *** days prior written request of FivePrime and
not more than *** in each ***, UCB shall permit an independent certified public accounting firm of nationally or internationally recognized standing selected by FivePrime and reasonably acceptable to UCB to have reasonable access
during normal business hours to inspect such relevant books and records as may be reasonably necessary to verify the accuracy of royalty payments made hereunder. Any such audit shall be limited to the most recent period of *** consecutive
Calendar Years ended prior to the date of such request, and shall include the relevant results and records in UCB’s or its Affiliates possession of any audits conducted by or on behalf of UCB of its Third Party sublicensees during such period.
The accounting firm shall, upon request by UCB, enter into a confidentiality agreement with UCB on mutually acceptable terms. The accounting firm shall only disclose to FivePrime whether the royalty reports are correct or incorrect, the details and
amount of any discrepancy. The auditors will also provide a copy of any audit reports and findings that are provided to FivePrime as a result of such inspection. 

    (a)    Underpayments or Overpayments. If such accounting firm
correctly identifies an underpayment or overpayment of royalties made by UCB during such period, UCB shall pay FivePrime the amount of the underpayment within *** days of the date FivePrime delivers to UCB such accounting firm’s written
report so concluding, and any overpayments will be fully creditable against amounts payable to FivePrime in subsequent periods. For clarity, upon expiration of the *** year period following the end of a Calendar Year, and absent willful
misconduct or fraud on the part of UCB or its Affiliates or Sublicensees, the calculation of royalties payable by UCB to FivePrime under this Agreement with respect to such Calendar Year shall be binding and conclusive on the Parties. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 39 

    (b)        Costs of Audits. FivePrime shall be
solely responsible for the costs and expenses of any audits conducted pursuant to this Section 8.7, including without limitation the fees charged by such accounting firm; provided, however, if such audit identifies an underpayment
of royalties by UCB that exceeds *** percent (***%) of the aggregate total of all royalty payments due for the period under audit, then UCB shall reimburse FivePrime for the documented, reasonable audit fees of such accounting firm.

 8.8        Payment Method and Exchange Rate. UCB shall pay all amounts due
hereunder in United States dollars by wire transfer of immediately available funds to the bank account FivePrime designates by written notice from time to time. In the case of any amounts payable or receivable in a foreign currency, the rate of
exchange to be used in calculating on a monthly basis the applicable royalty due FivePrime shall be the monthly rate of exchange utilized by UCB in its worldwide accounting system, as prevailing on the third to last Business Day of the month
preceding the month in which the relevant sales are recorded. 

8.9        Withholding Tax. If applicable Law requires withholding of any income taxes or
other taxes imposed upon FivePrime on account of any amounts paid to FivePrime under this Agreement, then UCB shall withhold such taxes as required by such Law from such payments and timely pay such withheld taxes to the proper tax authorities. UCB
shall promptly secure official receipts of payment of any withholding tax and send such receipts to FivePrime as evidence of such payment. UCB shall reasonably cooperate with FivePrime in the event FivePrime claims exemption from such withholding or
seeks deductions under any double taxation or other similar treaty or agreement from time to time in force. The foregoing notwithstanding, UCB shall be responsible for any incremental increase in non-exempt and non-recoverable withholding taxes
imposed upon FivePrime on account of any amounts paid to FivePrime under this Agreement which are incurred as a direct result of UCB assigning this Agreement pursuant to Section 14.2 to a non-Belgian entity without FivePrime’s prior
written consent. 
 9.      Confidentiality and Publication. 

9.1        Confidential Information. “Confidential Information” means any
and all proprietary or confidential data, information or Know-How Controlled by a Party (the “Disclosing Party”) and which is disclosed or otherwise made available, whether in writing, visually, orally or in electronic medium, to
the other Party (the “Receiving Party”) in connection with this Agreement. Collaboration Know-How or non-public information related to Collaboration Patents shall be treated as Confidential Information of both Parties, except to the
extent it is exclusively licensed to UCB pursuant to Section 6.1.2, during the term of which it shall be treated as Confidential Information of UCB. The terms of this Agreement shall be the Confidential Information of both Parties and both
Parties shall have the obligations set forth in this Section 9 with respect thereto. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 40 

 9.2      Nondisclosure Obligation.  Subject to
Sections 9.3 and 9.4, unless the Disclosing Party provides prior written consent, the Receiving Party shall maintain in confidence all Confidential Information of the Disclosing Party, shall not disclose such Confidential Information to any Third
Party and shall not use such Confidential Information for any purpose except to exercise such Party’s rights or fulfill its obligations under this Agreement. The Receiving Party may disclose or otherwise provide access to the Disclosing
Party’s Confidential Information to its and its Affiliates’ respective officers, directors, employees, agents, consultants, permitted (sub)licensees, and Contractors (“Agents”) as necessary in connection with the exercise
of its rights and/or performance of its obligations under this Agreement; provided that such individuals are subject to obligations of confidentiality and non-use which are consistent with the terms of this Agreement. The Receiving Party
shall be responsible for and liable under this Agreement with respect to any breach of its confidentiality and non-use obligations caused by its Agents. 
 9.3      Exceptions.  Each Party’s confidentiality and non-use obligations under this Agreement shall not apply to any portion of the Confidential
Information of the Disclosing Party that: 
   9.3.1.    Is known by the Receiving Party
at the time of its receipt, without obligation of confidentiality or non-use, and not through a prior confidential disclosure by the Disclosing Party, as documented by the Receiving Party’s written records; 

  9.3.2.    Is in the public domain before its receipt from the Disclosing Party, or thereafter
enters the public domain through no fault of the Receiving Party; 
   9.3.3.    Is
subsequently disclosed to the Receiving Party, without obligation of confidentiality or non-use, by a Third Party who may lawfully do so and who is not under an obligation of confidentiality to the Disclosing Party; or 

  9.3.4.    Is developed by the Receiving Party independently of Confidential Information received
from the Disclosing Party and without the aid, application or use of the Disclosing Party’s Confidential Information, and such independent development can be properly documented by the Receiving Party. 

Any combination of features or disclosures shall not be deemed to fall within the foregoing exclusions merely because individual features are published
or available to the general public or in the rightful possession of the Receiving Party unless the combination itself and principle of operation are published or available to the general public or in the rightful possession of the Receiving Party.

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 41 

 9.4    Permitted Disclosure.  Nothing in this Section 9
shall restrict the Receiving Party from disclosing Confidential Information of the Disclosing Party to the extent that such disclosure: 
 9.4.1.    Is made to governmental or other regulatory agencies in order to obtain Collaboration Patents, Protein Patents or UCB Product Patents, in each case which such Party
expressly has the right to obtain under the terms of this Agreement; provided that such disclosure is limited to the extent reasonably necessary to obtain such patents or authorizations and the Receiving Party takes reasonable measures to
obtain confidential treatment from regulatory agencies for such information; 
 9.4.2.    In the
case where UCB is the Receiving Party, is made to Regulatory Authorities in the Territory on or after the applicable License Effective Date in connection with any INDs, NDAs, BLAs or other similar authorizations to conduct clinical trials and/or to
obtain or maintain any Marketing Authorizations for Licensed Products; provided that such disclosure is limited to the extent reasonably necessary to obtain such authorizations; 

9.4.3.    In the case where FivePrime is the Receiving Party and solely with respect to Confidential
Information constituting Collaboration Know-How or Protein Know-How to the extent specifically related to a Non-Selected Protein or Terminated Protein, is made to Regulatory Authorities in the Territory in connection with any INDs, NDAs, BLAs or
other similar authorizations to conduct clinical trials and/or to obtain or maintain any Marketing Authorizations for Therapeutics or Diagnostics with respect to such Non-Selected Protein or Terminated Protein; provided that such disclosure
is limited to the extent reasonably necessary to obtain such authorizations; 
 9.4.4.    Is
required to comply with applicable Law, valid order of a court of competent jurisdiction, or other judicial or administrative process of governmental authority or agency, provided that the Receiving Party shall (i) promptly inform the
Disclosing Party of the disclosure that is being sought in order to provide the Disclosing Party, where possible, an opportunity to challenge, limit or receive confidential treatment for the required disclosure, (ii) upon request, reasonably
cooperate with any efforts by the Disclosing Party to challenge, limit or receive confidential treatment for, the required disclosure, and (iii) only disclose the minimum Confidential Information necessary to comply, as determined by the
Receiving Party’s legal counsel. 
 9.5        Strategic Transactions;
Investors.  Each Party shall have the right to disclose non-public information related to the terms and conditions of this Agreement solely if and to the extent necessary (as reasonably determined by its legal counsel) to be disclosed in
the context of a Strategic Transaction, to Third Parties and their counsel with whom such Party is negotiating a Strategic Transaction or to accredited investors, qualified institutional buyers, and qualified purchasers and their counsel as such
terms are defined in the United States securities Laws and each of whom is subject to written obligations of confidentiality no less restrictive than those set forth in this Agreement. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 42 

 9.6        Publicity.  Promptly
following the Effective Date, the Parties will issue a joint public announcement of the execution of this Agreement in the form of the press release attached hereto as Exhibit C and on such date and time as may be agreed by the Parties. Any
other proposed publication, news release or other public announcement by a Party relating to this Agreement, the terms and conditions set forth herein, or to the performance hereunder that would disclose information other than that already expressly
in the public domain prior to such publication, news release or other public announcement, shall only be made with the prior written consent of the other Party. For clarity, neither Party shall be obligated to obtain consent to re-issue or reiterate
information previously specifically disclosed with the consent of the other Party. Notwithstanding the foregoing, each Party shall have the right to disclose any such information that it is specifically required to disclose in order to comply with
applicable securities laws in the Territory. For each such disclosure, the Party required to disclose such information shall provide the other Party with a draft of such disclosure at least *** Business Days prior to its intended release and
shall consider in good faith any comments from the other Party with respect thereto. 

9.7        Publications.  As between the Parties, UCB shall have the sole and
exclusive right to publish manuscripts, abstracts, presentations or other articles in scientific journals or at scientific conferences relating to any Licensed Protein or Licensed Product without obtaining the prior written consent of FivePrime. UCB
shall provide FivePrime with a copy of any such manuscript, abstract, presentation or other article. FivePrime shall have the right to publish manuscripts, abstracts, presentation or other articles in scientific journals or at scientific conferences
relating to any Non-Selected Protein or Terminated Protein without obtaining the prior written consent of UCB; provided, however, that FivePrime shall not have any right to name or otherwise refer to UCB, its Affiliates, or any of its
or their employees without the prior written consent of UCB. In the event that either Party desires to make a publication pursuant to this Section 9.6, such Party shall provide a copy of the proposed publication (including abstracts, or
presentation to a journal, editor, meeting, seminar or other third party) to the other Party for comment at least *** days prior to its planned submission. If, during the *** days specified above the non-publishing Party notifies the
other Party that a proposed publication contains patentable subject matter which requires protection, the non-publishing Party shall delay the publication for a period of time not to exceed *** days from the date of such written notice to
seek appropriate patent protection for any subject matter in such publication that it reasonably believes may be patentable. The publishing Party shall delete from the proposed publication prior to submission all Confidential Information of the
non-publishing Party that the non-publishing Party identifies in good faith and requests to be deleted. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 43 

 10.    Intellectual Property. 

10.1    Ownership of Inventions.  FivePrime and UCB shall each own an undivided one-half right, title and
interest in and to the Collaboration Patents and Collaboration Know-How. Except to the extent that Collaboration Know-How and Collaboration Patents are exclusively licensed to UCB under this Agreement or as may otherwise be expressly set forth
herein, each Party may exploit, license, or sublicense (with the right to further sublicense) the Collaboration Know-How and Collaboration Patents without the consent of, or a duty of accounting to, the other Party. 

10.2    Filing, Prosecution and Maintenance of Patents. 

  10.2.1. Rights and Responsibilities with Respect to Certain Patents. 

      (a)    As between the Parties, FivePrime shall have the
sole right, at its sole discretion and expense, and outside of the scope of review by the JPC, to prepare, file, prosecute and maintain: (i) FivePrime Platform Patents; and (ii) FivePrime Background Patents. For clarity, in no event shall
UCB obtain the rights to prepare, file, prosecute or maintain Patents Controlled by FivePrime that are directed to FivePrime Platform Technology, FivePrime Background Know-How, or any Excluded Protein. 

      (b)    As between the Parties, UCB shall have the sole
right, at its discretion and expense, and outside of the scope of review by the JPC, to prepare, file, prosecute and maintain all Patents constituting UCB IP. 
   10.2.2. Collaboration Patents.  The Parties will be jointly responsible for, and shall cooperate through the JPC to control the preparing, filing, prosecuting and maintaining of
all Collaboration Patents, with each Party bearing ***% of the reasonable, documented out-of-pocket costs and expenses incurred in connection with the preparation, filing, prosecution and maintenance of such Collaboration Patents, including
without limitation the costs of Outside Counsel incurred with respect thereto. However, if one Party desires not to pursue patent protection with respect to certain Collaboration Know-How or Collaboration Patents it shall notify the other Party to
that effect. In such event, if the other Party desires to pursue such protection, then such other Party shall have the right to instruct Outside Counsel to prepare, file, prosecute and maintain such Collaboration Patents at such other Party’s
sole expense and sole discretion, and outside the scope of the JPC. 
   10.2.3. Cooperation.  In
connection with the preparation, filing, prosecution and maintenance of Collaboration Patents under Section 10.2.2, each Party shall have a reasonable opportunity to review, prior to filing, the draft text of each Collaboration Patent
application, and the draft text of the proposed response to each office action or substantive prosecution document 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 44 

 
(after the initial application is filed) for each such Collaboration Patent. The JPC and Outside Counsel shall consult with respect thereto, and each Party’s reasonable comments will be
taken into account when finalizing any such documents, provided such comments are provided in a timely manner. Each Party shall, as requested by Outside Counsel, cooperate in filing and prosecuting such Collaboration Patent, including
providing Outside Counsel and with such Collaboration Know-How as appropriate and executing all necessary paperwork. Outside Counsel shall keep each Party advised of the status of each Collaboration Patent, and shall promptly give notice to each
Party of the grant, lapse, revocation, surrender, invalidation, or abandonment of any such Collaboration Patent. The foregoing notwithstanding, in the event that one Party elects, in accordance with Section 10.2.2, not to pursue and share costs
to prepare, file, prosecute and maintain a given Collaboration Patent or to pursue patent protection with respect to Collaboration Know-How, then such non-paying Party shall have no further rights under this Section 10.2.3 to participate in any
aspects of the preparation, filing, prosecution and maintenance of the relevant Collaboration Patents. For clarity, in the event that the Parties use any Protein Know-How to prepare, file or otherwise support a Collaboration Patent, such use of
Protein Know-How shall not result in such Collaboration Patent being deemed a Protein Patent or cause such Protein Know-How to be treated as Collaboration Know-How. 
 10.2.4. Certain Actions.  All interferences, post-grant reviews, inter partes reviews, ex parte reviews, supplemental examinations, oppositions, appeals or petitions to any Board of
Appeals in the patent office, the Patent Trial and Appeal Board, appeals to any court for any patent office decisions, reissue proceedings and re-examination proceedings with respect to a Patent shall be considered patent prosecution matters and
shall be handled in accordance with this Section 10.2. 
 10.3    Enforcement and Defense.

 10.3.1. Each Party shall give the other Party written notice of any actual or threatened infringement of any
FivePrime Background Patents or Collaboration Patents by an unlicensed Third Party through the making, having made, using, selling, offering for sale or importing of any product that is within the scope of a Commercial License held by UCB (a
“Product Infringement”), within *** days after such Party has knowledge of such Product Infringement. UCB and FivePrime shall thereafter consult and cooperate to determine a course of action, including the commencement of
legal action by either or both UCB and FivePrime, to terminate any such Product Infringement. However, UCB, upon notice to FivePrime, shall have the first right to initiate and prosecute such legal action at its expense and in the name of FivePrime
or UCB, or to control the defense of any declaratory judgment action relating to such Product Infringement, provided that UCB shall not enter into any settlement or compromise that would materially diminish or adversely affect the scope,
exclusivity or duration of any FivePrime Background Patents, Collaboration Patents or FivePrime’s rights under this Agreement, without FivePrime’s prior written consent. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 45 

 10.3.2. In the event that UCB elects not to initiate and prosecute an action
pertaining to a Product Infringement, and FivePrime elects to do so, FivePrime shall bear the costs of any agreed-upon course of action to terminate such Product Infringement, including the costs of any legal action commenced or the defense of any
declaratory judgment, except that FivePrime shall not be responsible for any costs incurred by UCB unless such costs were incurred at FivePrime’s written request. FivePrime shall have the right to join UCB as a party to such action if UCB is a
necessary party to such action. 
 10.3.3. In connection with any action under this Section 10.3, UCB and FivePrime
will reasonably cooperate and will provide each other with any information or assistance that either may reasonably request. Each Party shall keep the other informed of developments in any such action or proceeding, including, to the extent
permissible by applicable Law, consultation on and approval of any settlement, the status of any settlement negotiations and the terms of any offer related thereto. Each Party shall have the right to be represented by counsel of its own choice at
its own expense for any action set forth in this Section 10.3. 
 10.3.4. If a Party desires to bring an
enforcement action under a Collaboration Patent, but is unable to do so solely in its own name, the other Party will, at the request of the enforcing Party, join such action as a party and will reasonably cooperate and cause its Affiliates to
reasonably cooperate to execute all documents necessary for the enforcing Party to initiate litigation to prosecute and maintain such action. 
 10.3.5. Any recovery obtained by either or both UCB and FivePrime in connection with or as a result of any action contemplated by this Section 10.3, whether by settlement or otherwise, shall
be shared in order as follows: 
     (a)      The
Party which initiated and prosecuted the action shall recoup all of its costs and expenses incurred in connection with the action; 
     (b)      The other Party shall then, to the extent possible, recover its costs and expenses incurred in connection with the action; and

     (c)      The Party initiating such action shall
retain any remainder, and in the event UCB is such Party, such remainder shall be deemed Net Sales and subject to the royalty payments to FivePrime under Section 8.4. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 46 

 11.    Representations, Warranties and Covenants. 

11.1    Representations and Warranties of Each Party.  Each Party represents and warrants to the other
Party that as of the Effective Date that: 
   11.1.1. It has the full right, power and authority to enter
into this Agreement and to perform its obligations hereunder; 
   11.1.2. This Agreement has been duly
executed by it and is legally binding upon it, enforceable against such Party in accordance with its terms, except as such enforceability may be subject to applicable bankruptcy, reorganization, insolvency, moratorium and similar Laws affecting the
enforcement of creditors’ rights generally and by general principles of equity; and 
   11.1.3. The
execution and delivery by such Party of this Agreement does not conflict in any material fashion with the terms of any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any
material applicable Law. 
 11.2    FivePrime Representation and Warranties.  FivePrime
represents and warrants to UCB that as of the Effective Date: 
   11.2.1. It has the full right, power and
authority to grant the licenses granted under this Agreement; 
   11.2.2. It has not previously assigned,
transferred, conveyed, exclusively licensed, or otherwise encumbered its right, title and interest in FivePrime Background Know-How or FivePrime Background Patents, if any, in any manner that would prevent it from granting the licenses set forth in
Section 6.1; 
   11.2.3. To the best of its knowledge, none of the Excluded Proteins are *** for
***. 
   11.2.4. FivePrime has not received any written notification alleging that the use of the
FivePrime Platform Technology and the FivePrime Background Know-How in performance of the Research Plan will infringe the patents or other intellectual property rights of any Third Party. 

11.3    UCB Representation and Warranties.  UCB represents and warrants to FivePrime that as of the
Effective Date: 
   11.3.1. It has the full right, power and authority to grant the licenses under this
Agreement; 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 47 

   11.3.2. It has not previously assigned, transferred, conveyed or
otherwise encumbered its right, title and interest in UCB Background Know-How or UCB Background Patents, if any, in any manner that would prevent it from granting the licenses set forth in Section 6.2; and 

  11.3.3. To the best of its knowledge, the use of the UCB Assays and the UCB Background Know-How in performance of the
Research Plan will not infringe the patents or other intellectual property rights of any Third Party. 

11.4    Covenants.  During the Research Term, neither Party will knowingly use any material, technology
or intellectual property rights in the conduct of the Research Plan that, to its knowledge, is encumbered by any Third Party restriction or any Third Party right or obligation that would conflict or interfere with any of the rights or licenses
granted to, or to be granted to, the other Party hereunder. As part of any amendment to the Research Plan by the JSC, the JSC members of each Party shall inform the JSC members of the other Party of any potential Third Party Patents or proprietary
Know-How that may be required to perform any activity to be added to the Research Plan as a result of such amendment, and the Parties shall discuss in good faith, and take into consideration and agree on a strategy on such Third Party Patents or
proprietary Know-How in finalizing the amendment to the Research Plan. 
 11.5    Warranty
Disclaimer.  EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS SECTION AGREEMENT, NEITHER PARTY MAKES ANY WARRANTY WITH RESPECT TO ANY PATENTS, KNOW-HOW, LICENSES, TECHNOLOGY, OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND HEREBY DISCLAIMS ANY
IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT WITH RESPECT TO ANY AND ALL OF THE FOREGOING. 

12.    Term and Termination. 
 12.1    Term and Expiration.  The term of this Agreement (the “Term”) shall commence on the Effective Date and, unless terminated earlier pursuant to this
Section 12, shall expire on a Licensed Product-by-Licensed Product and country-by-country basis upon the expiration of all payment obligations under Section 8, after which the licenses granted by FivePrime to UCB in Section 6 with
respect to such Licensed Product in such country shall become fully paid-up, perpetual and non-exclusive. 

12.2    Termination at Will.  UCB shall have the right, in its sole discretion, to terminate this
Agreement in its entirety, or on a Licensed Protein-by-Licensed Protein basis, in each case without cause and at any time during the Term, by giving FivePrime *** days prior written notice to that effect. Any such “at will”
termination by UCB shall be effective as of the end of such *** day period. In the event that such notice of termination occurs during the Research Term, FivePrime shall upon receipt of such notice use reasonable efforts to undertake and
complete during such notice period an orderly wind down of its then ongoing efforts under the Research Plan. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 48 

 12.3    Termination for Cause.  In the event that a Party is
in breach of one or more of its material obligations hereunder, the other Party shall have the right at any time during the Term to terminate this Agreement in its entirety, or on a Licensed Protein-by-Licensed Protein basis as determined at the
non-breaching Party’s discretion if and to the extent that such breach is only related to a specific Licensed Protein (and/or Licensed Products with respect thereto), by providing the breaching Party with written notice to that effect. Any such
notice of termination shall clearly set forth the nature of the alleged breach and such termination shall automatically be effective *** days after the date of such notice (or *** days in the event of a failure to timely make payment
of any amounts properly due hereunder) unless the breach is cured during such notice period. In the event of a good faith dispute between the Parties with respect to the existence of a material breach which is being resolved pursuant to
Section 14.6, the applicable notice period shall be tolled pending the outcome of such dispute resolution procedures. 

12.4    Termination for Bankruptcy.  A Party may terminate this Agreement in its entirety, if, at any
time during the Term, the other Party undertakes or experiences any of the following insolvency events: (i) files in any court or agency pursuant to applicable Law, a petition in bankruptcy or insolvency or for reorganization or winding up, or
for an arrangement or for the appointment of a receiver or trustee of the Party or of substantially all of its assets; (ii) proposes a written agreement of composition or extension of substantially all of its debts; (iii) is served with an
involuntary petition against it, filed in any insolvency proceeding, and such petition shall not be dismissed within *** days after the filing thereof; (iv) proposes or be a party to any dissolution or liquidation; or (v) makes an
assignment of substantially all of its assets for the benefit of creditors. Any such termination shall be upon written notice to the insolvent Party to that effect, which termination shall be immediately effective as of the date of such notice. The
Parties agree that all rights and licenses granted under or pursuant to any section of this Agreement are and shall otherwise be deemed to be for purposes of 11 U.S.C. §365(n), and under any analogous Laws in other countries in the Territory,
licenses of rights to “intellectual property” as defined in 11 U.S.C. §101(35A). The Parties shall retain and may fully exercise all of their respective rights and elections under the Bankruptcy Code of the United States and/or any
other analogous applicable Laws in the Territory. Upon the insolvency of a Party, the other Party shall further be entitled to a complete duplicate of, or complete access to, any such intellectual property that is licensed to it hereunder, which
intellectual property shall, if not already in its possession, be promptly delivered to the non-bankrupt Party, unless the bankrupt Party elects to continue, and continues, to perform all of its obligations under this Agreement. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 49 

 12.5 Additional Termination Rights.  FivePrime shall promptly notify UCB in
writing in the event that FivePrime becomes subject to an injunction or other similar court order during the Research Term which has the effect of preventing FivePrime from using any material elements of the FivePrime Platform Technology to screen
the FivePrime Library in accordance with the Research Plan. In such event, UCB shall have the right, in its sole discretion, to terminate this Agreement in its entirety and without cause, such termination to be effective immediately upon delivery of
written notice to FivePrime to that effect. 
 12.6    Consequences of Termination. 

  12.6.1. Effect of Expiration or Termination Generally.  The expiration or early termination of this Agreement
pursuant to this Article 12 shall not relieve the Parties of any of their respective obligations accruing under this Agreement prior to such expiration or termination. In the case of any termination pursuant Sections 12.2, 12.3 or 12.4, the date on
which such termination becomes effective is referred to herein as the “Termination Date”. UCB shall remain responsible for any unsatisfied financial obligations under Article 8 that were incurred or accrued prior to, as applicable,
the expiration of this Agreement or the Termination Date. However, for clarity, in the event of termination of this Agreement UCB shall not have any obligation to FivePrime with respect to any of the following payments: (i) any technology
access fees or research funding payments pursuant to Sections 8.1.2 or 8.1.3 which have not become due and payable prior to the Termination Date; (ii) any Optioning Fees or Commercial License Fees pursuant to Section 8.2 with respect to,
as applicable, any Confirmed Hits or UCB Reserved Proteins with respect to which UCB has not prior to the Termination Date provided FivePrime with written notice exercising, respectively, the Claiming Option or the License Option; or (iii) any
milestone payments under Sections 8.1.5 or 8.3 with respect to milestone events which have not occurred prior to the Termination Date. 
   12.6.2. Effects of “At Will” Termination.  In the event UCB terminates this Agreement under Section 12.2 or 12.5, then the terms of this Section 12.6.2 shall
govern the rights and obligations of the Parties. To the extent such termination only applies to a particular Licensed Protein, then the applicable provisions of this Section 12.6.2 shall apply solely with respect to such Licensed Protein (and
all Licensed Products with respect thereto), and shall not affect the rights and obligations of the Parties under this Agreement with respect to any other Licensed Proteins, and Licensed Products related thereto. 

    (a)    Within *** days after the Termination Date, UCB shall
pay all uncontested amounts payable to FivePrime hereunder that have accrued but have not been paid as of the Termination Date. 
     (b)    In the event of termination of the Agreement, all remaining Confirmed Hits and UCB Reserved Proteins shall as of the Termination Date become
Non-Selected Proteins, and the provisions of Section 6.4.5 shall thereafter apply with respect thereto. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 50 

     (c)    Effective as of
the Termination Date, the Licensed Proteins shall become Terminated Proteins, all of the licenses that were granted to UCB under Section 6.1 with respect to such Terminated Proteins shall be cancelled, and all such rights shall automatically
revert to FivePrime. In addition, UCB shall not thereafter use the Collaboration Patents and non-public Collaboration Know-How in connection with the development, manufacture or commercialization of any Terminated Protein and/or Therapeutics or
Diagnostics with respect thereto. UCB further covenants that it and its Affiliates will not thereafter perform or have performed on its behalf, any research, development or commercial activities for any Therapeutic or Diagnostic with respect to any
Terminated Protein; provided, however, that this restriction shall not apply to or otherwise limit the scope of any activities within the UCB Independent Research. 

    (d)    Disposition of Confidential Information.  No later than
*** days after the Termination Date, each Receiving Party shall return to the Disclosing Party (or, at the Disclosing Party’s request, shall destroy) all of the Disclosing Party’s Confidential Information (including all copies
thereof) that are in such Party’s possession; provided, however, that the Receiving Party may retain one (1) archival copy of the Disclosing Party’s Confidential Information in its confidential files solely for purposes
of identifying its continuing obligations under this Agreement with respect thereto. However, to the extent that UCB retains a Commercial License to one or more Licensed Proteins after the Termination Date, UCB may retain any Confidential
Information received from FivePrime that is within the scope of such continuing license. 

    (e)    Disposition of Materials.  No later than *** days
after the Termination Date, each Materials Receiving Party shall return to the Materials Transferring Party (or, at the Materials Transferring Party’s request, shall destroy) all of the Materials Transferring Party’s Materials (including
all progeny or derivatives thereof) that are remaining in such Party’s possession. However, to the extent that UCB retains a Commercial License to one or more Licensed Proteins after the Termination Date, UCB may retain any Materials received
from FivePrime that are within the scope of such continuing license. 

    (f)    Royalties.  In the event that UCB successfully develops
through the performance of UCB Independent Research and thereafter commercializes a Therapeutic with respect to a Terminated Protein, then UCB shall pay royalties to FivePrime pursuant to Section 8.5.2 on sales of such Therapeutic in such
countries (if any) in which there is a Protein Patent and/or a Collaboration Patent having a Valid Claim which covers the sale of such Therapeutic in such country. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 51 

     (g)    Provisions Regarding
Licensed Products.  The provisions of this Section 12.6.2(g) shall only apply in the event that UCB had, prior to the Termination Date, achieved one or more of the milestone events set forth in Section 8.3 with respect to a
Licensed Product related to a Terminated Protein. In such event, FivePrime shall have the option to request a license from UCB to develop, manufacture and commercialize Therapeutics and/or Diagnostics related to such Terminated Protein, on terms and
conditions to be agreed upon by the Parties. Such option may be exercised by FivePrime, in its sole discretion, at any time during a period of *** days after the Termination Date, by providing UCB with written notice to that effect. Following
receipt of such notice, the Parties will promptly meet to discuss in good faith and negotiate over a period of *** days the terms of such a license under the relevant Protein Patents, Protein Know-How, UCB Product Patents and UCB Product
Know-How. Nothing herein shall be construed as obligating either Party to enter into any such agreement on terms and conditions which are not acceptable to it, and each Party shall have the right to unilaterally discontinue all discussions and
negotiations with respect to such a transaction at any time after the end of such *** day negotiation period and without obligation or liability to the other Party. 
 12.6.3. Effects of Termination for Breach.  The termination of this Agreement by the non-breaching Party pursuant to Section 12.3 shall be without prejudice to any of the other rights and
remedies that may be available to such Party, whether at law or equity. To the extent such termination only applies to a particular Licensed Protein, then the applicable provisions of this Section 12.6.3 shall apply solely with respect to such
Licensed Protein (and all Licensed Products with respect thereto), and shall not affect the rights and obligations of the Parties under this Agreement with respect to any other Licensed Proteins, and Licensed Products related thereto. 

    (a)    Termination by FivePrime.  In the event that FivePrime
terminates this Agreement under Section 12.3 for UCB’s uncured material breach, then the rights and obligations of the Parties shall be the same as those set forth above in Section 12.6.2(a)-(g). 

    (b)    Termination by UCB.  In the event that UCB terminates
this Agreement under Section 12.3 for FivePrime’s uncured material breach, UCB’s licenses according to Section 6.1 shall remain in full force and effect on its own terms, provided that UCB fulfills its payment obligations
and other obligations under Section 8 net of any money damages for which FivePrime was found liable in any Arbitration with respect to such uncured material breach. In addition, and without limiting the foregoing, in the event that such
termination was the result of a breach by FivePrime during the Research Term of one or more of its obligations under Sections 3.5.6, 6.4.2 or 6.4.3, then all remaining unpaid milestone payments under Section 8.3 and future royalties under
Section 8.4 with respect to the first Licensed Product to be developed by UCB shall be reduced to *** percent (***%) of the amounts set forth therein. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 52 

 12.6.4. Effects of Termination for Bankruptcy.  The Parties intend that during
the relevant License Option Period, each License Option shall be treated as an existing license to intellectual property for purposes of section 12.4. Accordingly, in the event that this Agreement is terminated pursuant to Section 12.4 during
the relevant License Option Period with respect to one or more UCB Reserved Proteins, then the following shall apply: (i) UCB shall have the right to complete its evaluation and validation of such UCB Reserved Protein and to thereafter exercise
the License Option and obtain a Commercial License with respect thereto; (ii) all of the Parties respective rights and obligations under this Agreement with respect to such UCB Reserved Protein shall survive such termination and remain in full
force and effect during the remainder of such License Option Period; and (iii) in the event that UCB exercises the License Option in accordance with the terms of Section 4.3, then such UCB Reserved Protein shall thereafter be treated as a
Licensed Protein and the Commercial License with respect thereto shall be treated as a pre-existing license to intellectual property under the terms of Section 12.4. 
 12.7     Survival.  The provisions set forth in Sections 3.5.2, 3.5.3, 3.5.4, 3.5.5, 6.1.4(b), 6.3, 6.4.4, 6.4.5, 8.6, 8.7, 8.8, 8.9, 9, 10.1, 10.2, 11.5, 12.6, 12.7, 13
and 14 shall survive any expiration or early termination of this Agreement for the time periods set forth therein and if no such time period is specified, then indefinitely. 
 13.       Indemnification. 
 13.1
    Indemnification by FivePrime.  FivePrime shall indemnify, defend and hold UCB, its Affiliates, and its and their respective agents, employees, officers and directors (each a “UCB Indemnitee”)
harmless from and against any and all Third Party claims, suits, actions, demands, judgments, liabilities, expenses or losses, including reasonable legal expenses and attorneys’ fees (collectively, “UCB Losses”), to which any
UCB Indemnitee may become subject to the extent such UCB Losses are directly or indirectly caused by or otherwise arise out of or in connection with: (a) the performance by FivePrime (and/or its Affiliates, or permitted sublicensees or
subcontractors) of FivePrime’s obligations under this Agreement; (b) the material breach of any obligation, covenant, representation, warranty or other binding agreement made by FivePrime in this Agreement; or (c) the negligence or
willful misconduct of FivePrime or its Affiliates, except, in each case, to the extent such UCB Losses are caused by the negligence or willful misconduct of any UCB Indemnitee. 

13.2     Indemnification by UCB.  UCB shall indemnify, defend, and hold FivePrime, its Affiliates, and
its and their respective agents, employees, officers and directors (each a “FivePrime Indemnitee”) harmless from and against any and all Third Party claims, suits, actions, demands, judgments, liabilities, expenses, or losses,
including reasonable legal expenses and attorneys’ fees (collectively, “FivePrime Losses”) to which any FivePrime Indemnitee may 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 53 

 
become subject to the extent such FivePrime Losses are directly or indirectly caused by or otherwise arise out of or in connection with: (a) the performance by UCB (and/or its Affiliates, or
permitted sublicensees or subcontractors) of UCB’s obligations under this Agreement; (b) the development, manufacture, use, sale, offering for sale, distribution, export, import or other commercialization of Licensed Products pursuant to
this Agreement; (c) the material breach of any obligation, covenant, representation, warranty or other binding agreement made by UCB in this Agreement; or (d) the negligence or willful misconduct of UCB or its Affiliates, except, in each
case, to the extent such FivePrime Losses are caused by the negligence or willful misconduct of any FivePrime Indemnitee. 

13.3     Notice of Indemnification Obligation and Defense.  (As used in this Section 13.3, the term
“Losses” shall mean, as applicable, any and all FivePrime Losses or UCB Losses, and “Indemnitees” shall mean, as applicable, any and all FivePrime Indemnitees or UCB Indemnitees.) Any Party entitled to
indemnification under Section 13.1 or 13.2 shall promptly give notice to the indemnifying Party of any actual or potential Losses of which it becomes aware that may be subject to indemnification hereunder, but the failure or delay to so notify
the indemnifying Party shall not relieve the indemnifying Party from any liability under Section 13.1 or 13.2 except to the extent that the indemnifying Party’s ability to defend against such Losses was actually prejudiced as a result of
such failure or delay. The indemnifying Party shall have the right to assume and control the defense of such Losses (at its own expense) with outside counsel of its choice and reasonably satisfactory to the indemnified Party; provided,
however, that the indemnified Party shall have the right to retain and be represented by its own counsel (at its own expense) in connection therewith. The indemnified Party shall, upon request, cooperate with the indemnifying Party and its
legal representatives in connection with the investigation and defense of such Losses, including by providing or otherwise making available information in its possession with respect thereto. Neither Party shall settle or otherwise resolve any
claim, suit, action, or demand related to any Losses without the prior written consent of the other Party, if such settlement or other resolution would (a) result in the admission of any liability or fault on behalf of the other Party or its
Indemnitees, (b) result in or impose any payment obligations upon the other Party or its Indemnitees, (c) or subject the other Party to an injunction or otherwise limit the other Party’s ability to take any actions or refrain from
taking any actions under this Agreement. 
 13.4     LIMITATION OF LIABILITY.  IN NO EVENT WILL
EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR ANY SPECIAL, PUNITIVE, INDIRECT, INCIDENTAL, EXEMPLARY OR CONSEQUENTIAL DAMAGES (INCLUDING ANY CLAIMS FOR LOST PROFITS, SALES, REVENUES OR OPPORTUNITIES) ARISING OUT OF OR IN CONNECTION WITH THIS
AGREEMENT (OR THE EXERCISE OF ITS RIGHTS HEREUNDER) UNDER ANY THEORY OF LIABILITY, AND REGARDLESS OF ANY NOTICE OR KNOWLEDGE OF THE POSSIBILITY OF SUCH DAMAGES. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 54 

 14.       General Provisions. 

14.1     Force Majeure.  Neither Party shall be held liable to the other Party hereunder, nor be deemed
to have defaulted under or breached this Agreement, for failure or delay in performing any obligation under this Agreement to the extent such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party,
potentially including embargoes, war, acts of war (whether war be declared or not), acts of terrorism, sabotage, insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, earthquake, or other acts of God,
or acts, omissions or delays in acting by any governmental authority, and which is not caused by the gross negligence or intentional misconduct of such Party (each such event or cause referred to as “Force Majeure”). The affected
Party shall notify the other Party in writing of such Force Majeure circumstances as soon as reasonably practical, and shall promptly undertake all reasonable efforts necessary to cure such Force Majeure circumstances and resume performance of its
obligations under this Agreement. If circumstances constituting Force Majeure exist for more than *** days, the Parties shall meet to discuss and agree upon a mutually acceptable resolution to the problem, if practicable. The foregoing
notwithstanding, nothing herein shall require a Party to settle on terms unsatisfactory to such Party any strike, lock-out or other labor difficulty, or any investigation or proceeding by any public authority, or any litigation by any Third Party.

 14.2     Assignment.  Except as provided in this Section 14.2, neither Party may assign
or otherwise transfer this Agreement or any right or obligation hereunder, without the prior written consent of the other Party. Notwithstanding the foregoing, either Party may, without consent of the other Party, assign this Agreement or any of its
rights or obligations hereunder in whole or in part to: (i) an Affiliate of such Party; or (ii) its successor in interest in connection with a Strategic Transaction; provided, however, that in the case of assignment to an
Affiliate, the assigning Party shall, notwithstanding such assignment, remain responsible for the performance such Affiliate under this Agreement. Any attempted assignment not in accordance with this Section 14.2 shall be null and void and of
no legal effect. The terms and conditions of this Agreement shall be binding upon, and shall inure to the benefit of, the Parties and their respected successors and permitted assigns. 

14.2.1. Provisions Regarding Strategic Transactions.  Solely in the event that FivePrime experiences a Strategic Transaction
during the Research Term. FivePrime (or the Acquiror in such Strategic Transaction) shall within *** days of the effective date of such Strategic Transaction certify to UCB in writing signed by an authorized executive of FivePrime or such
Acquiror as follows: 
 (a)         That FivePrime, such Acquiror
or an Affiliate of such Acquiror will continue to timely and properly perform all of its remaining obligations under the Agreement; and 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 55 

 (b)         That to the
extent that such Acquiror or any of its Affiliates is engaged in the discovery, development or commercialization of human pharmaceutical products (other than those activities that were within the scope of FivePrime’s existing business
immediately prior to the Strategic Transaction), such Acquiror shall not allow FivePrime to provide access to any UCB Background Know-How, UCB Assays, Materials of UCB, Collaboration Know-How or other UCB Confidential Information in FivePrime’s
possession to such Acquiror or any such Affiliates and/or to any of its employees who are responsible for the management or performance of such discovery, development or commercialization activities. 

In addition to the foregoing, in the event that either Party experiences a Strategic Transaction at any time during the Term, the other Party shall not
as a result of such Strategic Transaction acquire any licenses or other rights under this Agreement with respect to any Know-How and/or Patents owned or controlled, immediately prior to the closing of such Strategic Transaction by the relevant
Acquiror and/or its then existing Affiliates. 
 14.3     Severability.  If any one or more of
the provisions contained in this Agreement is held invalid, illegal or unenforceable in any respect by a court or other governmental authority of competent jurisdiction, the validity, legality and enforceability of the remaining provisions contained
herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely affects the substantive rights of one or both of the Parties. The Parties shall in such an instance cooperate and use good
faith efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical, implements the purposes of this Agreement. 

14.4     Notices.  All notices that are required or permitted hereunder shall be in writing and
sufficient if (i) delivered personally, (ii) sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail, or internationally recognized express courier (e.g., Federal Express), (iii) sent by
internationally recognized express courier or (iv) sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows: 
  

			
	 if to FivePrime, to:
	  	 Five Prime Therapeutics, Inc.

2 Corporate Drive
 South San Francisco,
CA 94080
 USA
 Attention:
President & CEO
 Facsimile No.: +1-415-365-5601

		
	 and:
	  	 Five Prime Therapeutics, Inc.

2 Corporate Drive
 South San Francisco,
CA 94080

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 56 

			
		  	 USA
 Attention: Legal
Department
 Facsimile No.: +1-650-583-3164

		
	 With a copy to:
	  	 Cooley LLP
 3175 Hanover
Street
 Palo Alto, CA 94304

USA
 Facsimile: +1-650-849-7400

Attention: Lila Hope, Esq.

		
	 if to UCB, to:
	  	 UCB Pharma S.A.

Allée de la Recherche 60
 1070
Brussels
 Belgium
 Facsimile:
+32-2-559-9491
 Attention: General Counsel

 or to such other address(es) as the Party to whom notice is to be given may have furnished to the other Party in writing
in accordance herewith. Any such notice shall be deemed to have been given: (i) when delivered, if personally delivered or sent by facsimile on a Business Day (or if delivered or sent on a non-Business Day, then on the next Business Day);
(ii) on the Business Day of scheduled delivery, if sent by internationally recognized express courier; or (iii) on the *** Business Day following the date of mailing, if sent by mail. 

14.5     Applicable Law.  This Agreement shall be governed by and construed in accordance with the laws
of the State of New York without reference to any rules of conflict of laws. The Parties expressly exclude the applicability of the United Nations convention on contracts for the international sale of goods. 

14.6     Dispute Resolution.  The Parties shall negotiate in good faith and use reasonable efforts to
amicably settle any dispute, controversy or claim arising from or related to this Agreement or the breach thereof that is outside the scope of authority of the JSC, and except for any Excluded Claims (each, a “Dispute”). Either
Party shall have the right to refer any Dispute to *** (or their respective designees) who shall attempt in good faith to resolve such Dispute over a period of *** days. 

14.6.1. If the Parties do not fully settle a Dispute within *** days of referring such matter to the executive officers
pursuant to Section 14.6, then either Party may submit the Dispute for the final resolution by binding arbitration (an “Arbitration”) under arbitration rules of the International Chamber of Commerce, as then in effect (the
“ICC Rules”), except as provided 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 57 

 
in Section 14.6.4 with respect to discovery, and judgment on the Arbitration award may be entered in any court having jurisdiction thereof. The proceedings and decisions of the arbitrators
in any Arbitration under this Section 14.6 shall be confidential except as otherwise expressly permitted in this Agreement or required by applicable Law. 
 14.6.2. Each Arbitration shall be conducted by a panel of three arbitrators, each with substantial experience in the pharmaceutical or biotechnology business selected pursuant to the ICC Rules.
Within *** days after initiation of an Arbitration, each Party shall select one person to act as an arbitrator and the two Party-selected arbitrators shall select a third arbitrator within *** days of their appointment. If a Party
fails to timely select an arbitrator, or if the arbitrators selected by the Parties fail to timely agree upon the third arbitrator, then such arbitrator(s) shall be appointed by ICC Court of Arbitration. The place of arbitration shall be ***,
or such other location as may be agreed to by the Parties, and all proceedings and communications shall be in English. 

14.6.3. The Parties shall maintain the confidential nature of the Arbitration or except as may be necessary in connection with a
court application for a preliminary remedy, a judicial challenge to an award or its enforcement, or unless otherwise expressly required by applicable Law or judicial decision. 

14.6.4. Either Party may apply to the arbitrators for interim injunctive relief until the arbitration award is rendered or the
controversy is otherwise resolved. Either Party also may, without waiving any remedy under this Agreement, seek from any court having jurisdiction any injunctive or provisional relief necessary to protect the rights or property of that Party pending
the arbitration award. The arbitrators shall have no authority to award punitive, exemplary or any other type of damages excluded under Section 13.4, and the Parties hereby irrevocably waive any right to seek or recover any such damages. Each
Party shall bear an equal share of the arbitrators’ fees and any administrative fees of each Arbitration. The arbitrators’ decision shall be final, not appealable, and legally binding, and judgment may be entered thereon in a court of
competent jurisdiction. 
 14.6.5. Except to the extent necessary to confirm an award or as may be required by
applicable Law, neither a Party nor an arbitrator may disclose the existence, content, or results of an Arbitration without the prior written consent of both Parties. 
 14.6.6. All the obligations of the Parties under this Agreement that are not expressly disputed in the Arbitration shall remain in full force during the Arbitration. 

14.6.7. As used in this Section, the term “Excluded Claim” means a dispute, controversy or claim between the
Parties to the extent that it solely concerns: (a) the scope, validity, enforceability or infringement of Patents; and/or (b) compliance by the Parties with any Laws governing antitrust, anti-monopoly or competition law matters.

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 58 

 14.7     Entire Agreement; Amendments.  This Agreement,
together with the Exhibits hereto, constitutes the entire understanding of the Parties with respect to the subject matter hereof and supersedes and cancels all previous express or implied agreements (including the certain Mutual Non-Disclosure
Agreement between the Parties effective as of January 6, 2012, as amended (the “Pre-Existing NDA”), and understandings, negotiations, writings and commitments, either oral or written, in respect to the subject matter hereof.
For clarity, all information for which either Party had non-disclosure and non-use obligations pursuant to the Pre-Existing NDA shall be considered Confidential Information under this Agreement and such obligated Party shall be considered the
Receiving Party under this Agreement with respect to such Confidential Information. The Exhibits to this Agreement are incorporated herein by reference and are part of this Agreement. This Agreement may be amended, or any term hereof modified, only
by a written instrument duly executed by authorized representatives of both Parties. 
 14.8
    Headings.  The captions to the several Sections and subsections hereof are not a part of this Agreement, but are merely for convenience to assist in locating and reading the several Sections and subsections hereof.

 14.9     Independent Contractors.  It is expressly agreed that FivePrime and UCB shall be
independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency, and neither Party will treat the relationship between the Parties as a partnership, joint venture or other entity
for any purposes whatsoever. Neither FivePrime nor UCB shall have the authority to make any statements, representations or commitments of any kind on behalf of, or to otherwise binding or obligate the other Party, without the prior written consent
of such other Party. 
 14.10   Performance by Affiliates.  Each Party may discharge any obligations and
exercise any right hereunder through any of its Affiliates. Each Party hereby guarantees the performance by its Affiliates of such Party’s obligations under this Agreement, and shall cause its Affiliates to comply with the provisions of this
Agreement in connection with such performance. Any breach by a Party’s Affiliate of any of such Party’s obligations under this Agreement shall be deemed a breach by such Party, and the other Party may proceed directly against such Party
without any obligation to first proceed against such Party’s Affiliate. 
 14.11   Further Actions.
 Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as are reasonably necessary to carry out the purposes and intent of this Agreement. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 59 

 14.12   Waiver.  No waiver, modification, release or amendment of any
obligation under or provision of this Agreement shall be valid or effective unless in writing and signed by all Parties hereto. The failure of any Party to insist on the performance of any obligation hereunder shall not be deemed to be a waiver of
such obligation. Waiver of any provision hereunder or of any breach of any provision hereof shall not be deemed to be a continuing waiver or a waiver of any other breach of such provision (or any other provision) on such occasion or any succeeding
occasion. 
 14.13   Rule of Construction.  Each Party has had the opportunity to consult with counsel in
connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply. 

14.14   Counterparts.  The Parties may execute this Agreement in two or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument. This Agreement shall be deemed effective upon the exchange by the Parties of PDF copies of signed originals. 

14.15   No Third Party Beneficiaries.  The Parties agree that no provision of this Agreement shall be for the
benefit of, or shall be enforceable by any Third Party, including any creditor of either Party. 
 [Remainder of page
intentionally blank; signature page follows.] 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 60 

 IN WITNESS WHEREOF, the Parties have executed this Research Collaboration and License
Agreement as of the Effective Date. 
  

									
	UCB Pharma S.A.	 		 	Five Prime Therapeutics, Inc.
					
	By:	 	 /s/ Ismail Kola
	 		 	By:	 	 /s/ Lewis T. Williams

									
					
	Name:	 	 Ismail Kola
	 		 	Name:	 	 Lewis T. Williams

									
					
	Title:	 	 Executive VP, President
	 		 	Title:	 	 Chief Executive Officer

		 	 UCB New Medicines
	 		 		 	
			
	UCB Pharma S.A.	 		 	

									
					
	By:	 	 /s/ Anna Richo
	 		 		 	

									
					
	Name:	 	 Anna Richo
	 		 		 	

									
					
	Title:	 	 Executive VP & General Counsel
	 		 		 	

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
 61 

 Exhibit A 
 Research Plan 
 UCB and FivePrime are parties to a Research Collaboration and License
Agreement, effective March 14, 2013 (the “Collaboration Agreement”), to which this Research Plan is attached as Exhibit A. Capitalized terms used in this Research Plan without definition shall have the respective meanings set forth in
the Collaboration Agreement. To the extent that any of the terms or conditions in this Research Plan conflict with any of the terms or conditions set forth in the Collaboration Agreement, the terms of the Collaboration Agreement shall govern.

 For purposes of this Research Plan the term “FPT” means FivePrime and the term “WG” means Working Group. 

*** 

  
 ***
INDICATES TWENTY-FOUR PAGES OF MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED. 
 A-1 

 Exhibit B 
 Excluded Protein List 
 (as of March 14, 2013) 

 

	
	 FivePrime
Internal
 Tracking Number

	***

  
 ***
INDICATES THREE PAGES OF MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED. 
 B-1 

 Exhibit C 
 Form of Initial Press Release 
 UCB AND FIVE PRIME THERAPEUTICS ANNOUNCE

 STRATEGIC DISCOVERY COLLABORATION 
 BRUSSELS, BELGIUM & SOUTH SAN FRANCISCO, CALIFORNIA – March __, 2013. UCB and Five Prime Therapeutics announced today that they have entered into a strategic
collaboration for the discovery of innovative biologics targets and therapeutics in the areas of fibrosis-related inflammatory diseases and central nervous system (CNS) disorders. This collaboration gives UCB exclusive access to FivePrime’s
drug discovery platforms in up to five programs to identify new targets and disease mechanisms. 
 Under the terms of the agreement, UCB and
FivePrime will collaborate to design assays to screen FivePrime’s comprehensive, proprietary library of approximately 5600 functional secreted proteins and transmembrane receptor proteins (ligand traps). FivePrime will apply its technology
platforms to identify potential drug targets and drug candidates in fibrosis-related inflammatory diseases and CNS disorders. UCB has an option to license exclusively rights to selected protein targets discovered by FivePrime in the collaboration.

 FivePrime will be eligible to receive approximately $16 million from a combination of an upfront fee, technology access fees, research
funding and success-based research milestone payments. In addition, FivePrime would be eligible for potential option exercise fees and product-related milestone payments, as well as tiered royalties on global net sales on future products related to
each licensed protein. 
 Ismail Kola, Executive Vice President and President, NewMedicines at UCB said, “The collaboration with
FivePrime is another example of UCB building supernetworks of innovation that aim to create superior and sustainable value for patients. FivePrime’s protein library of nearly every antibody target and ligand trap is unique in the industry, and
FivePrime’s in vitro and in vivo screening technologies offer powerful means of finding new targets and biologic medicines that are integral to supporting UCB’s strategy aiming to improve the lives of people living with severe
diseases.” 
 “We are delighted to enter into this strategic collaboration with UCB to discover new protein targets and test
potential drug candidates for fibrosis-related inflammatory diseases and CNS-related disorders. UCB is a global leader in the research and development of biologics and brings tremendous expertise to this collaboration,” said Lewis T.
“Rusty” Williams, MD, PhD, Founder, President and CEO of FivePrime. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 C-1 

 About UCB 
 UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with
severe diseases of the immune system or of the central nervous system. With 9000 people in approximately 40 countries, the company generated revenue of EUR 3.4 billion in 2012. UCB is listed on Euronext Brussels (symbol: UCB). 

About FivePrime 

Five Prime Therapeutics, Inc. is a clinical-stage, privately held, biotechnology company discovering and developing innovative antibody and protein
therapeutics. Using its integrated discovery platform, FivePrime is building a pipeline of oncology and immunology drug candidates. FivePrime mines its comprehensive library of secreted and extracellular human proteins to screen for medically
relevant new therapeutic proteins and antibody targets. FivePrime has entered into a collaboration agreement to develop and commercialize its lead product, FP-1039, with Human Genome Sciences, Inc. (which GlaxoSmithKline has acquired) in the United
States, Canada and the EU. FivePrime has also established significant collaborations for the discovery of innovative biologic targets and therapeutics in specific therapeutic areas with several leading pharmaceutical companies, including Pfizer,
Centocor and GlaxoSmithKline. For more information about FivePrime, please visit FivePrime’s web site at www.fiveprime.com. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 C-2EX-10.18

 Exhibit 10.18 
 *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
 EXECUTION COPY 

CONFIDENTIAL 
  

 
 License and
Collaboration Agreement 
 by and between 
 Five Prime Therapeutics, Inc. 
 and 

Human Genome Sciences, Inc. 
  

 
  

 LICENSE AND COLLABORATION AGREEMENT 

This LICENSE AND COLLABORATION AGREEMENT (this “Agreement”) is made as of this 16th day of March, 2011 (the “Effective Date”), by and
between Five Prime Therapeutics, Inc., a corporation organized and existing under the laws of Delaware, having its principal place of business at Two Corporate Drive, South San Francisco, CA 94080, USA (“FivePrime”) and Human Genome
Sciences, Inc., a corporation organized and existing under the laws of Delaware having its principal place of business at 14200 Shady Grove Road, Rockville, MD 20850, USA (“HGS”). HGS and FivePrime are referred to in this Agreement
individually as a “Party” and collectively as the “Parties.” 
 RECITALS

 WHEREAS, FivePrime is a biotechnology company focused on the discovery and development of innovative protein and antibody
drugs; 
 WHEREAS, HGS is a biopharmaceutical company working to create, develop and commercialize novel therapies that can
expand and improve quality of life; 
 WHEREAS, FivePrime owns and/or controls valuable proprietary technology (including an
engineered fusion protein compound, other materials, manufacturing processes, pre-clinical and clinical data and results and regulatory filings) relating to its proprietary protein drug candidate known as FP-1039, which is under active development
by FivePrime as of the Effective Date; and 
 WHEREAS, HGS wishes to obtain from FivePrime certain exclusive rights to further
develop, manufacture and commercialize FP-1039 in the United States, the European Union and Canada, and FivePrime wishes to grant such rights to HGS, all under the terms and conditions set forth herein. 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, the receipt and sufficiency of
which are hereby acknowledged, HGS and FivePrime hereby agree as follows: 
 ARTICLE 1 

DEFINITIONS 
 Unless the context otherwise requires, the terms in this Agreement with initial letters capitalized, shall have the meanings set forth below, or the meaning as designated in the indicated places
throughout this Agreement. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 1 

 1.1        “Active
Ingredient” means the clinically active material(s) that provide pharmacological activity in a pharmaceutical product (excluding formulation components such as coatings, stabilizers, excipients or solvents, adjuvants or controlled release
technologies). 
 1.2        “Affiliate” means, with respect to
a Party, any person that controls, is controlled by, or is under common control with that Party. For the purpose of this definition, “control” shall mean, direct or indirect, ownership of fifty percent (50%) or more of the shares of
stock entitled to vote for the election of directors, in the case of a corporation, or fifty percent (50%) or more of the equity interest in the case of any other type of legal entity, status as a general partner in any partnership, or any
other arrangement whereby the entity or person controls or has the right to control the board of directors or equivalent governing body of a corporation or other entity, or the ability to cause the direction of the management or policies of a
corporation or other entity. 
 1.3        “Alliance Manager” is
defined in Section 3.1. 
 1.4        “Biosite” means
Biosite Incorporated, or any successor thereto. 
 1.5        “Biosite
Agreement” means the Collaboration and License Agreement by and between FivePrime and Biosite, effective January 13, 2006. 
 1.6        “BLA” means a biologics license application or equivalent (e.g., new drug application) for Regulatory Approval of a Product that
is Filed with the FDA. 
 1.7        “Bulk Drug Substance” means
the final purified unpackaged, unlabeled drug substance (that is not in final form ready for use) obtained from the manufacturing process for a Phase 3 Clinical Trial or for commercial supply. 

1.8        “Business Day” means any day other than a Saturday, a Sunday
or a day on which commercial banks located in United States are authorized or required by law to remain closed. 

1.9        “Calendar Quarter” means the respective periods of three
(3) consecutive calendar months ending on March 31, June 30, September 30 and December 31. 

1.10    “Calendar Year” means a period of twelve (12) consecutive months ending on
December 31. 
 1.11    “cGMPs” shall mean all then-current applicable Laws and
recognized good manufacturing practices that apply to the Manufacture of any Active Ingredient, Compound or Product and govern the standards of manufacture of any product intended for human use, including, as applicable: (a) the United States
regulations set forth under Title 21 of the United 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 2 

 
States Code of Federal Regulations parts 210, 211, as well as applicable guidance published by the FDA; (b) the EU good manufacturing practices set forth in the European Community directives
2003/94/EC 2001/83/EC as amended by 2004/27/EC, all relevant implementations of such directives and all relevant principles and guidelines including ICH Tripartite Guidance Q7A and Volume 4 of the Rules Governing Medicinal Products in the European
Union: Medicinal Products for Human and Veterinary Use; and (c) the Ministry of Health Labor and Welfare GMP/GQP ordinances and accompanying regulations in Japan, in each case as may be modified or supplemented during the Term. 

1.12    “Change of Control” means any of the following events: (a) any Third Party (or
group of Third Parties acting in concert) becomes the beneficial owner, directly or indirectly, of more than fifty percent (50%) of the total voting power of the stock then outstanding of HGS normally entitled to vote in elections of directors,
as a result of a single transaction or a series of related transactions; (b) HGS consolidates with or merges into another corporation or entity, or any corporation or entity consolidates with or merges into HGS, in either event pursuant to a
transaction in which more than fifty percent (50%) of the total voting power of the stock outstanding of the surviving entity normally entitled to vote in elections of directors is not held by the parties holding at least fifty percent
(50%) of the outstanding shares of HGS immediately preceding the execution of the agreement governing such consolidation or merger; or (c) HGS conveys, transfers or leases all or substantially all of its assets to any Third Party.

 1.13    “Claims” means all Third Party demands, claims, actions, proceedings and
liability (whether criminal or civil, in contract, tort or otherwise) for losses, damages, reasonable legal costs and other reasonable expenses of any nature. 
 1.14    “Code” is defined in Section 11.3(c). 
 1.15    “Combination Product” is defined in Section 1.103 (definition of “Net Sales”). 

1.16    “Commence” or “Commencement” means, with respect to a clinical trial
of any Compound or Product: *** 
 1.17    “Commercialization” means all
activities directed to marketing, distribution, Detailing or selling a Product (as well as importing and exporting activities in connection therewith), all activities directed to obtaining Pricing Approvals, and all activities directed to Phase 4
Studies. 
 1.18    “Commercially Reasonable Efforts” means efforts and resources
that a similarly situated biotechnology or pharmaceutical company would use as part of an active and continuing program of development and/or commercialization of a pharmaceutical or biologic product

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 3 

 
owned by such company or to which such company has rights, of similar market potential and similar stage of product life, taking into account the establishment of the Licensed Products in the
marketplace, the competitiveness of the marketplace, the proprietary position of the Licensed Product, the regulatory status involved, the pricing and launching strategy and the relative safety and efficacy of the Licensed Product, and the projected
profitability of the Licensed Product. “Commercially Reasonable Efforts” shall require that such Party (on its own and/or acting through any of its Affiliates, sublicensees or subcontractors), at a minimum: (a) promptly assign
responsibility for such obligations to qualified employees, set annual goals and objectives for carrying out such obligations, and monitor and hold employees accountable for progress with respect to such goals and objectives; (b) set and seek
to achieve specific and meaningful objectives for carrying out such obligations; and (c) make and implement decisions and allocate resources designed to diligently advance progress with respect to such objectives. 

1.19    “Company Core Data Sheet” is defined in Section 5.2(a). 

1.20    “Completion” means: (a) for any human clinical trial that is conducted by or on
behalf of HGS or its Affiliates or sublicensees, ***; or, as the case may be, (b) for any human clinical trial that is conducted by or on behalf of FivePrime or its Affiliates, licensees or sublicensees, ***. 

1.21    “Compound” means any of the following: (a) FP-1039; (b) any fragment of at
least *** contiguous amino acids of the sequence of the extracellular domain of FGFR1 that is fused to an Fc Domain; and/or (c) any other fusion protein consisting of an Fc Domain and a protein fragment of at least *** contiguous
amino acids, which protein fragment is at least *** percent (***%) identical at the amino acid level to either: (i) the extracellular domain of FGFR1; or (ii) a fragment of the extracellular domain of an FGFR1 as described in
subsection (b) above. 
 1.22    “Confidential Information” means all
proprietary Know-How, unpublished patent applications and other information and data of a financial, commercial, business, operational or technical nature which: (a) the disclosing Party or any of its Affiliates has supplied or otherwise made
available to the other Party or any of its Affiliates, whether made available orally, in writing or in electronic form; or (b) the receiving Party has learned from the disclosing Party in the course of the collaboration under this Agreement, in
each case including information comprising or relating to concepts, discoveries, inventions, data, designs or formulae in relation to this Agreement. 
 1.23    “Confidentiality Agreement” is defined in Section 14.7. 
 1.24    “Contract Manufacturer” means any Third Party contract manufacturer with which a Party or its Affiliate(s) or sublicensee(s) contracts for the
Manufacture of any Compound or Product. As of the Effective Date, Contract Manufacturer includes ICOS and ***, each of which as of the Effective Date are under contract with FivePrime for the Manufacture of clinical supplies of FP-1039.

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 4 

 1.25    “Control” or
“Controlled” means, with respect to any Know-How, Patent Rights, other intellectual property rights, or any proprietary or trade secret information, the legal authority or right (whether by ownership, license or otherwise) of a
Party to grant a license or a sublicense under such Know-How, Patent Rights, or intellectual property rights to another Person, or to otherwise disclose such proprietary or trade secret information to another Person, in each case without breaching
the terms of any agreement with a Third Party, or misappropriating the proprietary or trade secret information of a Third Party. 
 1.26    “Co-Promotion/Co-Promote” means co-Detailing activities of the Products to Prescribers to be conducted by FivePrime in the United States in the event
that FivePrime exercises its rights under Section 7.2. 
 1.27    “Co-Promotion
Agreement” is defined in Section 7.2(b). 
 1.28    “Co-Promotion
Term” is defined in Section 7.2(a). 
 1.29    “Critical Issue” means
the decision as to whether HGS will, either by itself or through any of its Affiliates or sublicensees: ***. 

1.30    “Current Milestone” is defined in Section 8.2(c). 

1.31    “Detail” means an interaction between a sales representative and a Prescriber for the
purposes of informing such Prescriber of the characteristics of a Product and providing Product-related information and/or services. When used as a verb, the term “Detail” or “Detailing” means to perform a Detail.

 1.32    “Develop” or “Development” means all research and
development activities for any Compound or Product, including all non-clinical, preclinical and clinical activities, testing and studies of any Compound or Product, Manufacturing development, process development, toxicology studies, distribution of
Compounds and Products for use in clinical trials (including placebos and comparators), research and development of companion diagnostics for use in connection with clinical trials of Compounds and Products as well as approved Products, statistical
analyses, and the preparation, filing and prosecution of any Marketing Approval Application for any Product, as well as all regulatory affairs related to any of the foregoing. 
 1.33    “Development Plan” is defined in Section 4.2(a). 
 1.34    “DMF” means a Drug Master File maintained with the FDA or its equivalent Regulatory Filing maintained with a Regulatory Authority in any other country.

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 5 

 1.35    “Effective Date” is defined in the first
(1st) paragraph of this Agreement. 

1.36    “EMA” means the European Medicines Agency or any successor entity thereto.

 1.37    “Endometrial Foreign INDs” is defined in Section 5.1(a). 

1.38    “EU” or the “European Union” means the European Union and its member
states as of the Effective Date, which are: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxemburg, Malta, Netherlands, Poland, Portugal, Romania,
Slovakia, Slovenia, Spain, Sweden and the United Kingdom, and their successors to the extent such successors occupy the same territory. 
 1.39    “Excluded Claim” is defined in Section 14.6(f). 
 1.40    “Existing IND” is defined in Section 5.1(a). 
 1.41    “Fc Domain” means any of the following: (a) the modified hinge and native CH1 and CH2 regions of human immunoglobulin G1 contained in FP-1039,
(b) any other Fc regions (whether or not including the hinge region) contained in human immunoglobulin G2, G3 and G4 and combinations thereof; and (c) any fragment of at least *** contiguous amino acids or derivative at least
*** percent (***%) identical at the amino acid level to any of the regions described in subsection (a) or (b) above. 
 1.42    “FDA” means the United States Food and Drug Administration or any successor entity thereto. 

1.43    “FDC Act” means the United States Federal Food, Drug and Cosmetic Act, as may be
amended from time to time. 
 1.44    “FGFR1” means human fibroblast growth factor
receptor 1. 
 1.45    “FGFR2” means human fibroblast growth factor receptor 2.

 1.46    “Field” means all companion diagnostic (for use in connection with a
Product), therapeutic and prophylactic uses for humans. Solely for purposes of the Sublicensed UCSF Patent Rights, the “Field” does not include any “Licensed Services” as such term is defined in the UCSF Agreement.

 1.47    “Filing” of a Marketing Approval Application means the acceptance by a
Regulatory Authority of a Marketing Approval Application for filing and review, if applicable, or otherwise the date of submission of such Marketing Approval Application. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 6 

 1.48    “First Commercial Sale” means, with
respect to any Product in any country or jurisdiction in the Licensed Territory, the first (1st) sale to a Third Party for distribution, use or consumption of any such Product in such country or jurisdiction after the Regulatory Approvals and any applicable Pricing Approvals have been obtained
for such Product in such country or jurisdiction. 
 1.49    “FivePrime-Conducted
Trials” is defined in Section 4.2(d). 
 1.50    “FivePrime-Conducted Trials
Budget” means the budget for FivePrime-Conducted Trials, an estimate of which is set forth as Exhibit D and incorporated herein by reference. The Parties agree that the estimated external costs set forth in Exhibit D will be
updated from time to time by FivePrime to reflect the then-current estimated external costs agreed upon between FivePrime and its subcontractors. 
 1.51    “FivePrime Development Activities” means any and all Development activities with respect to any Compounds or Products that are conducted by FivePrime
for the purpose of supporting Regulatory Approvals for the Product in the Retained Territory, either by itself or through any of its Affiliates, licensees or subcontractors. 
 1.52    “FivePrime Existing Inventory” is defined in Section 6.1(c). 
 1.53    “FivePrime Indemnitee” is defined in Section 13.2. 
 1.54    “FivePrime Know-How” means any and all Know-How Controlled by FivePrime or any of its Affiliates as of the Effective Date or thereafter during the Term
that *** for the use, Development, Manufacture or Commercialization of the any Compound or Product, including any such Know-How included in Inventions Controlled by FivePrime. “FivePrime Know-How” shall include
FivePrime’s interest in any Joint Know-How. 
 1.55    “FivePrime Licensed Territory
Patents” is defined in Section 9.2(a)(i). 
 1.56    “FivePrime Manufacturing
Know-How” is defined in Section 6.2(a)(i). 
 1.57    “FivePrime
Patents” means any and all Patent Rights (including Sublicensed Patent Rights) Controlled by FivePrime and/or its Affiliate(s) as of the Effective Date or thereafter during the Term that: (a) claim the composition of matter of, or the
method of Manufacturing or using, any Compound or Product; or (b) that are *** for the use, Development, Manufacture or Commercialization of any Compound or Product. FivePrime Patents existing as of the Effective Date are set forth in
Exhibit A. “FivePrime Patents” shall include FivePrime’s interest in any Joint Patents. 

1.58    “FivePrime Technology” means FivePrime Know-How and FivePrime Patents. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 7 

 1.59    “FP-1039” means the soluble fusion
protein consisting ***, as such protein is described in the Existing IND. 

1.60    “FP-1039 Endometrial Trial (FP-1039-002)” is defined in Section 4.2(d).

 1.61    “FP-1039 Phase 1 Trial” is defined in Section 4.2(d). 

1.62    “FP-1039 Phase 1b Trial” means a Phase 1b clinical trial that HGS will conduct in
accordance with the Development Plan that is designed to test the safety of FP-1039 administered in combination with one or more therapeutic agents indicated for the treatment of cancer. 

1.63    “FTE” means the equivalent of a full time individual’s work for a twelve
(12) month period (consisting of *** hours per year of dedicated effort). FTE efforts shall not include the work of general corporate or administrative personnel. 
 1.64    “FTE Rate” means an initial rate of *** Dollars ($***) per FTE per hour for all hours worked in a year related directly to the performance
of this Agreement. Commencing January 1, 2012, the FTE Rate shall be changed annually on a calendar year basis by the JDC to reflect any year-to-year percentage increase or decrease (as the case may be) in ***. 

1.65    “GAAP” means United States Generally Accepted Accounting Principles, consistently
applied by a Party or its successor, e.g. International Financial Reporting Standards (“IFRS”). 

1.66    “Generic Product” means, with respect to any Product, any pharmaceutical product
that: (a) is sold by a Third Party under a Regulatory Approval granted by a Regulatory Authority to such Third Party, which Third Party is not a licensee or sublicensee of HGS or its Affiliates, or any of their licensees or sublicensees, and
has not obtained such Product from a chain of distribution including HGS or any of its Affiliates, licensees or sublicensees or further sublicensees; (b) contains the Compound applicable to such Product as an Active Ingredient; and (c) is
approved as a biologics equivalent of an A/B rated generics in reliance, in whole or in part, on the prior approval of such Product as determined by the applicable Regulatory Authority. “Generic Product” does not include any Product
licensed or produced by HGS or any of its Affiliates or sublicensees (i.e., an authorized generic product). 

1.67    “Global Safety Database” is defined in Section 5.2. 

1.68    “Government Authority” means any federal, state, national, state, provincial or local
government, or political subdivision thereof, or any multinational organization or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing authority or power, any
court or tribunal (or any department, bureau or division thereof, or any governmental arbitrator or arbitral body). 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 8 

 1.69    “HGS Development Activities” means any
and all Development activities with respect to any Compound or Product conducted by HGS under this Agreement for the purpose of supporting Regulatory Approvals of the Product within the Licensed Territory, either by itself or through any of its
Affiliates, sublicensees or subcontractors, including FP-1039 Endometrial Trial (FP-1039-002) and FP-1039 Phase 1 Trial. 

1.70    “HGS Indemnitee” is defined in Section 13.1. 

1.71    “HGS Know-How” means any and all Know-How Controlled by HGS or any of its Affiliates
as of the Effective Date or thereafter during the Term that is *** for the use, Development, Manufacture or Commercialization of any Compound or Product, including any such Know-How included in Inventions Controlled by HGS. “HGS
Know-How” shall include HGS’ interest in any Joint Know-How. 
 1.72    “HGS
Manufacturing Know-How” is defined in Section 6.2(b)(i). 
 1.73    “HGS
Patents” means any and all Patent Rights Controlled by HGS or any of its Affiliates as of the Effective Date and/or thereafter during the Term that: (a) claim the composition of matter of, or any method of Manufacturing or using, any
Compound or Product; or (b) are otherwise *** for the use, Development, Manufacture or Commercialization of any Compound or Product. “HGS Patents” shall include HGS’ interest in any Joint Patents. 

1.74    “HGS Retained Territory Patents” is defined in Section 9.2(c)(i). 

1.75    “HGS Technology” means HGS Know-How and HGS Patents. 

1.76    “ICOS” means: (a) ICOS Corporation, predecessor-in-interest to CMC ICOS; and
(b) CMC ICOS Biologics, Inc. as successor in interest to ICOS Corporation. 

1.77    “ICOS Agreement” means the CHEF1 Non-Exclusive License Agreement by and between
FivePrime and ICOS, effective as of April 18, 2006, as amended. 

1.78    “IND” means any investigational new drug application, clinical study application,
clinical trial exemption or similar or equivalent application or submission for approval to conduct human clinical investigations filed with or submitted to a Regulatory Authority in conformance with the requirements of such Regulatory Authority.

 1.79    “Indemnified Party” is defined in Section 13.3. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 9 

 1.80    “Indemnifying Party” is defined in
Section 13.3. 
 1.81    “Indication” means any human disease or condition in
the Field that can be treated, prevented or cured or the progression of which can be delayed and for which a Compound or Product is specifically developed in order to obtain Regulatory Approval for use of a Product pursuant to an approved label
claim. A single Indication shall include the primary disease and variants or subdivisions or subclassifications within such primary disease. Treatment, stage of disease, modulation and/or prophylaxis of the same disease, including line extensions
and regardless of the patient population, shall be treated as the same Indication. Treatment as monotherapy or treatment in combination with another Active Ingredient or product shall be treated as the same Indication. 

1.82    “Initial Development Outline” is defined in Section 4.2(a). 

1.83    “Invention” shall mean any process, method, composition of matter, article of
manufacture, discovery or finding that is invented as a result of a Party exercising its rights or carrying out its obligations under this Agreement, including all rights, title and interest in and to the intellectual property rights therein.

 1.84    “JAMS Rules” is defined in Section 14.6(a). 

1.85    “Joint Commercialization Committee” or “JCC” is defined in
Section 3.5(b). 
 1.86    “Joint Development Committee” or
“JDC” is defined in Section 3.2. 
 1.87    “Joint Know-How”
is defined in Section 9.1. 
 1.88    “Joint Patents” is defined in
Section 9.1. 
 1.89    “Joint Technology” means Joint Know-How and Joint
Patents. 
 1.90    “Know-How” means any information and materials, including
discoveries, improvements, modifications, processes, methods, protocols, formulas, data, inventions, know-how and trade secrets, patentable or otherwise, but excluding any Patent Rights. 

1.91    “Knowledge” means, with respect to FivePrime, the actual knowledge (without imputed
knowledge, constructive knowledge, but including the duty to make reasonable inquiry with its employees), of the following ***. 
 1.92    “Law” means any federal, state, local, foreign or multinational law, statute, standard, ordinance, code, rule, regulation, resolution or promulgation,
or any order by any Government Authority, or any license, franchise, permit or similar right granted under any of the foregoing, or any similar provision having the force or effect of law. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 10 

 1.93    “Lead Oncology Company” is defined in
Section 2.2(b). 
 1.94    “Licensed Territory” means: (a) the United
States; (b) Canada; and (c) the European Union. 
 1.95    “MAA” means a
marketing approval application for Regulatory Approval of a Product that is Filed with the EMA. 

1.96    “Major Markets” means each of the following: ***. 

1.97    “Manufacture” means all activities directed to the manufacture, receipt, incoming
inspections, storage and handling of raw materials and the manufacture, processing, formulation, packaging, labeling, warehousing, quality control testing (including in-process release and stability testing), supplying, shipping and release of any
Active Ingredient, Compound or Product, as the case may be and to the extent applicable, including manufacturing process development, scale-up and validation. 
 1.98    “Manufacturing Costs” means the cost incurred by HGS or any of its Affiliates and includes the fully allocated cost of manufacturing any Compound or
Product, as such costs are specifically allocated to such Compound or Product and as computed in accordance with GAAP and HGS’ internal standards applied consistently among its products, consisting of: 

    (a)        Materials cost, which means the price paid for raw
material, intermediates, components and finished goods which are purchased from outside vendors as well as any freight and duty where applicable; 
     (b)        Direct labor costs, which means the allocable employment cost of all personnel directly engaged in the Manufacture of the
Compound or Product within the relevant manufacturing operating unit, to the extent allocated to the actual Manufacture of the Compound or Product; 
     (c)        Direct costs and allocated factory overhead costs, which means the cost of specific activities that are provided by
support functions either on or off-site, provided they are directly related to the Manufacture (including fill and finish activities) or packaging of Compound or Product and not a general overhead allocation or charge. Overhead costs consists
of expenses associated with quality assurance testing, quality compliance, stability testing, batch review, equipment maintenance costs, manufacturing utilities, waste removal, storage, transportation, insurance for the factory, its contents or
other directly related items, factory management and factory administrative expenses, factory changeover or preventative 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 11 

 
maintenance, factory facilities costs, which may include lease payments made by HGS to a Third Party, environmental engineering and property taxes. These expenses shall be reasonably allocated to
the Manufacture of Compound or Product on a pro rata basis based on the allocation methodology appropriate at the Manufacturing site. Such expenses shall exclude costs relating to available capacity which is not used in the Manufacture of the
Compound or Product, however such expenses will include costs relating to available capacity specifically reserved for the Manufacture of the Compound or Product based on forecast or order placed by FivePrime, its Affiliates or licensees, unless HGS
can fill another manufacturing campaign not related to the Compound or Product; 

    (d)        Depreciation costs in lieu of capital expenditures,
which represent the annual amortization of original purchase costs reasonably allocated to the Manufacture of Compound or Product on a pro rata basis based on the allocation methodology appropriate at the Manufacturing site over the useful life of
the asset; 
     (e)        Scrap, rejected material or
other appropriate costs associated with the production of Compound or Product; 

    (f)        The out-of-pocket costs of freight and tariffs and
other expenses associated with transporting Compound or Product from the source of manufacture to a distribution center, inclusive of any interim points of delivery, but excluding (i) any such costs which are separately invoiced to a customer,
and (ii) FTEs involved in the management of supply chain logistics, and expressly excludes: (a) any royalties or other payments payable by HGS or any of its Affiliates to any Third Party with respect to any Compound or Product; and
(b) any process development costs incurred in connection with the Manufacturing of such Compound or Product, unless mutually agreed by the Parties; 
     (g)        If HGS has Product manufactured by a Contract Manufacturer, the cost for supply of such Product for FivePrime Development
Activities and Commercialization shall be at the pass through cost from the Contract Manufacturer and the applicable HGS FTEs to manage/oversee the delivery of the Product at the FTE Rate; and 

    (h)        The Manufacturing Costs shall not include any costs or
expenses as described in subsections (a) through (g) above that are attributable to any failed or rejected manufacturing runs for production of Compound produced for commercial supply. 

1.99    “Manufacturing Process Yield” means, in determining the amount of milestone payment
triggered by the achievement of a particular milestone event, the average quantity, in grams, of Bulk Drug Substance of Compound obtained per liter of fermentation working volume in the first *** successfully completed cGMP manufacturing runs
(where all such runs were devoid of any major process deviations), at a working volume of at least *** liters per 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 12 

 
fermentation run, in which such manufacturing runs are performed for production of Compound for a Phase 3 Clinical Trial (if such milestone is a development, regulatory or approval milestone) or
for commercial supply (if such milestone is a commercial milestone). In the event the Manufacturing Process Yield calculated for the first *** successfully completed cGMP runs as described above is less than or equal to *** g/L, and
subsequently the Manufacturing Process Yield rises above *** g/L, then all subsequent milestone payments shall be calculated using the improved yield, but the determination of all previous milestone payments shall remain unchanged despite
such yield improvement. 
 1.100    “Marketing Approval Application” means a BLA,
MAA or similar application for Regulatory Approval that is Filed with the applicable Regulatory Authorities in any country or jurisdiction in the Licensed Territory. 
 1.101    “Marketing/Medical Affairs Costs” is defined in Section 7.2(e). 
 1.102    “Mutant Endometrial Cancer” means endometrial cancer of the endometrioid histotype where the tumor cells harbor an FGFR2 mutation. 

1.103    “Net Sales” means with respect to any Product, the gross amount recognized by HGS,
any Affiliate, or sublicensee for sales of such Product to a Third Party less deductions, to the extent reasonable, customary, and consistent with HGS’ business practices, for: 

    (a)        transportation charges, and other charges, such as
insurance, relating thereto; 
     (b)        sales and
excise taxes or customs duties paid by the selling party and any other governmental charges imposed upon the sale of such Product and actually paid; 
     (c)        discounts and chargebacks actually accrued, granted, allowed or incurred in connection with the sale of such
Product; 
     (d)        allowances or credits to
customers actually accrued, granted, allowed or incurred and not in excess of the selling price of such Product, on account of rejection, outdating, recalls or return of such Product; and 

    (e)        rebates, reimbursements, fees or similar payments to
or accruals for (i) wholesalers and other distributors, pharmacies and other retailers, buying groups (including group purchasing organizations), health care insurance carriers, pharmacy benefit management companies, health maintenance
organizations, Governmental Authorities, or other institutions or health care organizations; or (ii) to patients and other Third Parties arising in connection with any program applicable to a Product under which HGS or its Affiliates provides
to low income, uninsured or other patients the opportunity to obtain HGS’ pharmaceutical products at reduced cost. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 13 

 For the avoidance of doubt, if a single item falls into more than one of the categories set
forth in clauses (a)-(e) above, such item may not be deducted more than once. 
 Sales between HGS and its Affiliates and
sublicensees shall be disregarded for purposes of calculating Net Sales except if such purchaser is an end user. 
 Net Sales
will be calculated on an accrual basis, in a manner consistent with HGS’ accounting policies for external reporting purposes, as consistently applied, in accordance with GAAP. To the extent any accrued amounts used in the calculation of Net
Sales are estimates, such estimates shall be trued-up in accordance with HGS’ accounting policies for external reporting purposes, as consistently applied, and Net Sales and related payments under this Agreement shall be reconciled as
appropriate. 
 If a Product either (i) is sold in the form of a combination product containing both a Compound and one or
more Active Ingredient(s) as separate molecular entity(ies) that are not Compounds; or (ii) is sold in a form that contains (or is sold bundled with) a delivery device therefor (in either case ((i) or (ii)), a “Combination
Product”), the Net Sales of such Product for the purpose of calculating royalties and sales-based milestones owed under this Agreement for sales of such Product, shall be determined as follows: first, HGS shall determine the actual Net
Sales of such Combination Product (using the above provisions) and then such amount shall be multiplied by the fraction A/(A+B), where A is the invoice price of the Product, if sold separately, and B is the total invoice price of any other Active
Ingredient or delivery device in the Combination Product if sold separately. If any other Active Ingredient or delivery device in the Combination Product is not sold separately, Net Sales shall be calculated by multiplying actual Net Sales of such
Combination Product by a fraction A/C where A is the invoice price of the Product if sold separately, and C is the invoice price of the Combination Product. If neither the Product nor any other Active Ingredient (or delivery device) in the
Combination Product is sold separately, the adjustment to Net Sales shall be determined by the Parties in good faith to reasonably reflect the fair market value of the contribution of the Product in the Combination Product to the total fair market
value of such Combination Product. 
 With respect to any sale of any Product in a given country for any substantive
consideration other than monetary consideration on arm’s length terms (which has the effect of reducing the invoiced amount below what it would have been in the absence of such non-monetary consideration), for purposes of calculating the Net
Sales under this Agreement, such Product shall be deemed to be sold exclusively for cash at the average Net Sales price charged to Third Parties for cash sales in such country during the applicable reporting period (or if there were only de
minimis cash sales in such country, at the fair market value as determined in good 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 14 

 
faith based on pricing in comparable markets). Notwithstanding the foregoing, Net Sales shall not include amounts (whether actually existing or deemed to exist for purposes of calculation) for
Products distributed for use in clinical trials or as samples. 
 1.104    “Non-Resident
Party” is defined in Section 4.4. 
 1.105    “Other FivePrime-Conducted
Activities” is defined in Section 4.2(d)(ii). 
 1.106    “Patent
Cost” means the reasonable out-of-pocket costs and expenses (including the fees and expenses paid to outside counsel and filing and maintenance fees paid to governmental authorities) incurred and recorded as an expense by a party or any of
its Affiliates after the Effective Date, during the Term of and pursuant to the Agreement, (a) in connection with the Prosecution of FivePrime Patents and (b) the reasonable costs and expenses for litigation (enforcement or defense) or
other proceedings with respect to FivePrime Patents. For the avoidance of doubt, “Patent Costs” shall not include damages awarded by a court or other governmental authority or monetary settlements entered into by the litigants.

 1.107    “Patent Rights” means all patents and patent applications (which for the
purpose of this Agreement shall be deemed to include certificates of invention and applications for certificates of invention), including all divisionals, continuations, substitutions, continuations-in-part, re-examinations, reissues, additions,
renewals, revalidations, extensions, registrations, pediatric exclusivity periods and supplemental protection certificates and the like of any such patents and patent applications, and any and all foreign equivalents of the foregoing. 

1.108    “Person” means any individual, partnership, limited liability company, firm,
corporation, association, trust, unincorporated organization or other entity. 

1.109    “Pharmacovigilance Agreement” is defined in Section 5.2(a). 

1.110    “Phase 1 Clinical Trial” shall mean a human clinical trial of a Compound or Product
that would satisfy the requirements under Title 21 of the United States Code of Federal Regulations part 312.21(a), regardless of whether such trial is referred to as a “phase 1 clinical trial” in the Development Plan. 

1.111    “Phase 2 Clinical Trial” shall mean a controlled human clinical trial of a Compound
or Product that would satisfy the requirements under Title 21 of the United States Code of Federal Regulations part 312.21(b), regardless of whether such trial is referred to as a “phase 2 clinical trial” in the Development Plan.

 1.112    “Phase 3 Clinical Trial” shall mean a controlled or uncontrolled human
clinical trial of a Compound or Product that would satisfy the requirements under Title 21 of the United States Code of Federal Regulations part 312.21(c), regardless of whether such trial is referred to as a “phase 3 clinical trial” in
the Development Plan. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 15 

 1.113    “Phase 4 Study” means any study or data
collection effort in respect to any Product for a particular Indication that is initiated after receipt of Regulatory Approval for the Product for such Indication. 
 1.114    “Prescriber” means any healthcare professional authorized to prescribe a Product. 

1.115    “Pricing Approvals” means, with respect to a Product in any country or jurisdiction
in the Licensed Territory, all pricing and reimbursement approvals for the Product from Government Authorities required by applicable Law or Governmental Authorities. 
 1.116    “Product” means any pharmaceutical preparation in final form, including all dosage forms, formulations and line extensions thereof, containing a
Compound as an Active Ingredient (alone or as part of a Combination Product). Except when referred to in the Net Sales definition, all references to Product in the Agreement shall be deemed to include Combination Product. 

1.117    “Product Infringement” is defined in Section 9.3(a). 

1.118    “Product Marks” has the meaning set forth in Section 9.5. 

1.119    “Product-Specific FivePrime Licensed Territory Patents” is defined in
Section 9.2(a)(i). 
 1.120    “Prosecution” means the filing, prosecution and
maintenance of patents and patent applications, including any post-grant proceeding such as patent interference proceeding, opposition proceeding, revocation proceeding, reexamination and reissuance. 

1.121    “Regulatory Approval” means, with respect to a Product in any country or
jurisdiction in the Licensed Territory, the approvals by the applicable Regulatory Authority in such country or jurisdiction (other than Pricing Approvals) necessary for the Commercialization of the Product for an Indication. 

1.122    “Regulatory Authority” means any applicable Government Authority responsible for
granting Regulatory Approvals for Products, including the FDA, the EMA and any corresponding national or regional regulatory authorities. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 16 

 1.123    “Regulatory Filings” means, with
respect to the Compounds or Products, any submission to a Regulatory Authority of any appropriate regulatory application specific to Compounds or Products, and shall include any submission to a regulatory advisory board and any supplement or
amendment thereto. “Regulatory Filings” includes any IND and any Marketing Approval Application. 

1.124    “Remainder” is defined in Section 9.3(e). 

1.125    “Remedial Action” is defined in Section 5.6. 

1.126    “Resident Party” is defined in Section 4.4. 

1.127    “Retained Territory” means all countries and territories of the world outside of the
Licensed Territory. 
 1.128    “Royalty Term” has the meaning set forth in
Section 8.3(b). 
 1.129    “Sales & Royalty Report” means a written
report or reports showing on a Product-by-Product and country-by-country basis each of: (a) the gross recognized amount for each Product in the Licensed Territory during the reporting period by HGS and its Affiliates and sublicensees;
(b) the deductions taken in calculating Net Sales for each Product during such reporting period, and the Net Sales for each such Product; (c) any applicable currency conversions; and (d) the royalties payable with respect to such Net
Sales in United States Dollars. 
 1.130    “Sales Costs” is defined in
Section 7.2(e). 
 1.131    “Sublicensed ICOS Patent Rights” means the Patent
Rights in-licensed by FivePrime under the ICOS Agreement. 
 1.132    “Sublicensed Patent
Rights” means, collectively, the Sublicensed ICOS Patent Rights and the Sublicensed UCSF Patent rights. 

1.133    “Sublicensed UCSF Patent Rights” means the Patent Rights in-licensed by FivePrime
under the UCSF Agreement. 
 1.134    “Technology Transfer Period” means the period
commencing on the Effective Date and continuing thereafter for *** months. 

1.135    “Term” is defined in Section 11.1. 

1.136    “The Regents” means The Regents of the University of California, a California
corporation, or any successor thereto pursuant to the UCSF Agreement. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 17 

 1.137    “Third Party” means any Person other
than a Party or an Affiliate of a Party. 
 1.138    “Third Party Patent Proceeding”
is defined in Section 9.4. 
 1.139    “Transferred Materials” is defined in Section
2.5(c). 
 1.140    “UCSF Agreement” means the Exclusive License Agreement by and
between The Regents of the University of California and FivePrime for Receptors for Fibroblast Growth Factors, effective September 7, 2006, a copy of which is attached hereto as Exhibit B. 

1.141    “United States” or “US” means the United States of America
including its territories and possessions. 
 1.142    “Valid Claim” means, with
respect to any country: (a) a claim of an issued and unexpired patent (as may be extended through supplementary protection certificate or patent term extension or the like) that has not been revoked, held invalid or unenforceable by a patent
office, court or other governmental agency of competent jurisdiction in a final and non-appealable judgment (or judgment from which no appeal was taken within the allowable time period) and which claim has not been disclaimed, denied or admitted to
be invalid or unenforceable through reissue, re-examination or disclaimer or otherwise; or (b) a pending claim of an unissued US patent application, which application has not been pending for more than *** years since its effective
filing date (which for the sake of clarity is the earliest priority date of the patent application); or (c) a pending claim of an unissued Canadian (CA) or European (EP) patent application, which application has not been pending for more than
*** years since the date such application enters into such a national stage in such country), provided that with respect to US, CA or EP applications, such ***year period shall be tolled for the duration of any pre-grant
opposition proceeding, any interference proceeding or any appeal, in each case with respect to such patent application. 

1.143    Interpretation. In this Agreement, unless otherwise specified: 

    (a)        “includes” and “including” shall
mean respectively includes and including without limitation; 

    (b)        words denoting the singular shall include the plural
and vice versa and words denoting any gender shall include all genders; 

    (c)        words such as “herein”, “hereof”,
and “hereunder” refer to this Agreement as a whole and not merely to the particular provision in which such words appear; and 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 18 

 (d)        the Exhibits and other
attachments form part of the operative provision of this Agreement and references to this Agreement shall include references to the Exhibits and attachments. 
 ARTICLE 2 
 LICENSE 

2.1        License to HGS under FivePrime Technology. 

    (a)        Subject to the terms and conditions of this Agreement,
FivePrime hereby grants to HGS: (i) an exclusive license, with the right to grant sublicenses in accordance with Section 2.2, under the FivePrime Technology to Develop and use Compounds and Products, Commercialize, and sell and offer for
sale Products, in each case in the Field in the Licensed Territory; and (ii) a worldwide, exclusive license (except with respect to FivePrime to the extent FivePrime supplies HGS pursuant to Sections 6.1(c) and 6.2(a)), with the right to grant
sublicenses solely to its Affiliates and Contract Manufacturers, under the FivePrime Technology to Manufacture, have Manufactured, import and export Compounds and Products solely for the purpose of: (A) supplying HGS, its Affiliates and
sublicensees for the activities under the license granted in subsection (i) and (B) supplying FivePrime, its Affiliates, licensees and sublicensees in accordance with Section 6.1. The license granted to HGS under this
Section 2.1(a) shall not grant any rights for HGS to Develop, Commercialize, make, have made, use, sell, offer for sale or import any other proprietary compound (including protein product of any kind) of FivePrime (including any proprietary
compound that FivePrime licenses to a Third Party) that is not a Compound. 

    (b)        HGS acknowledges and agrees that: (i) FivePrime
obtained the rights to the Sublicensed Patent Rights included in the FivePrime Patents under the UCSF Agreement and ICOS Agreement, respectively, and, as a result, FivePrime’s rights and obligations with respect to such Sublicensed Patent
Rights are subject to the terms and conditions of the UCSF Agreement and ICOS Agreement, as applicable; (ii) the license granted by FivePrime to HGS under Section 2.1(a) under such Sublicensed Patent Rights constitutes a sublicense under
the UCSF Agreement or ICOS Agreement, as applicable; (iii) such sublicense is subject to the terms and conditions of the UCSF Agreement or ICOS Agreement, as applicable, including the obligations to the federal government of the United States
set forth in Sections 2.4 and 2.7 of the UCSF Agreement, the irrevocable grant of rights to a Third Party pursuant to Section 2.5 of the UCSF Agreement, and the rights reserved to The Regents pursuant to Section 2.6 of the UCSF Agreement;
and (iv) HGS shall comply with all applicable terms of the UCSF Agreement as if HGS were the “Licensee” pursuant to the UCSF Agreement and FivePrime were “The Regents” pursuant to the UCSF Agreement, as required under
Section 4.3 of the UCSF Agreement. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 19 

 (c)        HGS acknowledges and agrees that:
(i) FivePrime is a party to the Biosite Agreement, under which FivePrime granted Biosite an exclusive license under the FivePrime Technology for certain compound-related diagnostic uses, with FivePrime retaining the right under the FivePrime
Technology, and receiving a license under Patents and Know-How owned or in-licensed by Biosite, for ***; (ii) the license granted by FivePrime to HGS under Section 2.1(a) in the field of *** confers to HGS the right solely to
develop, manufacture, use and commercialize ***, and such license includes a sublicense under the license obtained by FivePrime from Biosite under the Biosite Agreement; (iii) in the event FivePrime transfers to HGS any ***
discovered, developed, owned or in-licensed by Biosite, HGS’ use, development and commercialization of such ***, or any product containing such ***, as *** shall be subject to the terms and conditions of the Biosite
Agreement; and (iv) in the event HGS desires to sublicense any FivePrime Technology to a Third Party for use in connection with the development, manufacture, use and/or commercialization of ***, HGS shall first obtain FivePrime’s
prior written consent. 
 (d)        FivePrime acknowledges and agrees that it
shall not, without HGS’ prior written consent, amend the UCSF Agreement, ICOS Agreement or Biosite Agreement subjecting HGS to any additional obligations or burdens, financial or otherwise. 

2.2        Sublicense Rights. Subject to the terms and conditions of this Agreement:

 (a)        HGS may exercise its rights and perform its obligations under this
Agreement by itself or through the engagement of any of its Affiliates without the prior written consent of FivePrime. 

(b)        HGS may sublicense the rights granted to it under Section 2.1(a) to one
(1) or more Third Parties; provided that: (i) HGS may not sublicense to a Third Party the exclusive right to Develop the Product in any of the Major Markets without the prior written consent of FivePrime, which consent shall not to
be unreasonably withheld, delayed or conditioned; (ii) HGS may not sublicense the right to Commercialize the Product in any of the Major Markets to a Third Party that is not a Lead Oncology Company (as defined below) without the prior written
consent of FivePrime, which consent shall not to be unreasonably withheld, delayed or conditioned; (iii) HGS may sublicense to any Lead Oncology Company the right to Commercialize the Product in any of the Major Markets without the prior
written consent of FivePrime but by providing FivePrime with written notification of such sublicense grant promptly thereafter; and (iv) HGS may sublicense to any Third Party the right to Develop and/or Commercialize the Product in any country
in the Licensed Territory that is not a Major Market, without the prior written consent of FivePrime but by providing FivePrime with written notification of such sublicense grant promptly thereafter. “Lead Oncology Company” means a
pharmaceutical company that is ranked top *** in the United States or top *** in the Major Markets other than the *** by oncology sales revenue (as determined by the then-current sales

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 20 

 
revenue data at the time of such proposed sublicense grant, published by IMS Health Incorporated or successor thereto) in the country and/or territory in which HGS seeks to grant such sublicense
rights. Subject to Sections 2.2(c) and 4.5, HGS may, as HGS deems appropriate and without the prior written consent of FivePrime, subcontract to Third Parties the performance of tasks and obligations with respect to: (A) the Development or
Manufacture of any Compound or Product, or (B) the distribution of any Product in a particular country or territory where HGS remains the entity marketing the Product, bearing product liability for the Product and responsible for submitting
Regulatory Filings and seeking Regulatory Approval for the Products, and in each case grant a limited sublicense to such Third Parties solely for the purpose of performing such tasks and obligations. 

(c)        HGS shall remain responsible for all of its obligations under this Agreement
that have been delegated, subcontracted or sublicensed to any of its Affiliates, sublicensees or subcontractors. 

(d)        In addition to the terms and conditions set forth in Sections 2.2(a),
(b) and (c), with respect to the Sublicensed UCSF Patent Rights, HGS shall have the right to grant any “Further Sublicense” (as defined in the UCSF Agreement) only in accordance with Sections 4.2 and 4.3 of the UCSF Agreement, and
such Further Sublicense shall be subject to the terms and conditions of the UCSF Agreement. 

2.3        FivePrime’s Retained Rights; License to FivePrime. 

(a)        FivePrime’s Retained Rights. FivePrime and its Affiliates hereby retain
the exclusive right under the FivePrime Technology to: (i) practice and license FivePrime Technology outside the scope of the exclusive license granted to HGS under Section 2.1(a), including conducting FivePrime Development Activities,
Commercializing the Product in the Retained Territory, and Manufacturing, having Manufactured, importing and exporting the Compounds and Products to supply FivePrime Development Activities and the Commercialization of the Product by FivePrime, its
Affiliates and sublicensees in the Retained Territory; (ii) practice FivePrime Technology to exercise its rights (including the conduct of FivePrime-Conducted Trials and Other FivePrime-Conducted Activities, as well as FivePrime’s right to
Co-Promote in the United States) and perform its obligations under this Agreement; (iii) maintain and use the Compound, or fragment thereof, in FivePrime’s libraries and to support drug discovery activities; and (iv) use the Compound
or fragment thereof as a reference standard in drug discovery and non-clinical development activities, provided FivePrime shall ensure that the Compound is not identifiable by a Third Party in the results generated from such activities.

 (b)        License to FivePrime under HGS Technology. Subject to the terms
and conditions of this Agreement, HGS hereby grants to FivePrime: (i) a non-exclusive, fully paid, royalty-free license, without the right to grant sublicenses (but with the right to engage any

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 21 

 
Affiliates and/or subcontractors and grant limited sublicenses to such Affiliates and/or subcontractors solely for the purpose of fulfilling their obligations as such subcontractors of
FivePrime), under the HGS Technology for the purposes of exercising FivePrime’s rights and performing FivePrime’s obligations under this Agreement (including the conduct of the FivePrime-Conducted Trials and Other FivePrime-Conducted
Activities, as well as FivePrime’s right to Co-Promote in the United States); (ii) an exclusive, fully-paid, royalty-free license, with the right to grant sublicenses solely to licensee(s) and/or sublicensee(s) obtaining the right to
Develop and/or Commercialize the Product in the Retained Territory, under the HGS Technology to Develop and use Compounds and Products, and Commercialize, sell and offer for sale Products, in each case in the Retained Territory; and (iii) a
worldwide, exclusive license (except with respect to HGS to the extent HGS supplies FivePrime pursuant to Section 6.1(b)), with the right to grant sublicenses, under the HGS Technology to Manufacture, have Manufactured, import and export
Compounds and Products solely for the purpose of supplying FivePrime, its Affiliates, licensees and sublicensees for the activities under the license granted in subsections (i) and (ii) and to fulfill FivePrime’s supply obligations to
HGS pursuant to Sections 6.1(c) and 6.2(a). 
 2.4        No Implied Licenses;
Negative Covenant. Except as set forth herein, neither Party shall acquire any license or other intellectual property interest, by implication or otherwise, under any trademarks, patents or patent applications owned or Controlled by the other
Party. For clarity, the license granted to each Party under any particular Patent Rights or Know-How Controlled by the other Party shall confer exclusivity to the Party obtaining such license only to the extent the Party granting such license
Controls the exclusive rights to such Patent Rights or Know-How. Each Party shall not, and shall not permit any of its Affiliates or sublicensees to, practice any Patent Rights or Know-How licensed to it by the other Party outside the scope of the
license granted to it under this Agreement. 
 2.5        Disclosure of Know-How.

 (a)        Technology Transfer by FivePrime. Commencing as soon as
practicable after the Effective Date, but no later than *** days from the Effective Date, and continuing through the expiration of the Technology Transfer Period, FivePrime shall disclose to HGS FivePrime Know-How pertaining to the
Manufacture and Development of any Compounds or Products that has not previously been provided to HGS, at no additional cost to HGS, except as expressly set forth in Section 6.2(a). After the Technology Transfer Period on a continuing basis
during the Term, FivePrime shall disclose within a commercially reasonable time to HGS additional FivePrime Know-How that comes into existence from time to time, and perform other technology transfer activities as set forth in this Agreement, in
each case at HGS’ cost and expense. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 22 

 (b)        Technology Transfer by HGS. On a
continuing basis during the Term, HGS shall disclose within a commercially reasonable time to FivePrime HGS Know-How that has not been previously disclosed to FivePrime, or that comes in to existence from time to time, and perform other technology
transfer activities as set forth in this Agreement, in each case at FivePrime’s cost and expense. 

(c)        Documentation and Material Transfer. In performing its technology transfer
obligations under this Section 2.5 or under Section 6.2, each Party shall transfer to the other Party the Know-How Controlled by the transferring Party as such Know-How exists in such transferring Party’s possession, and shall not be
required to translate, reformat or reformulate any such Know-How. The transfer of Know-How under this Section 2.5 may involve a Party’s transfer of certain chemical or biological materials to the other Party (such materials, and for
clarity not including any Compounds or Products supplied by HGS to FivePrime under Section 6.1(b) or from FivePrime to HGS under Section 6.1(c) or 6.2(a), the “Transferred Materials”). Each Party agrees that: (i) it
shall use any Transferred Materials received from the other Party solely for the purpose of practicing the licenses granted to such receiving Party; (ii) it shall not transfer such Transferred Materials received from the other Party to any
Third Party other than to its Affiliates, sublicensees or subcontractors solely for the purpose of fulfilling its obligations or exercising its rights hereunder, provided that such Affiliates, sublicensees or subcontractors are bound by
written obligation of non-transfer and non-use as set forth in this Section 2.5(c); (iii) such Transferred Materials may be experimental in nature and each Party agrees to use such Transferred Materials received from the other Party with
caution and at its own risk, and not to administer such Transferred Materials to humans; and (iv) EACH PARTY PROVIDES SUCH TRANSFERRED MATERIALS TO THE OTHER PARTY AS IS, WITHOUT ANY EXPRESS OR IMPLIED WARRANTY, OR WARRANTY FOR FITNESS FOR A
PARTICULAR PURPOSE. 
 ARTICLE 3 
 GOVERNANCE 
 3.1      Alliance
Managers. Within *** days following the Effective Date, each Party will appoint (and notify the other Party of the identity of) a representative to act as its alliance manager under this Agreement (“Alliance Manager”).
The Alliance Managers will serve as the primary contact points between the Parties and will be primarily responsible for facilitating the flow of information, interaction and collaboration between the Parties. Each Party may replace its Alliance
Manager on written notice to the other Party. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 23 

 3.2        Joint Development Committee.

 (a)        The Parties will establish a joint development committee, composed
of up to *** representatives from each Party, with equal numbers from each Party (the “Joint Development Committee” or the “JDC”). At each Party’s option, its Alliance Manager may be a member of the JDC
or a non-voting participant at the JDC meetings. Within *** days following the Effective Date, each Party will designate its initial members to serve on the JDC and notify the other Party of the dates of availability for the first meeting of
the JDC. Each Party may replace its representatives on the JDC on written notice to the other Party. 

(b)        The JDC shall oversee the HGS Development Activities and their related
Manufacture activities. In addition, the JDC shall serve as a forum for FivePrime to share with HGS information with respect to FivePrime Development Activities. In accordance with the foregoing, the JDC shall: 

 

	 	 (1)	        Oversee, review and discuss activities conducted pursuant to the Development Plan and the actual spend of
development costs under the Development Plan; 

  

	 	 (2)	        review, approve and amend the Development Plan (including the associated budgets) as needed;

  

	 	 (3)	        oversee HGS’ Manufacturing activities under this Agreement; 

 

	 	 (4)	        exchange information with respect to FivePrime Development Activities, subject to any of FivePrime’s
confidentiality obligation to any Third Party licensee; 

  

	 	 (5)	        monitor the progress and performance of any other joint committee established pursuant to this Agreement, except
for the JCC; 

  

	 	 (6)	        determine any matter with respect to which an agreement cannot be reached by any other joint committee
established pursuant to this Agreement, except for the JCC; and 

  

	 	 (7)	        consider and act upon such other matters as specified in this Agreement. 

(c)        The JDC shall not have the authority to: (i) modify or amend the terms
and conditions of this Agreement; (ii) waive either Party’s compliance with the terms and conditions of under this Agreement; or (iii) determine any such issue in a manner that would conflict with the express terms and conditions of
this Agreement. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 24 

 3.3        Meetings of the Joint Development
Committee. 
  (a)        Meetings. The JDC shall meet on a quarterly
basis and at such other times as the Parties may agree. The first meeting of the JDC shall be held as soon as reasonably practicable, but in no event later than *** days following the Effective Date. Meetings shall be held at such dates and
places as are mutually agreed or by teleconference or videoconference. 

 (b)        Attendance. Each Party may from time to time invite a reasonable number
of participants, in addition to its representatives, to attend JDC meetings in a non-voting capacity; provided that if FivePrime intends to have any Third Party (including any consultant) attend such a meeting, the attendance of such Third
Party shall be subject to the prior approval of HGS (such consent not to be unreasonably withheld, delayed or conditioned, including not withholding such consent to allow the participation of a reasonable number of Third Party invitee(s) having
subject matter expertise relevant to the agenda of the applicable meeting) and such Third Party shall be bound by confidentiality and non-use obligations consistent with the terms of this Agreement. 

 (c)        Chairpersons. HGS shall appoint one (1) of its representatives on
the JDC to act as a chairperson of the JDC. The chairperson shall set agendas for JDC meetings with input from FivePrime, provided that the agendas will include any matter requested by either Party. The chairperson shall be responsible for
recording, preparing and, within a reasonable time, issuing minutes of each JDC meeting, which draft minutes shall be subject to review and approval by the JDC at its next regular meeting. 

3.4        Decision-Making. The JDC shall make decisions unanimously, with each
Party’s representatives collectively having one (1) vote and at least one (1) representative from each Party participating in such decision. In the event the JDC determines that it cannot reach an agreement regarding a decision within
the JDC’s authority, then, within *** Business Days after such determination: (a) for any matter that is not a Critical Issue *** shall have the final decision making authority on such matter; and (b) for any matter that
is a Critical Issue, the matter shall be referred to FivePrime’s Chief Executive Officer (or designee) and HGS’ Chief Executive Officer (or designee) for resolution. If such executives cannot resolve the matter within *** Business
Days, then the Chief Executive Officer of *** (or designee) shall have the final decision making authority on such matter. Notwithstanding the foregoing, the Development Plan shall not be amended, without FivePrime’s prior written
approval (which approval may be withheld in FivePrime’s sole discretion), to: (i) increase or materially change the nature of FivePrime-Conducted Trials or Other FivePrime-Conducted Activities; or (ii) require FivePrime to continue
any FivePrime-Conducted Trial if FivePrime, in its reasonable judgment, decides not to continue such trial for any business, scientific, safety, efficacy, enrollment or ethical reason, provided that, in the event FivePrime so decides to
discontinue such trial, HGS shall have no further obligation to reimburse FivePrime under Section 4.2(d) except with respect to costs 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 25 

 
already incurred by FivePrime prior to such discontinuation and any and all standard close out costs incurred thereafter, and HGS shall have the right to continue such trial by itself at its
expense. When *** make a final determination under this Section 3.4, that final determination must be consistent with the terms of this Agreement. 
 3.5        Sub-Committees. 

(a)        Formation. The JDC may, at any time it deems necessary or appropriate,
establish additional joint committees and delegate such of its responsibilities as it determines appropriate to such joint committees. 
 (b)        JCC. In the event FivePrime initiates the Co-Promotion Term pursuant to Section 7.2, within a timeframe to be set forth in the Co-Promotion
Agreement, the JDC will establish a Joint Commercialization Committee (“JCC”), which shall serve largely as an advisory and information-sharing body for the purpose of coordinating the Parties’ Co-Promotion activities, with
HGS’ representatives on the JCC having final decision making authority in the event of any dispute between the Parties. The responsibilities and operations of the JCC shall be set forth in the Co-Promotion Agreement. Prior to any establishment
of the JCC, HGS shall keep FivePrime informed of the market potential for the Product, as well as the planned activities and strategies for the pre-launch activities for, and the Commercialization of, any Product in the Licensed Territory, through
the Alliance Managers or other forum to be agreed upon by the Parties. 

3.6        Costs of Governance. The Parties agree that the costs incurred by each Party in
connection with its participation at any meetings under this Article 3 shall be borne by such Party. 

3.7        Discontinuation of Participation on a Committee. The activities to be performed
by each committee shall solely relate to governance under this Agreement, and shall not involve the delivery of services. Each committee shall continue to exist until the first to occur of: (a) the Parties mutually agreeing to disband the
committee; or (b) FivePrime providing written notice to HGS of its intention to disband and no longer participate in such committee. Once FivePrime has provided such written notice or the Parties mutually agree to disband such committee, such
committee shall have no further obligations under this Agreement and HGS shall have the right to solely decide, without consultation, any matters previously subject to the approval by any such committee. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 26 

 ARTICLE 4 
 DEVELOPMENT 

4.1        General. Subject to the terms and conditions of this Agreement (including
FivePrime’s right to conduct the FivePrime-Conducted Trials and any Other FivePrime-Conducted Activities), HGS shall be the Party responsible for the conduct of HGS Development Activities at its cost and expense, and FivePrime shall be the
Party responsible for the conduct of FivePrime Development Activities at its cost and expense. 

4.2        HGS Development Activities. 

(a)        Development Plan. As of the Effective Date, the Parties have agreed upon an
initial development plan outlining the plans and timelines for the HGS Development Activities, attached to this Agreement as Exhibit C (the “Initial Development Outline”). Within *** days after the Effective Date, the
Parties, through the JDC, will agree (in accordance with Section 3.4) upon a development plan that, subject to any clinical, scientific, or business inputs, is reasonably consistent with the Initial Development Outline in scope and timeline,
which will set forth plans and timelines for the HGS Development Activities for the Compounds and Products, as well as plans and timelines for HGS’ Manufacture of Compounds and Products for use in connection with such HGS Development Activities
(the “Development Plan”). For further clarity, in agreeing to the Development Plan, HGS shall have final decision making authority (in accordance with Section 3.4) over any changes and deviations from the Initial Development
Outline. The Development Plan shall be updated on annual basis, subject to JDC review and approval (in accordance with Section 3.4), and such revision shall become effective upon the approval of the JDC. 

(b)        Diligence. HGS shall use Commercially Reasonable Efforts to Develop at least
one (1) Product and shall conduct all HGS Development Activities in accordance with the Development Plan. Specifically and without limiting the foregoing, HGS shall: (i) by ***, either Commence or open for patient enrollment in at
least *** clinical sites a FP-1039 Phase 1b Trial administering FP-1039 in at least *** combination regimens; and (ii) in the event HGS undergoes a Change of Control, either Commence or open for patient enrollment in at least
*** clinical sites a Phase 2 Clinical Trial for the Product in an Indication other than Mutant Endometrial Cancer within *** months after the Completion of the FP-1039 Phase 1b Trial, unless HGS decides to discontinue the Development
of such Product due to scientific, safety or efficacy issues, provided that in each case, when HGS has exercised and is exercising Commercially Reasonable Efforts, such timeline shall be reasonably extended to account for (i) any delay
caused by any shortage of Product due to Manufacturing-related issues outside of HGS’ reasonable control or (ii) any regulatory delays beyond HGS’ reasonable control. 

(c)        Reporting. During the Term, no later than *** business days prior to
each scheduled meeting of the JDC, the Parties will provide the other Parties’ representatives of the JDC with a written report (e.g. slides) summarizing the status and progress of the HGS Development Activities carried out since the last such
report. Such report from HGS shall be in 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 27 

 
sufficient detail for FivePrime to ascertain HGS’ fulfillment of its diligence obligations under Section 4.2(b) and for FivePrime to fulfill its reporting obligations under the UCSF
Agreement and the ICOS Agreement, respectively. In addition, each Party shall make available to the other Party additional information pertaining to HGS Development Activities as may be reasonably requested by such other Party from time to time.

 (d)        FivePrime-Conducted Trials; Other FivePrime Activities under the
Development Plan. The Parties acknowledge that, as of the Effective Date, FivePrime is conducting a Phase 1 Clinical Trial for a Product comprising FP-1039 (the “FP-1039 Phase 1 Trial”) and a Phase 2 Clinical Trial for FP-1039
in Mutant Endometrial Cancer (“FP-1039 Endometrial Trial (FP-1039-002)”). The FP-1039 Phase 1 Trial and FP-1039 Endometrial Trial (FP-1039-002) are referred to collectively as the “FivePrime-Conducted Trials.” The
Parties agree that, after the Effective Date, FivePrime will continue to be the Party conducting such FP-1039 Phase 1 Trial on behalf of HGS as part of the HGS Development Activities, and HGS shall reimburse FivePrime for expenses (including
FivePrime’s internal FTE expenses and out-of-pocket costs) incurred after the Effective Date by or on account of FivePrime in connection with the conduct of the FP-1039 Phase 1 Trial in accordance with the Development Plan consistent with the
FivePrime-Conducted Trials Budget. 
  (i)        FivePrime shall have the
right to continue to conduct the FP-1039 Endometrial Trial (FP-1039-002) on behalf of HGS as part of the HGS Development Activities in accordance with the Development Plan, and HGS shall reimburse FivePrime for expenses (including FivePrime’s
internal FTE expenses and out-of-pocket costs) incurred after the Effective Date by or on account of FivePrime in connection with the conduct of the FP-1039 Endometrial Trial (FP-1039-002) in accordance with the Development Plan consistent with the
FivePrime-Conducted Trials Budget. 
  (ii)        From time to time during
the Term, FivePrime may conduct other activities on behalf of HGS as part of the HGS Development Activities, at HGS’ request and cost and expense and as agreed upon by the Parties in the Development Plan (such activities, the “Other
FivePrime-Conducted Activities”). 
  (iii)        Changes to
FivePrime-Conducted Trials and/or Other FivePrime-Conducted Activities shall only be made upon prior approval by the JDC in accordance with Section 3.4 and any such approved changes shall be set forth in the Development Plan. 

 (iv)        For as long as FivePrime is conducting the FivePrime-Conducted Trials
and/or any Other FivePrime-Conducted Activities, no later than *** business days prior to each scheduled meeting of the JDC, FivePrime will provide each Parties’ representatives of the JDC with a written report on the status and progress
of the FivePrime-Conducted Trials and Other FivePrime-Conducted Activities carried out since the last such report. In addition, 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 28 

 
FivePrime shall make available to HGS all information about FivePrime-Conducted Trials and Other FivePrime-Conducted Activities as may be reasonably requested by HGS from time to time during the
Term. The status, progress and results of the FivePrime-Conducted Trials and Other FivePrime-Conducted Activities under this Section 4.2(d) shall be discussed in reasonable detail at meetings of the JDC. 

4.3        FivePrime Development Activities. As between the Parties, FivePrime shall be
the Party responsible for the conduct of FivePrime Development Activities, at its discretion and expense. For as long as FivePrime is conducting any FivePrime Development Activities, no later than *** business days prior to each scheduled
meeting of the JDC, FivePrime will provide each Parties’ representatives of the JDC with a summary report on the status and progress of the FivePrime Development Activities carried out since the last such report, subject to any of
FivePrime’s confidentiality obligations to any Third Party licensee. 

4.4        Cross-Territory Development Activities. 

(a)        Cross-Territory Development. The Parties acknowledge that during the Term, it
may be beneficial for the Development of the Product for a Party, in support of its Regulatory Filings and Regulatory Approvals of the Product in its own territory, to conduct clinical trials for the Product in the other Party’s territory (the
Party desiring to conduct such clinical trial, the “Non-Resident Party” and the other Party, the “Resident Party”). In that respect, subject to Sections 4.4(b) and 4.4(c), as applicable, each Party (either by itself
or through any of its Affiliates, licensees or sublicensees) shall be permitted to conduct any clinical trials for the Product as a Non-Resident Party in the Resident Party’s territory by providing the Resident Party at least *** days advance
written notification through the JDC or pursuant to the notice provision in Section 14.4, which notification shall be accompanied by the following information: a synopsis of such clinical trial that describes the objectives, the patient
population to be enrolled in such clinical trial, the proposed procedure, schema, endpoints and statistical rationale, the countries in which such clinical trial will be conducted, and the estimated enrollment and duration for such clinical trial,
provided that the Non-Resident Party (either by itself or through any of its Affiliates, licensees or sublicensees) shall have the right, without the need to provide any prior notification to the Resident Party to discuss any proposed
clinical trial with investigators and clinical institutions in the Resident Party’s territory. 

(b)        Cross-Territory Development in the Licensed Territory. Notwithstanding
Section 4.4(a), FivePrime’s Development activities in the Licensed Territory shall be subject to the following restrictions. FivePrime (either by itself or through any of its Affiliates, licensees or sublicensees) shall not, unless HGS
provides its prior written consent: 
 (i)        File an IND or Commence a
clinical trial of a Product in the Licensed Territory for any Indication that is included in the Development Plan with respect to which HGS (A) is then conducting a clinical trial of a Compound or Product in such Indication or (B) has a
bona fide intention to Commence a clinical trial of a Compound or Product in such Indication within *** thereof; or 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 29 

 (ii)        File an IND or Commence a
clinical trial of a Product in an Indication in (A) the United States or Canada if HGS is Commercializing a Product and has received Regulatory Approval for such Product in such Indication in the United States or Canada or (B) the EU if
HGS is Commercializing a Product and has received Regulatory Approval for such Product in such Indication in any country in the EU, provided that this Section 4.4(b)(ii) shall not be construed as requiring FivePrime (either by itself or
through any of its Affiliates, licensees or sublicensees) to suspend or terminate any ongoing clinical trials that it is conducting of a Product for such Indication in United States, Canada or the EU, as the case may be, that Commenced prior to the
first sale of such Product to a Third Party for distribution, use or consumption in the United States, Canada or the EU, respectively, after the receipt of the Regulatory Approval for such Indication by HGS, or any of its Affiliates or sublicensees
in the United States, Canada or the EU, respectively. 
 (c)        Cross-Territory
Development in the Retained Territory. Notwithstanding Section 4.4(a), HGS’ Development activities in the Retained Territory shall be subject to the following restrictions: 

(i)        If FivePrime (either by itself or through any of its Affiliates, licensees or
sublicensees) is Commercializing a Product and has received Regulatory Approval for such Product in a particular Indication in any country in the Retained Territory, HGS (either by itself or through any of its Affiliates or sublicensees) shall not
be permitted to, unless FivePrime provides its written consent, conduct or attempt to conduct any clinical trial of a Product for such Indication in such country, provided that this Section 4.4(c)(i) shall not be construed as requiring
HGS (either by itself or through any of its Affiliates or sublicensees) to suspend or terminate any ongoing clinical trials that it is conducting of a Product for such Indication in such country that Commenced prior to the first sale of such Product
to a Third Party for distribution, use or consumption in such country after the receipt of the Regulatory Approval for such Indication by FivePrime, or any of its Affiliates, licensees or sublicensees; 

(ii)        HGS (either by itself or through any of its Affiliates or sublicensees) shall
not be permitted to, unless FivePrime provides its prior written consent, file an IND or initiate any clinical trial of a Product in the Retained Territory in an Indication for which, at the time such Indication was added to the Development Plan, a
Phase 3 Clinical Trial for a Product in such Indication is open for patient enrollment in the Retained Territory by or on behalf of FivePrime or any of its Affiliates, licensees or sublicensees; 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 30 

  (iii)        If FivePrime (either by
itself or through any of its Affiliates, licensees or sublicensees) is conducting a clinical trial of a Product in a particular Indication in the Retained Territory, HGS (either by itself or through any of its Affiliates or sublicensees) shall not
be permitted to, unless FivePrime provides its written consent, conduct or attempt to conduct any clinical trial of a Product in such Indication at the same clinical sites where FivePrime, its Affiliates, licenses or sublicensees is conducting such
clinical trial for such Indication; and 
  (iv)        HGS (either by
itself or through any of its Affiliates or sublicensees) shall not, unless FivePrime provides its prior written consent, file any IND or initiate or conduct any clinical trial of any Product in any Indication in Japan. 

(d)        Notwithstanding anything to the contrary in this Section 4.4, once a
Non-Resident Party (either by itself or through any of its Affiliates, licensees or sublicensees) Commences a clinical trial in the other Party’s territory in accordance with the rest of this Section 4.4, such Non-Resident Party shall have
the right to complete such trial without seeking further consent from the Resident Party. In the event the Non-Resident Party (either by itself or through any of its Affiliates, licensees or sublicensees) conducts a clinical trial in the Resident
Party’s territory, the data and results obtained by such Non-Resident Party in the course of such clinical trial shall be disclosed and shared with the Resident Party and shall be subject to the use by such Resident Party (and/or its Third
Party collaborator(s)), in each case pursuant to Section 5.5. 

4.5        Compliance; Subcontractors. Each Party agrees that in performing its
obligations or exercising its rights under this Agreement: (a) it shall comply in all material respects with all applicable Laws; and (b) it will not employ or engage any Person who has been debarred by any Regulatory Authority, or, to
such Party’s knowledge, is the subject of debarment proceedings by a Regulatory Authority. The Parties shall comply with pharmacovigilance procedures set forth in Section 5.2 and as further agreed in writing by the Parties in the course of
Developing, Manufacturing and Commercializing Compounds and Products hereunder. Each Party shall have the right to engage subcontractors for purposes of conducting activities assigned to it under the Development Plan, provided that any such
subcontractor is bound by written obligations of confidentiality and non-use consistent with this Agreement and has agreed to assign to the Party engaging such subcontractor (or grant a fully-paid, royalty-free, worldwide license to such Party, with
the right to sublicense to the other Party, under) inventions made by such subcontractor in the course of performing such subcontracted work that relate to any Compound or Product or their use, Manufacture or sale. Each Party shall remain
responsible for any obligations under the Development Plan that have been delegated or subcontracted to any subcontractor, and shall be responsible for the performance of its subcontractors, and each Party will have the right to designate any such
subcontractor as the recipient of any technology transfer from the other Party. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 31 

 4.6        Coordination between the Parties.
The Parties acknowledge that FivePrime may seek one (1) or more Third Party collaboration partner(s) for the Development and/or Commercialization of the Product in the Retained Territory (such partner, the “Retained Territory
Partner”). After FivePrime grants any such Retained Territory Partner a license to Develop and/or Commercialize the Product in the Retained Territory, FivePrime will notify HGS in writing. Upon either FivePrime’s or HGS’ request,
FivePrime, HGS and such Retained Territory Partner(s) shall discuss in good faith to coordinate the Development activities for the Product in the Licensed Territory and the Retained Territory. 

ARTICLE 5 

REGULATORY 
 5.1        Regulatory Filings. 

(a)        Existing IND. As of the Effective Date, FivePrime holds an IND for FP-1039 in
the U.S. with the IND No. *** (FP-1039) (the “Existing IND”), under which it is conducting the FivePrime-Conducted Trials. As of the Effective Date, FivePrime plans to complete the FP-1039 Phase 1 Trial, and to continue
conducting the FP-1039 Endometrial Trial (FP-1039-002) in the U.S. under the same IND and in other countries under INDs to be filed in such other countries that are substantially foreign equivalents of the Existing IND (such future INDs, the
“Endometrial Foreign INDs”). 
 (b)        Transition to HGS.
Promptly after the Effective Date, FivePrime shall transfer and assign to HGS the Existing IND, so that after such transfer and assignment, HGS shall be the exclusive owner of the Existing IND. HGS shall fully cooperate with and shall assist and
facilitate FivePrime: (i) to continue to conduct the FP-1039 Phase 1 Trial under the Existing IND without interruption in accordance with Section 4.2; (ii) to continue to conduct the portion of the FP-1039 Endometrial Trial
(FP-1039-002) in the U.S. under the Existing IND in accordance with Section 4.2; and (iii) to prepare and file the remaining Endometrial Foreign INDs, including by providing FivePrime the right to reference the Existing IND in connection
therewith and by timely executing any documentation that is required therefor. 

(c)        HGS Regulatory Filings. After the transfer of the Existing IND to HGS, HGS
shall be responsible for: (i) making all Regulatory Filings, submissions, reports, updates and supplements with any Regulatory Authority with respect to any Compound or Product, itself or through any of its Affiliates or sublicensees, including
filing INDs in HGS’ name for Phase 2 Clinical Trials and Phase 3 Clinical Trials for FP-1039 to be conducted by HGS under the Development Plan; and (ii) obtaining, holding and maintaining all Regulatory Approvals and Pricing Approvals
throughout the Licensed Territory in the name of HGS or any of its Affiliates or sublicensees, in each case at its expense and with the oversight of the JDC. All Regulatory 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 32 

 
Filings filed by HGS for a Compound or Product, as well as the Existing IND after its transfer to HGS, shall be collectively referred to as “HGS Regulatory Filing”. HGS shall
provide FivePrime copies of all material Regulatory Filings (e.g. protocols, study reports and investigator brochures) and material correspondence (e.g. end of clinical trials meeting minutes) between HGS and any Regulatory Authority. In the event
HGS fails to provide such Regulatory Filings or material correspondence on its own, FivePrime may request and HGS shall be obligated to, within *** days, respond to such request and provide such requested material that is in HGS’
possession or is otherwise accessible by HGS. 
 (d)        Meetings with Regulatory
Authorities. HGS will lead all discussions and meetings with any Regulatory Authority in support of Regulatory Approval of any Product in the Licensed Territory during the Term, provided that HGS shall seek FivePrime’s input for, and
FivePrime shall have the right to participate in, such discussions and meetings pertaining to the FivePrime-Conducted Trials and any Other FivePrime-Conducted Activities. On a regular basis through the JDC, HGS shall provide FivePrime with updates
on its discussions and meetings with Regulatory Authorities. In no event shall HGS submit any Regulatory Filings to seek Regulatory Approvals for the Product in the Retained Territory. 

5.2        Adverse Events. Within *** days after the Effective Date, the Parties shall
discuss in good faith and enter into a pharmacovigilance and adverse event reporting agreement setting forth the worldwide pharmacovigilance procedures for the Parties with respect to the life cycle development (leading up to and during
Commercialization) of the Product, such as transfer of safety data and corresponding regulatory reporting history, safety data exchange, adverse event monitoring and reporting (the “Pharmacovigilance Agreement”). Such
Pharmacovigilance Agreement shall govern the global pharmacovigilance procedures to be agreed upon by HGS, FivePrime, and their respective Affiliates, licensees and sublicensees. The terms of the Pharmacovigilance Agreement shall allow HGS to
establish and maintain the company core data sheet covering essential clinical safety (the “Core Safety Information”), indications, dosing and other Product information such as prescriber or patient information or the packaging
information (collectively the “Company Core Data Sheet”), and FivePrime shall have the right to access, review and comment on such Company Core Data Sheet, and use the information contained therein, including Core Safety
Information, in connection with the Development and Commercialization of the Compound and Product by FivePrime or any of its Affiliates, licensees or sublicensees. HGS shall be responsible for the creation and maintenance of the master global safety
database which shall cross-reference any and all worldwide adverse events relating to the Compound or Product (“Global Safety Database”) in accordance with the procedures set forth in the Pharmacovigilance Agreement. As promptly as
reasonably practicable following the Effective Date, FivePrime will deliver to HGS copies of all relevant information in FivePrime’s possession concerning any and all safety data, including side effects, injuries, toxicities or pregnancy or
sensitivity events associated with the clinical use of FP-1039 in humans. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 33 

 5.3        No Harmful Actions. If either
Party believes that the other Party, as the case may be, is taking or intends to take any action with respect to the Product that could reasonably be expected to have a material adverse impact upon the regulatory status of the Product in the
Retained Territory or the Licensed Territory, such Party shall have the right to bring the matter to the attention of the JDC. 

5.4        Notification of Threatened Action. Each Party shall immediately notify the
other Party of any information it receives regarding any threatened or pending action, inspection or communication by any Regulatory Authority, which may affect the safety or efficacy claims of the Product or the continued marketing of the Product.
Upon receipt of such information, the Parties shall consult with each other in an effort to arrive at a mutually acceptable procedure for taking appropriate action. 
 5.5        Data Exchange and Use. This Section 5.5 shall not apply to any pharmacovigilance data (which is addressed in Section 5.2). FivePrime
and/or its Third-Party collaborator shall disclose to and permit HGS and/or its Third Party collaborator (if any) to use preclinical or clinical data, in the form final study reports, from trials or studies conducted by FivePrime and/or its
Third-Party collaborator for the Compound in HGS’ regulatory filings in the Territory at no additional cost to HGS. Similarly, HGS and its Third Party collaborator (if any) shall disclose to and permit FivePrime and/or its Third-Party
collaborator to use preclinical or clinical data, in the form final study reports, from trials or studies conducted by HGS for the Compound in regulatory filings outside of the Territory at no cost to FivePrime. All such final study reports provided
by one Party or its Third Party collaborator (if any) to the other Party or such other Party’s Third Party collaborator (if any) shall be provided, to the extent reasonably available to the providing Party, in formats reasonably useable by the
receiving Party for purposes of cross-filing with a Regulatory Authority (e.g., final study reports should be provided electronically in file formats that allow information to be reorganized or sorted). 

5.6        Remedial Actions. Each Party will notify the other immediately, and promptly
confirm such notice in writing, if it obtains information indicating that the Product may be subject to any recall, corrective action or other regulatory action with respect to a Product taken by virtue of applicable law in the Licensed Territory (a
“Remedial Action”). The Parties will assist each other in gathering and evaluating such information as is necessary to determine the necessity of conducting a Remedial Action. HGS shall, and shall ensure that its Affiliates and
sublicensees will, maintain adequate records to permit the Parties to trace the manufacture of the Product and the distribution and use of the Product. In the event HGS determines that any Remedial Action with respect to the Product in the Licensed
Territory should be commenced or Remedial Action is required by any Regulatory Authority having jurisdiction over the matter, HGS will control and coordinate all efforts necessary to conduct such Remedial Action, at its cost and expense. As between
the Parties, FivePrime shall have sole discretion with respect to any matters relating to any Remedial Action in the Retained Territory, at its cost and expense, 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 34 

 
except to the extent such Remedial Action is attributed to the non-compliance or non-conformity of any Product supplied to FivePrime by HGS, in which case HGS shall bear all cost and expense in
connection with such Remedial Action in proportion to the extent such Remedial Action is attributable to such non-compliance or non-conformity. 
 ARTICLE 6 
 MANUFACTURING 

6.1        Manufacture and Supply. 

(a)        HGS’ Responsibility. Subject to Section 6.2(a) below, HGS shall be
responsible for the Manufacture and supply of Compounds and Products used in all HGS Development Activities (including, in a timely manner, supply Products for the FivePrime-Conducted Trials and any Other FivePrime-Conducted Activities) and for use
in the Commercialization of the Product in the Licensed Territory by HGS, its Affiliates and sublicensees, at its cost and expense (including being responsible for any Third Party payment obligations in accordance with Section 8.4). The Parties
shall cooperate in the transfer of the FivePrime Manufacturing Know-How to HGS in a timely manner in accordance with Section 6.2(a) below, and HGS shall Manufacture Compounds and Products as soon as practicable. 

(b)        At FivePrime’s request, and subject to Section 6.2(a), HGS shall
Manufacture or, at its sole option, have Manufactured by a Third-Party contract manufacturing organization and supply to FivePrime Compound and/or filled and finished Product, including Product containing FP-1039 (and placebo, if requested by
FivePrime) in accordance with specifications agreed upon by the Parties. Such supply shall be: (i) at *** if such Product is used in connection with its conduct of FivePrime-Conducted Trials and any Other FivePrime-Conducted Activities;
(ii) at *** percent (***%) of HGS’ Manufacturing Costs for such Product if such Product is used in connection with the conduct of FivePrime Development Activities that are Phase 1 Clinical Trials or Phase 2 Clinical Trials;
(iii) at *** percent (***%) of HGS’ Manufacturing Costs for such Product if such Product is used in connection with the conduct of FivePrime Development Activities that are Phase 3 Clinical Trials or Phase 4 Studies; and
(iv) at *** percent (***%) of HGS’ Manufacturing Costs for such Product if such Product is used in connection with the Commercialization of the Product by FivePrime, its Affiliates or sublicensees. In the event FivePrime
exclusively sublicenses its rights under Section 2.3 of this Agreement to a licensee or sublicensee (a “FivePrime Exclusive Licensee”) or FivePrime undergoes a Change of Control (either such event, a “FivePrime Rights
Transferred Event”), HGS’ obligation of supply under this Section 6.1(b) shall terminate: (i) *** after the effective date of the FivePrime Rights Transferred Event, if the FivePrime Rights Transferred Event occurs
after the first (1st) sale by or on behalf of
FivePrime or such FivePrime Exclusive Licensee to any Person other than FivePrime, any FivePrime Exclusive Licensee or an Affiliate 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 35 

 
thereof for distribution, use or consumption of any Product in a country or jurisdiction in the Retained Territory after obtaining (A) all required approvals by applicable Regulatory
Authorities in such country or jurisdiction necessary for the Commercialization of such Product for an Indication and (B) all required pricing and reimbursement approvals for such Product in such country or jurisdiction from Government
Authorities required by applicable Law or Governmental Authorities (“First Retained Territory Commercial Sale”); or (ii) *** after the First Retained Territory Commercial Sale, if the FivePrime Rights Transferred Event
occurs prior to the First Retained Territory Commercial Sale. HGS shall have the right to establish, in lieu of the Manufacturing Costs, a transfer price as set forth in a supply agreement (as further contemplated below), which transfer price will
represent HGS’ good faith estimate of the Manufacturing Costs that would be incurred with respect to the Manufacturing activities to which the transfer price applies. For sake of clarity, such transfer price will include any applicable mark-up
in accordance with the mark-up described in sub numerals *** above, which is intended to cover other HGS manufacturing related expenses not accounted for in the Manufacturing Costs. In the event HGS supplies FivePrime such Compound and/or
Product through a Contract Manufacturer: (A) HGS shall first submit to FivePrime for approval the identity of at least *** such proposed Contract Manufacturers and FivePrime shall have the opportunity to approve at least *** of
the proposed Contract Manufacturers. In the event FivePrime declines to approve at least *** of the proposed Contract Manufacturers, HGS shall be deemed to have satisfied its supply obligations under this Agreement; (B) HGS shall
negotiate with such Contract Manufacturer so that FivePrime is a party to, or a third party beneficiary of, the supply agreement between HGS and such Contract Manufacturer; and (C) HGS may request that FivePrime allow such Contract Manufacturer
to directly invoice FivePrime for Manufacturing Costs and such permission shall not be unreasonably withheld. The terms and conditions (including key performance indicators, scheduling details, and production planning) for such Manufacturing and
supply shall be set forth in a supply agreement to be agreed upon by the Parties in good faith in advance, provided, and assuming that HGS or the Contract Manufacturer contracted by HGS has manufactured at least *** lots of Product,
HGS shall not be required to supply to FivePrime the initial order of Product (other than Product as part of, or Manufactured using, FivePrime Existing Inventory as described in Section 6.1(c) below) with a delivery date that is earlier than
the date that is *** months after FivePrime first places an order for such Product, otherwise HGS shall not be required to supply to FivePrime such initial order of Product with a delivery date that is earlier than the date that is ***
months after FivePrime first places an order for such Product. The Parties further agree that such supply agreement shall also contemplate terms and conditions customarily included in supply agreements with contract manufacturing organizations,
including limitation of liability, representations and warranties and insurance requirements. 

(c)        FivePrime Existing Inventory. The Parties acknowledge that, as of the
Effective Date, FivePrime is in possession of certain quantities of FP-1039 in both drug substance and drug product forms that were procured by FivePrime prior to the Effective Date 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 36 

 
(the “FivePrime Existing Inventory”). After the Effective Date, FivePrime shall continue to possess and hold all of such FivePrime Existing Inventory for the purpose of
conducting the FivePrime-Conducted Trials, provided, however, FivePrime shall provide HGS, at no cost, with sufficient quantities of FivePrime Existing Inventory on an as-needed basis for performance of pre-clinical studies, as well as
*** of cGMP-grade Product for testing purposes. 
 6.2        Transfer of
Manufacturing Know-How. 
 (a)        Transfer of FivePrime Manufacturing
Know-How. The Parties desire that HGS be able to commence the Manufacture of Compounds and Products (including FP-1039) as soon as practicable after the Effective Date. To enable HGS to commence such Manufacture, FivePrime shall perform
technology transfer to HGS as set forth below, all at HGS’ cost and expense. HGS shall reimburse FivePrime for the fully burdened FTE costs at the FTE Rate of FivePrime personnel directly involved in such technology transfer allocated to
efforts spent on such technology transfer, and shall reimburse FivePrime for all reasonable out-of-pocket costs incurred by the Parties in connection with such technology transfer (including any payment due to any Contract Manufacturer, such as
ICOS, for its assistance in connection therewith). The Parties agree that, until such time as HGS is able to Manufacture the Compounds and Products at its facilities but for no longer than a period of *** months after the Effective Date,
FivePrime shall continue to obtain supply of Compounds and Products for clinical use by both Parties from its existing Contract Manufacturer and shall provide clinical supplies of Compounds and Products to HGS for clinical use pursuant to the
Development Plan until such time as HGS is able to Manufacture Compounds and Products at its facilities. HGS shall pay FivePrime for such clinical supplies delivered to HGS in an amount equal to the direct costs incurred by FivePrime for such
Compounds and Products under its agreement with its existing Contract Manufacturer plus any FTE costs incurred by FivePrime at the FTE Rate as necessary to manage and/or oversee the supply of Compounds and Products to HGS pursuant to the previous
sentence. 
  (i)        Within *** days after the Effective Date,
FivePrime shall make available and transfer copies to HGS of the FivePrime Technology that are *** in the Manufacture of Compounds or Product and as of such date are being used by FivePrime or its Contract Manufacturers to Manufacture
FP-1039, including batch record summaries and other applicable documentation (the “FivePrime Manufacturing Know-How”), solely for HGS to Manufacture or have Manufactured Compounds and Products for use in connection with exercising
its rights or performing its obligations hereunder; 
  (ii)        During
the Technology Transfer Period, when requested by HGS, FivePrime shall make available to HGS, its Affiliates or Contract Manufacturers a reasonable number of appropriately trained personnel of FivePrime to provide, on a mutually convenient
timetable, technical assistance in the transfer and demonstration of the FivePrime Manufacturing 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 37 

 
Know-How that is *** for HGS to Manufacture Compounds and Products. After the Technology Transfer Period, if requested by HGS, FivePrime will in good faith endeavor to provide additional
technical assistance to HGS, its Affiliates or Contract Manufacturers as reasonably requested; 

 (iii)        FivePrime shall allow HGS, its Affiliates or Contract Manufacturers to
cross reference FivePrime’s or its Contract Manufacturers’ DMF or such other regulatory submissions, in each case Controlled by FivePrime and applicable to the Manufacture of Compounds and/or Product, if any; 

 (iv)        FivePrime shall use Commercially Reasonable Efforts to cause its
Contract Manufacturers for FP-1039 to provide reasonable technical assistance in the transfer of FivePrime Manufacturing Know-How. At HGS’ request, FivePrime will use Commercially Reasonable Efforts to assist HGS in entering into supply
agreements with one (1) or more of FivePrime’s Contract Manufacturers for the Manufacture of Compounds or Products; and 
  (v)        FivePrime acknowledges and agrees that during the initial transfer of FivePrime Manufacturing Know-How, FivePrime shall continue, at
HGS’ expense, all ongoing stability testing and similar activities until all assays have been transferred to HGS. 

(b)        Transfer of HGS Manufacturing Know-How. The Parties desire that FivePrime be
able to Manufacture and have Manufactured Compounds and Products during the Term. To enable FivePrime to do so, HGS shall perform technology transfer to FivePrime as set forth below, all at FivePrime’s cost and expense. FivePrime shall
reimburse HGS, at the FTE Rate, for HGS personnel directly involved in such technology transfer allocated to efforts spent on such technology transfer, and shall reimburse HGS for all reasonable out-of-pocket costs incurred by the Parties in
connection with such technology transfer (including any payment due to any Contract Manufacturer for its assistance in connection therewith). 
  (i)        From time to time during the Term, HGS shall make available and transfer copies to FivePrime of the HGS Technology that are *** in
the Manufacture of Compounds or Product, including batch record summaries (the “HGS Manufacturing Know-How”), solely for FivePrime to Manufacture or have Manufactured Compounds and Products for use in connection with exercising its
rights or performing its obligations hereunder; 
  (ii)        when
reasonably requested by FivePrime, HGS shall make available to FivePrime, its Affiliates or Contract Manufacturers a reasonable number of appropriately trained personnel of HGS to provide, on a mutually convenient timetable, technical assistance in
the transfer and demonstration of the HGS Manufacturing Know-How that is *** for FivePrime to Manufacture Compounds and Products, and HGS shall, upon FivePrime’s reasonable request, in good faith endeavor to provide additional technical
assistance to FivePrime, its Affiliates or Contract Manufacturers as reasonably requested; and 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 38 

 (iii)        allow FivePrime, its Affiliates
or Contract Manufacturers to cross reference HGS’ or its Contract Manufacturers’ DMF or such other regulatory submissions, in each case Controlled by HGS and applicable to the Manufacture of Compounds and/or Product, if any. 

6.3        Compliance with Law. HGS warrants that Compounds and Products Manufactured by
or on behalf of HGS or any of its Affiliates or sublicensees, whether supplied to FivePrime or retained by HGS for its own use, shall be Manufactured in accordance with all applicable Laws and cGMPs and shall not be adulterated or misbranded within
the meaning of the FDC Act, or any similar law of any other jurisdiction, or deemed an article which may not, under the provisions of the FDC Act, or any similar law of any other jurisdiction, be introduced into interstate commerce. 

ARTICLE 7 

COMMERCIALIZATION 
 7.1        Commercialization. 

(a)        General. Subject only to FivePrime’s right to elect to Co-Promote each
Product in the United States as set forth in Section 7.2, HGS will be responsible for Commercialization of Products throughout the Licensed Territory and the Manufacture of the Compounds and Products for commercial supply, and shall use
Commercially Reasonable Efforts to Commercialize Products in each Major Market promptly after obtaining the Regulatory Approval to do so. As between the Parties, FivePrime shall have the sole and exclusive right to Commercialize Products throughout
the Retained Territory. 
 (b)        Scientific and Medical Leaders. After the
Effective Date and during the Term, each Party shall make reasonable efforts, but have no obligation, to include the other Party in activities involving scientific and medical leaders and experts in such first Party’s territory. Each Party
shall have the right to attend conferences in the other Party’s territory and to give presentations and host booths at such conferences with respect to the Compound and/or the Product, provided that such attending Party shall not promote
any Compound or Product at such conferences to Prescribers in such other Party’s territory. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 39 

 7.2        FivePrime Co-Promotion Right.
FivePrime shall have the right to elect to Co-Promote the Product in the United States pursuant to this Section 7.2. 

(a)        Initiation of Co-Promotion Term. FivePrime shall have the right to Co-Promote
any Product in the United States during the co-promotion term for such Product (the “Co-Promotion Term”). The Co-Promotion Term with respect to a particular Product may be initiated by FivePrime as follows. HGS shall notify
FivePrime in writing, if possible, at least *** months, but in any event no later than *** months, prior to the anticipated Filing of the first (1st) BLA for such Product (the “BLA Notification”), followed by written notification to FivePrime of
the actual Filing of such BLA. FivePrime shall have the right, but not the obligation, to initiate the Co-Promotion Term for such Product, until the date that is the later of: (i) *** after the Filing of such BLA; or (ii) ***
after FivePrime’s receipt of the BLA Notification from HGS (the “FivePrime Election Period”). At the time HGS provides FivePrime with the BLA Notification, HGS shall also provide FivePrime in writing the following information
known to HGS at such time, relating to the Co-Promotion opportunity for such Product in the United States: (A) the estimated total number and positions of annual Details, the territory configuration and types of Prescribers (as well as managed
care accounts) ranked by prescribing and purchasing volume, the structure of the field force and other Commercialization personnel to be deployed, and distribution plans; (B) HGS’ estimated Product pricing and revenue forecast for the
potential Co-Promotion Term; and (C) estimated budgets (firm for launch year and estimates for the first *** years after launch) of launch and Commercialization costs, including estimated budgets for, and reasonable itemization (to the
extent available) of, Marketing/Medical Affairs Costs and Sales Costs (each as defined below). In the event that FivePrime wishes to initiate the Co-Promotion Term with respect to any particular Product in the United States, FivePrime shall notify
HGS in writing of such initiation on or before the end of the FivePrime Election Period. FivePrime shall be deemed to have decided not to initiate the Co-Promotion Term with respect to such Product in the United States, if FivePrime does not provide
to HGS written notice of such initiation by the end of such FivePrime Election Period. In the event FivePrime initiates such Co-Promotion Term, FivePrime shall have the right to provide *** percent (***%) of the total anticipated
Details for such Product using a sales force that consists of full-time FivePrime employees (it being understood that such employees shall not be required to *** percent (***%) *** under the Co-Promotion Agreement). 

(b)        Co-Promotion Agreement. Promptly after FivePrime initiates a Co-Promotion Term
for a Product in the United States, HGS and FivePrime shall commence negotiations in good faith and enter into a co-promotion agreement (the “Co-Promotion Agreement”) for such Product that shall be in accordance with the terms and
conditions of this Agreement (including this Section 7.2). The Parties shall use Commercially Reasonable Efforts to enter into and execute the Co-Promotion Agreement for a particular Product within *** months following FivePrime’s
initiation of the Co-Promotion Term for each Product under Section 7.2(a). The Co-Promotion Agreement shall set forth the budgets mutually agreed upon by the Parties for Marketing/Medical Affairs Costs and Sales Costs applicable to
Section 7.2(e) which budgets shall be consistent with the estimated budgets provided by HGS to FivePrime at the time of notification pursuant to Section 7.2(a) unless the Parties otherwise agree in writing. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 40 

 (c)        Co-Promotion Term. The
Co-Promotion Term with respect to a particular Product shall continue for as long as such Product is being sold in the United States, unless: (i) FivePrime provides HGS with a *** prior written notice of FivePrime’s decision to
relinquish its Co-Promotion rights with respect to such Product; (ii) HGS terminates FivePrime’s right to Co-Promote for FivePrime’s uncured material breach in its Co-Promotional activities in accordance with Section 11.2(b); or
(iii) either Party terminates the Co-Promotion arrangements, which either Party shall be entitled to do upon the entry of a Generic Product to such Product in the United States, by providing the other Party with a *** advance written
notification of its election to so terminate the Co-Promotion arrangements for such Product. In the event of any termination of a Co-Promotion Term hereunder: (A) HGS and FivePrime shall reasonably cooperate to transition all of
FivePrime’s Co-Promotion activities with respect to such Product to HGS or any of its Affiliates or sublicensees (as designated by HGS) so as to minimize disruption to sales activity; (B) FivePrime shall withdraw its sales representatives
from such Co-Promotion activities in an orderly manner; and (C) FivePrime’s Co-Promotion obligation under the Co-Promotion Agreement and funding obligation under Section 7.2(e) shall cease upon the effective date of such termination.

 (d)        Sales Force Allocation. If FivePrime initiates the Co-Promotion
Term for a particular Product in the United States, HGS shall have the right to allocate between the Parties the Prescribers to whom each Party will provide sales calls, provided that, except as otherwise mutually agreed by the Parties in a
Co-Promotion Agreement for a given Product: (i) the Prescribers assigned to FivePrime shall correspond to the top Prescribers with regard to their prescribing and purchasing volume of pharmaceutical products for cancer, in the top ***
(***%) of Prescribers with regard to prescribing and purchasing volume of pharmaceutical products for the Indication for which the Product is being promoted; and (ii) HGS’ sales force will also be assigned to the Prescribers
assigned to FivePrime to increase promotional effort for the Product by providing coverage from both Parties. 

(e)        Cost Sharing. Each Party shall bear all costs and expenses incurred by such
Party in connection with its own Co-Promotional activities for any Product in the United States. In addition, on a rolling Calendar Quarterly basis, for as long as FivePrime has initiated its Co-Promotion Term and such Co-Promotion Term has not been
terminated pursuant to Section 7.2(c), FivePrime shall bear *** of the total Marketing/Medical Affairs Costs and Sales Costs (each as defined below) incurred by the Parties specific to the Product in the United States, and FivePrime
shall make any reimbursement payment to HGS on a Calendar Quarterly basis within *** days after receiving an invoice from HGS, provided, however, FivePrime’s obligation to cost-share under this Section 7.2(e) and the
Co-Promotion Agreement for any Marketing/Medical Affairs Costs and Sales Costs incurred prior to the first royalty payment from HGS to FivePrime shall be deferred as follows: (i) HGS shall provide FivePrime with an invoice detailing such
deferred payment within *** 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 41 

 
days after the First Commercial Sale of the Product, and FivePrime shall pay such deferred costs ratably on a quarterly basis over a period of *** years after such First Commercial Sale.
The mechanism for calculating and submitting such payments shall be set forth in the Co-Promotion Agreement. For purposes of this Agreement and the Co-Promotion Agreement, the following terms shall have the following meanings: 

   (i)        “Marketing/Medical Affairs Costs” means the
specific direct costs incurred by HGS for marketing a Product being Co-Promoted in the United States and the conduct of medical affairs activities in connection with the Co-Promotion of such Product in the United States, including its internal costs
(at a rate to be agreed upon by the Parties in the Co-Promotion Agreement) and costs for outside services and expenses (including consultants, agency fees, meeting costs and free goods), but in all cases only as actually incurred and directly
applicable to the Product being Co-Promoted in the United States. Marketing/Medical Affairs Costs do not include any costs or expenses related to distribution or Detailing to Prescribers for any Product, or related to any activities that promote
either Party’s business as a whole or are otherwise not specific to a Product in the United States (e.g., corporate image advertising), but shall include out-of-pocket costs associated with medical science liaisons. 

   (ii)        “Sales Costs” means costs incurred by HGS
for sales force training, sales force materials, and any other costs of items or services used by both Parties’ sales forces specifically in connection with the Co-Promotion of a Product being Co-Promoted in the United States; provided,
however, that: (A) Sales Costs shall not include any costs associated with salary, benefits, travel, incentive compensation or other compensation for Commercialization personnel, or any overhead, infrastructure and vehicle costs for any
Product in the United States, which each Party shall bear on its own as part of any Co-Promotion under this Agreement; and (B) Sales Costs shall not include any Marketing/Medical Affairs Costs, and vice versa. 

   (f)        Decision-Making. Regardless of whether or not FivePrime
elects to Co-Promote any Product(s) in the United States, HGS shall retain all decision-making authority with respect to Commercialization of Products in the United States and the remainder of the Licensed Territory, including with respect to
Product branding, selection of Product trademarks, advertising materials, regulatory and legal affairs, design and implementation of launch activities, total sales force to be employed for each Product, and Product pricing and distribution,
provided that HGS shall make such decisions in accordance with the terms and conditions of this Agreement and the Co-Promotion Agreement. HGS shall book all sales for Products under this Agreement. 

7.3        Patent Marking; Product Marking; Advertisement. HGS shall mark all Products in
accordance with the applicable patent marking laws, and shall require all of its Affiliates and sublicensees to do the same. To the extent permitted by applicable Law, HGS shall indicate on Product packaging, advertisement and promotional materials
that the Product is in-licensed from FivePrime. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 42 

 7.4        Diversion. Each Party hereby
covenants and agrees that it will not, and will ensure that its Affiliates, sublicensees and subcontractors will not, either directly or indirectly, promote, market, distribute, import, sell or have sold Products, including via the Internet or mail
order, to any Third Party address or Internet Protocol (“IP”) address in the other Party’s territory. As to such countries in the other Party’s territory: (i) such Party shall not engage in any advertising or
promotional activities relating to the Product directed primarily to customers or other buyers or users of the Product located in such countries; and (ii) such Party shall not solicit orders from any prospective purchaser located in such
countries. If a Party receives any order from a prospective purchaser located in a country in the other Party’s territory, such Party shall immediately refer that order to such other Party and shall not accept any such orders. Neither Party may
deliver or tender (or cause to be delivered or tendered) any Product in the other Party’s territory. 
 ARTICLE 8

 FINANCIAL PROVISIONS 
 8.1        Upfront Payment. HGS shall pay to FivePrime a one-time, non-refundable, non-creditable upfront payment of fifty million dollars (US $50,000,000)
in cash by wire transfer within *** business days after the Effective Date. FivePrime acknowledges and agrees that its receipt of this payment shall trigger its obligation to pay a Sublicense Fee to The Regents pursuant to the UCSF Agreement,
and FivePrime agrees to make such payment within *** Business Days after receiving the payment from HGS under this Section 8.1. For sake of clarity, HGS shall have no further obligation to reimburse FivePrime for its obligation to pay
such Sublicense Fee triggered by the upfront payment received by FivePrime under this Section 8.1. FivePrime shall provide HGS with proof of payment to UCSF within *** business days of making such payment. 

8.2        Milestone Payments. 

  (a)        Milestones. HGS shall pay to FivePrime the non-refundable,
non-creditable milestone payments set forth below, in each case upon the first (1st) achievement of such milestone for each Product by or on behalf of HGS or any of its Affiliates or sublicensees (except when a milestone event is with respect to Mutant Endometrial Cancer, such
milestone may be achieved by or on behalf of HGS, FivePrime, or both): 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 43 

					
	  	  	  

Milestone Payment

 

	
Milestone
  
	  	 If then current

Manufacturing Process
 Yield is less than or
 equal to *** g/L

 
	  	 If then
current
 Manufacturing Process
 Yield is greater than ***
 g/L

 

	  

Development Milestones

 

	 	 	 
	 1.     The
Commencement of the FP-1039 Endometrial Trial (FP-1039-002)
  
	  	$***	  	$***
	 	 	 
	 2.     The
Completion of the FP-1039 Endometrial Trial (FP-1039-002) that involved the dosing of at least 10 patients
  
	  	$***	  	$***
	 	 	 
	 3.     The
Completion of the FP-1039 Phase 1b Trial
  
	  	$***	  	$***
	 	 	 
	 4.     The
Commencement of a first Phase 2 Clinical Trial of a Product in an Indication other than Mutant Endometrial Cancer
  
	  	$***	  	$***
	 	 	 
	 5.     The
Commencement of a first Phase 3 Clinical Trial of a Product in an Indication other than Mutant Endometrial Cancer
  
	  	$***	  	$***
	 
	
Regulatory Milestones

 

	 	 
	 Milestone

 
	  	 Milestone Payment

 

	 	 	 
	 6.     The
Filing of a BLA with the FDA for a Product for the first Indication
  
	  	$***	  	$***
	 	 	 
	
7.     The Filing of a MAA with the EMA (or in *** of the five (5) Major Markets in the
EU) for a Product for the first Indication
  
	  	$***	  	$***

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 44 

					
	
Approval Milestones

 

	 	 	 
	 8.     The
receipt of Regulatory Approval in the United States of a Product for the first Indication other than Mutant Endometrial Cancer
  
	  	$***	  	$***
	 	 	 
	 9.     The
receipt of Regulatory Approval in the *** of the five (5) Major Markets in the European Union of a Product for the first Indication other than Mutant Endometrial Cancer
  
	  	$***	  	$***
	 	 	 
	 10.   The receipt of
Regulatory Approval in Canada for a Product for the first Indication other than Mutant Endometrial Cancer
  
	  	$***	  	$***
	 	 	 
	 11.   The receipt of
Regulatory Approval in the United States of a Product for Mutant Endometrial Cancer or a second Indication other than Mutant Endometrial Cancer

 
	  	$***	  	$***
	 	 	 
	 12.   The receipt of
Regulatory Approval in *** of the five (5) Major Markets in the European Union of a Product for Mutant Endometrial Cancer or a second Indication other than Mutant Endometrial Cancer

 
	  	$***	  	$***
	 	 	 
	
13.   The receipt of Regulatory Approval in Canada of a Product for Mutant Endometrial Cancer or a
second Indication other than Mutant Endometrial Cancer
  
	  	$***	  	$***

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 45 

					
	  

Commercial Milestones

 

	 	 	 
	
14.   First (1st) Calendar Year in which aggregate total Net Sales by HGS, its Affiliates and sublicensees for such Product throughout
the Licensed Territory exceed $***
  
	  	$***	  	$***
	 	 	 
	 15.   First (1st) Calendar Year in which aggregate total Net Sales by HGS, its
Affiliates and sublicensees for such Product throughout the Licensed Territory exceed $***
  
	  	$***	  	$***
	 	 	 
	
16.   First (1st) Calendar Year in which aggregate total Net Sales by HGS, its Affiliates and sublicensees for such Product throughout
the Licensed Territory exceed $***
  
	  	$***	  	$***

 (b)        HGS shall notify FivePrime in writing and make
the corresponding milestone payment as set forth in Section 8.2(a) within *** days following the achievement of each milestone event, provided that for all Commercial Milestones, payment shall be made by the earlier of
(i) *** Business Days after the date of the report of HGS’ independent registered public accounting firm with respect to the audit by such firm of HGS’ consolidated statements of operations for the period ended December 31
of the Calendar Year during which such sales milestone has been achieved or (ii) *** days from the end of the Calendar Year during which such sales milestone has been achieved. 

(c)        With respect to the milestone payments set forth in this Section 8.2:
(i) each of the milestone payments set forth in Section 8.2(a) shall be payable only once for each Product to achieve such milestone; (ii) in the event the Parties discontinue the Development activities of the lead Product for safety
or efficacy reasons, and HGS elects to initiate or continue Development activities for any back-up Product, HGS shall not be required to pay a milestone payment triggered by the achievement of a milestone event for such back-up Product that has
already been triggered and made by HGS for the discontinued lead Product; (iii) if more than one (1) commercial milestones have been met for the first time during the same Calendar Year for a

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 46 

 
particular Product, then HGS shall remain obligated to make payments to FivePrime for milestone payments triggered by the occurrence of each and every such commercial milestone event;
(iv) the achievement of a milestone event (the “Current Milestone”) with respect to a Product shall be conclusive evidence of the achievements of all preceding milestone events for such Product, and, to the extent any milestone
payment corresponding to any such preceding milestone event has not been made for such Product, such milestone payment shall become due concurrently with the milestone payment triggered by such Current Milestone; and (v) the identity of the
“first Indication” and the “second Indication” shall be separately determined for each milestone event based solely upon the order in which such milestone event is achieved. For example, in the case where the first Commencement
of a Phase 3 Clinical Trial is for non-small cell lung cancer, the second Commencement of a Phase 3 Clinical Trial is for renal cell carcinoma, the first acceptance for MAA Filing is for renal cell carcinoma and the second acceptance for MAA Filing
is for non-small cell lung cancer, then non-small cell lung cancer is the “first Indication” for the milestone triggered by the Commencement of Phase 3 Clinical Trial and the “second Indication” for milestone triggered by the
acceptance of MAA Filing, and renal cell carcinoma is the “second Indication” for the milestone triggered by the Commencement of Phase 3 Clinical Trial and the “first Indication” for the milestone triggered by the acceptance of
MAA Filing. 
 8.3        Royalty Payments. 

  (a)        Royalty Rates. Subject to the other terms of this
Section 8.3, HGS shall make quarterly royalty payments to FivePrime as provided under Section 8.5 for all Products under this Agreement based on annual Calendar Year total aggregate Net Sales of all Products in the Licensed Territory by
HGS and any of its Affiliates or sublicensees, at the applicable rates set forth below: 
  

			
	  

Total Net Sales of all Products
 Throughout the Licensed Territory in
 any Calendar Year by HGS and any
of
 its Affiliates or Sublicensees
  
	  	
Royalty Rate

 

	 	 
	Portion of Net Sales of all Products less than or equal
to $***	  	 *** percent (***%)
of
 Net Sales

 

	 	 
	 Portion of
Net Sales of all Products greater than $*** but less than or equal to $***
  
	  	 *** percent (***%)
of
 Net Sales

 

	 	 
	 Portion of
Net Sales of all Products greater than $*** but less than or equal to $***
  
	  	 *** percent (***%)
of
 Net Sales

 

	 	 
	Portion of Net Sales of all Products greater than
$***	  	 *** percent (***%)
of
 Net Sales

 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 47 

 (b)        Royalty Term. For each Product,
on a Product-by-Product and country-by-country basis, HGS’ royalty payment obligations under this Section 8.3 shall commence upon the First Commercial Sale of such Product in such country and expire upon the later of: (i) the
expiration of the last-to-expire Valid Claim included in FivePrime Patents in such country within the Licensed Territory claiming the composition of matter of, or the method of making or using, such Product; or (ii) the twelfth
(12th) anniversary of the First Commercial Sale of such
Product in such country (“Royalty Term”). 
 (c)        Royalty
Reduction For a Product Subject to Generic Competition in a Country. For any period during the Royalty Term in which a Generic Product is being sold in a particular country during the Term, on a Product-by-Product and country-by-country basis,
the royalty due under Section 8.3(a) shall be reduced *** percent (***%) for Net Sales of such Product in such country. 
 (d)        Basis for Royalty. This Section 8.3 is intended to provide for payments to FivePrime *** to the percentages of Net Sales set forth in
this Section 8.3 for the duration of the Royalty Term. In establishing this payment structure, the Parties recognize, and HGS acknowledges, the substantial value of the various actions and investments undertaken by FivePrime prior to the
Effective Date and that FivePrime will undertake under this Agreement, and that the value of the FivePrime Technology licensed to HGS hereunder resides substantially in FivePrime Know-How. As a result, the Parties attribute such value to
FivePrime’s leading proprietary knowledge in the subject matter, its discovery, design and optimization of the composition of FP-1039 for pharmaceutical applications using FivePrime proprietary discovery technology, proprietary manufacturing
process for FP-1039 including trade secrets, preclinical and clinical data pertaining to FP-1039, and Regulatory Filings made by FivePrime prior to the Effective Date, in each case created or generated by FivePrime through the expenditure of
significant resources and as a result of the innovative capabilities unique to FivePrime. The Parties agree that because FivePrime is not separately compensated under this Agreement for such additional benefits, a royalty, including a reduced
royalty rate for Net Sales of Products after a Generic Product enters into the market, is appropriate. The Parties have agreed to the payment structure set forth herein as a convenient and fair mechanism for both Parties in order to compensate
FivePrime for these additional benefits. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 48 

   (e)        Royalty Adjustment for
Co-Promoted Products. In the event FivePrime initiates the Co-Promotion Term for a Product in the United States under Section 7.2, for as long as the Co-Promotion Agreement applicable to such Product remains in full force and effect, the
royalty rates applicable for such Product in the United States shall increase by *** above the rates otherwise applicable to such Net Sales of such Product in the United States, and such increase shall not be subject to any offset or
reduction by operation of Section 8.3(c) or Section 8.4. For avoidance of doubt, the royalty increase as contemplated herein shall be FivePrime’s only compensation pursuant to the Co-Promotion Agreement. The Co-Promotion shall not
provide for and FivePrime shall not be entitled to any other form of profit split. 

8.4        Third Party Obligations 

  (a)        UCSF Agreement and ICOS Agreement. Except as otherwise provided in
Section 6.1 with regard to a Sublicense Fee, HGS shall be solely responsible for the payment of: (i) subject to Section 8.4(iii) below, the milestone payments, set forth in Section 9 of the UCSF Agreement and Section 3.3 of
the ICOS Agreement; and (ii) payment obligations arising on or after the First Commercial Sale of a Product, including royalty payments, in each case under Section 8 of the UCSF Agreement and Section 3.5 of the ICOS Agreement and
attributable to the Manufacture, Development and Commercialization of the Compounds and Products by or on behalf of HGS or any of its Affiliates or sublicensees, in addition to its obligations to make payments to FivePrime under this Article 8,
without the right to offset any of the payments due under the UCSF Agreement and/or the ICOS Agreement against HGS’ payment obligation to FivePrime hereunder. In particular: 

     (i)        All milestone payments owed to The Regents under
the UCSF Agreement and/or to ICOS under the ICOS Agreement, pursuant to Section 8.4(a), are due within *** days after the occurrence of each milestone event under the UCSF Agreement or ICOS Agreement, as applicable. HGS shall make to
FivePrime any such milestone payment that is attributable to the Manufacture, Development and/or Commercialization of the Product by or on behalf of HGS, its Affiliates or sublicensees, no later than *** days after the occurrence of each such
milestone event under the UCSF Agreement and the ICOS Agreement. FivePrime shall pass on any such milestone payment to UCSF or ICOS, as applicable, no later than the due date for such payment under the UCSF Agreement or the ICOS Agreement.

      (ii)        All royalties owed to The Regents,
pursuant to Section 8.4(a), under the UCSF Agreement are due on or before the end of each Calendar Quarter for the preceding Calendar Quarter, as provided in Section 5.2 of the UCSF Agreement, and all royalties owed to ICOS, pursuant to
Section 8.4(a), under the ICOS Agreement are due within *** days after the end of a Calendar Quarter for such Calendar Quarter. HGS shall make to FivePrime any and all such royalty payment that is attributable to the Manufacture,
Development and/or Commercialization of the Product by or on behalf of HGS, its Affiliates or sublicensees, no later 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 49 

 
than *** days after the end of the Calendar Quarter to which such royalties apply, calculated in accordance with the terms and conditions of the UCSF Agreement and ICOS Agreement, as
applicable, and accompanied by the quarterly royalty reports required under Section 11.7 of the UCSF Agreement and Sections 5.1 and 5.2 of the ICOS Agreement, as applicable. FivePrime shall pass on any such royalty payment and quarterly royalty
report to The Regents and to ICOS no later than the due date for such payment and report under the UCSF Agreement and ICOS Agreement, as applicable. If there is any deficiency in the payment by HGS of royalties owed to The Regents or ICOS, HGS shall
promptly correct any such deficiency upon request by FivePrime. FivePrime shall provide to HGS proof of payments made by FivePrime to The Regents and to ICOS on behalf of HGS after HGS has submitted such payment to FivePrime under
Section 8.4(a), no later than *** business days after FivePrime’s submitting such payment. 

     (iii)        In the event FivePrime, its Affiliates,
licensees or sublicensees first achieves the milestones set forth in Section 9 of the UCSF Agreement and Section 3.3 of the ICOS Agreement as a result of FivePrime Development Activities and/or Commercialization of the Products in the
Retained Territory, FivePrime shall be solely responsible for such milestones to The Regents and ICOS. In such event, HGS shall no longer be responsible for such milestone payments owed to The Regents under the UCSF Agreement and/or to ICOS under
the ICOS Agreement, pursuant to Section 8.4(a). 
   (b)        HGS
Agreements with Third Parties. In the event that HGS reasonably determines that rights to intellectual property owned or Controlled by a Third Party are *** to use, Develop, Manufacture, Commercialize or import any Compound or Product,
HGS shall have the right to negotiate and acquire such rights through a license or otherwise. HGS shall be solely responsible for all payments to such Third Party in exchange of such rights with no offset of HGS’ payment obligations to
FivePrime under this Agreement, except that HGS shall have the right to offset *** percent (***%) of the royalties it pays to such Third Party in exchange for obtaining a license under any Valid Claim that claims ***, in the
Licensed Territory, against HGS’ royalty obligations to FivePrime for the same Product and for the same royalty period, provided that in no event shall any single royalty payment from HGS to FivePrime be reduced to less than ***
percent (***%) of the amount that would otherwise be payable to FivePrime hereunder. 

  (c)        Royalty Reductions. The Parties agree that, notwithstanding the
royalty rate reduction mechanisms set forth herein, by operation of all of the offsets set forth in Sections 8.3(c) and 8.4 combined: (i) in the event the incremental royalty increase set forth in Section 8.3(e) does not apply, the royalty
rate for a particular Product shall in no event be reduced to below *** percent (***%) of the royalty rate set forth in Section 8.3(a); and (ii) in the event the incremental royalty increase set forth in
Section 8.3(e) applies, the royalty rate for a particular Product applicable to the Net Sales of such Product in the United States shall in no event be reduced to below *** percent (***%) of the royalty rate set forth in
Section 8.3(a) plus *** percentage points (***%). 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 50 

 8.5        Reports; Payment of Royalty; Annual
Reconciliation. During the Term, following the First Commercial Sale of a Product and on a Calendar Quarter basis, HGS shall furnish to FivePrime a Sales & Royalty Report and any additional information necessary for FivePrime to fulfill
its reporting obligations under the UCSF Agreement and the ICOS Agreement. Reports shall be due within *** days following the close of each Calendar Quarter. Royalties shown to have accrued by each Sales & Royalty Report shall be due
and payable on the date such royalty report is due. If no royalty payment is due for a particular royalty period, the Sales & Royalty Report shall so state. HGS shall keep complete and accurate records in sufficient detail to enable the
royalties payable hereunder to be determined. HGS shall pay royalties to FivePrime under Section 8.3 based on estimated total annual Calendar Year Net Sales, as follows: 
    (a)        for each of the first three (3) Calendar Quarters of the Calendar Year, HGS shall make quarterly payments of royalties owed
to FivePrime under Section 8.3 on the basis of HGS’ good faith estimates of total aggregate Net Sales for all Products (subject to any applicable adjustment under this Agreement) for each of such first three (3) Calendar Quarters,
with each such quarterly payment to be made by the deadline set forth above; 

   (b)        for the fourth (4th) Calendar Quarter of the Calendar Year, HGS shall calculate and
pay the royalty owed for such fourth (4th) Calendar
Quarter by the deadline set forth above on the basis of actual annual Net Sales of total aggregate Net Sales for all Products (subject to any applicable adjustment under this Agreement) for such Calendar Quarter and the three (3) preceding
Calendar Quarters, with appropriate adjustment after reconciling the estimates and payments for the three (3) preceding Calendar Quarters against actual amounts for such first three (3) Calendar Quarters; and 

   (c)        if such reconciliation shows that HGS owes FivePrime any
additional royalties for such prior Calendar Quarters, such additional amount shall be paid together with the amount owed for the fourth (4th) Calendar Quarter, and if such reconciliation shows that HGS has overpaid FivePrime for such prior Calendar
Quarters, the overpayment shall be offset against the amount owed for the fourth (4th) Calendar Quarter. 

8.6        Currency; Exchange Rate. All payments to be made by HGS to FivePrime under this
Agreement shall be made in United States dollars by bank wire transfer in immediately available funds to a bank account designated by written notice from FivePrime to HGS. In the case of sales outside the United States, the rate of exchange to be
used in computing the monthly amount of currency equivalent in United States dollars due FivePrime shall be made at the monthly rate of exchange utilized by HGS in its worldwide accounting system. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 51 

 8.7        Reports for Reimbursement. Within
*** days after the end of each Calendar Quarter, each Party shall submit to the other Party a written report setting forth in reasonable detail all applicable JDC approved Development expenses, along with Technology Transfer, Manufacturing
and Patent related costs. Each Party shall provide approval of the other Party’s written report within *** days of receipt. If either Party, in a given Calendar Quarter, has no applicable Development, Technology Transfer, Manufacturing
or Patent related expense to report, the report shall so state. Within *** days after approval of each Party’s report, HGS shall, using the FivePrime Report and the HGS Report, prepare a reconciliation report which shall show the
Development, Technology Transfer, Manufacturing and/or Patent expenses owed by HGS to FivePrime or by FivePrime to HGS, as the case may be. The Party owing the other Party a reconciliation payment shall make such payment within *** days
following receipt of the reconciliation report. 
 8.8        Late Payments. If a
Party does not receive payment of any sum due to it on or before the due date therefor, simple interest shall thereafter accrue on the sum due to such Party from the due date until the date of payment at a per-annum rate of prime plus ***
percentage point or the maximum rate allowable by applicable Law, whichever is less. 

8.9        Taxes. 

   (a)        Taxes on Income. Each Party shall be solely responsible for
the payment of all taxes imposed on its share of income arising directly or indirectly from the activities of the Parties under this Agreement. 
    (b)        Withholding Tax. The Parties agree to cooperate with one another and use reasonable efforts to avoid or reduce tax withholding
or similar obligations in respect of royalties, milestone payments, and other payments made by HGS to FivePrime under this Agreement. To the extent HGS is required to deduct and withhold taxes on any payment to FivePrime, HGS shall pay the amounts
of such taxes to the proper Governmental Authority in a timely manner, provided that, in the event any deduction or withholding of tax obligation arises or is increased as a result of an action by or on behalf of HGS, so that: (i) the
payments arise or are deemed to arise in a territory triggering withholding tax obligations; (ii) there is a change in the tax residency of HGS; or (iii) the payments arise or are deemed to arise through a branch of HGS in a territory
triggering withholding tax obligations (the “HGS Withholding Tax Action”), then the payment by HGS shall be increased by the amount necessary to ensure that FivePrime receives an amount equal to the same amount that it would have
received had no HGS Withholding Tax Action occurred. 

   (c)        Tax Cooperation. FivePrime shall provide HGS any tax forms
that may be reasonably necessary in order for HGS to not withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty. FivePrime shall use reasonable efforts to provide

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 52 

 
any such tax forms to HGS in advance of the due date. Each Party shall provide the other with reasonable assistance to enable the recovery, as permitted by Law, of withholding taxes or similar
obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the Party bearing such withholding tax under this Section 8.9. 
 8.10        FivePrime Records and HGS Audit Rights. 
      (a)        FivePrime shall keep complete, true and accurate books and records in relation to its activities the costs and
expenses of which are reimbursable by HGS under this Agreement. Upon the written request of HGS and not more than once in each Calendar Year (other than for cause), FivePrime shall permit an independent certified public accounting firm or audit
firm, selected by HGS and subject to FivePrime’s approval, not to be unreasonably withheld, to have access during normal business hours to such of the records of FivePrime as may be reasonably necessary to verify the accuracy of such costs and
expenses for any Calendar Year ending not more than *** prior to the date of such request. HGS shall provide *** days written notice for such request and audits shall not take place during the months of December through March. HGS
shall treat all financial information subject to review under this Section 8.10 in accordance with the confidentiality and non-use provisions of this Agreement. 
      (b)        HGS shall bear its internal expenses and the out-of-pocket costs for engaging such accounting firm and/or audit firm
in connection with performing such audits; provided, however, that if any such audit uncovers an overbilling by FivePrime of the costs and expenses associated with such activities that exceeds *** percent (***%) of the
total owed for such activities then FivePrime shall reimburse HGS for the expenses and costs for such audit. 

     (c)        If such accounting firm and/or audit firm
organization identifies an overbilling by FivePrime during such period, FivePrime shall pay HGS the amount of the discrepancy within *** days of the date HGS delivers to FivePrime such accounting firm’s and/or audit firm’s
organization’s written report. 
 8.11        HGS Records and FivePrime Audit
Rights. 
      (a)        HGS shall keep complete,
true and accurate books and records in relation to this Agreement. Upon the written request of FivePrime and not more than once in each Calendar Year (other than for cause), HGS shall permit an independent certified public accounting firm or audit
firm selected by FivePrime, but subject to HGS’ approval not to be unreasonably withheld, to have access during normal business hours to such of the records of HGS as may be reasonably necessary to verify the accuracy of the royalty reports
hereunder for any Calendar Year ending not more than *** prior to the date of such request. FivePrime shall provide *** days written notice for such request and audits shall not take place during the months of December through March.
FivePrime shall treat all financial information subject to review under this Section 8.11 or under any sublicense agreement in accordance with the confidentiality and non-use provisions of this Agreement. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 53 

    (b)        FivePrime shall
bear its internal expenses and the out-of-pocket costs for engaging such accounting firm in connection with performing such audits; provided, however, that if any such audit uncovers an underpayment of milestones payments or royalties
by HGS that exceeds *** percent (***%) of the total owed for such payment or payment period, as applicable, then HGS shall reimburse FivePrime for the expenses and costs for such audit. 

   (c)        If such accounting firm identifies an underpayment by HGS
during such period, HGS shall pay FivePrime the amount of the discrepancy within *** days of the date FivePrime delivers to HGS such accounting firm’s written report. 

   (d)        HGS shall include in each sublicense granted by it pursuant
to this Agreement a provision requiring the sublicensee to make reports to HGS, to keep and maintain records of sales made pursuant to such sublicense and to grant access to such records by FivePrime’s independent accountant to the same extent
required of HGS under this Agreement. If such HGS sublicense includes any Sublicensed Patent Rights, HGS shall also include in such sublicense such provisions as are required pursuant to the UCSF Agreement and ICOS Agreement, as applicable,
including a provision requiring the sublicensee to comply with the UCSF Agreement and ICOS Agreement, as applicable, including fulfill any and all payment obligations thereunder that arise as a result of the grant such sublicense or the
sublicensee’s exercising of its rights under such sublicense. 
 ARTICLE 9 

INTELLECTUAL PROPERTY RIGHTS 
 9.1        Ownership of Inventions. Ownership of all Inventions shall be based on inventorship, as determined in accordance with the rules of
inventorship under United States patent laws. Specifically: (a) Inventions invented solely by or on behalf of a Party shall be owned solely by such Party; and (b) Inventions invented jointly by or on behalf of the Parties shall be owned
jointly by FivePrime and HGS, with each Party owning an undivided half interest, without a duty of accounting or an obligation to seek consent from the other Party for the exploitation or license thereof (subject to the exclusive licenses granted
hereunder). Know-How generated by the Parties jointly under the Agreement, including Know-How that is included in such jointly-owned Inventions, shall be referred to as “Joint Know-How”, and Patents claiming such jointly-owned
Inventions shall be referred to as “Joint Patents”. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 54 

 9.2        Patent Prosecution. 

   (a)        FivePrime Patents (other than Joint Patents). 

     (i)        The Prosecution of FivePrime Patents (other than
Joint Patents) in the Licensed Territory as well as all patent applications that are filed pursuant to the Patent Cooperation Treaty while such patent applications are in the international phase (the “FivePrime Licensed Territory
Patents”), shall be pursued by outside counsel jointly selected by the Parties; provided that in the event the Parties disagree on the selection of such outside counsel, HGS shall have the deciding vote. FivePrime and HGS will confer
on the Prosecution of FivePrime Licensed Territory Patents. With respect to FivePrime Licensed Territory Patents that claim a Compound or Product, but do not claim any compounds or products comprising or directed to ***
(“Product-Specific FivePrime Licensed Territory Patents”), HGS shall be responsible for Prosecution, and shall reimburse FivePrime for *** Percent (***%) of Patent Costs incurred by or on account of FivePrime or HGS
after the Effective Date in connection with conducting such activities after the Effective Date. With respect to all other FivePrime Licensed Territory Patents, FivePrime will be responsible for Prosecution, and HGS shall reimburse FivePrime for
*** Percent (***%) of Patent Costs incurred by or on account of FivePrime or HGS after the Effective Date in connection with conducting such activities after the Effective Date. In addition to HGS’ obligation to bear a portion of
Patent Costs as described above, HGS shall also reimburse FivePrime for any and all payments made by FivePrime to The Regents after the Effective Date as reimbursement for The Regents’ Patent Prosecution Costs (as defined in the UCSF Agreement)
pursuant to Section 20.4 of the UCSF Agreement, but only to the extent that the Patent Prosecution Costs are incurred for FivePrime Licensed Territory Patents. For all FivePrime Licensed Territory Patents the responsible Party will consult with
the other Party and keep such other party reasonably informed of the status of such FivePrime Licensed Territory Patents and will promptly provide the other Party with material correspondences received from patent authorities. In addition, the
responsible Party will promptly provide the other Party with drafts of all proposed material filings and correspondences to the patent authorities with respect to such FivePrime Licensed Territory Patents for the other Party’s review and
comment prior to the submission of such proposed filings and correspondences. The responsible Party will confer with the other Party and take into consideration the other Party’s comments prior to submitting such filings and correspondences,
provided that the other Party will provide such comments within *** days of receiving the draft filings and correspondences from the responsible Party. If the other Party does not provide comments within such period of time, then the
other Party shall be deemed to have no comment to such proposed filings or correspondences. In case of disagreement between the Parties on ***, the matter shall be referred to the JDC for resolution in accordance with the procedures set forth
in Section 3.4, provided that, in the event the matter is escalated to FivePrime’s Chief Executive Officer (or designee) and HGS’ Chief Executive Officer (or designee) pursuant to Section 3.4 and such executives cannot
agree on such matter, then the final decision shall be made by *** Chief Executive Officer (or designee) on matters 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 55 

 
with respect to Prosecution of Product-Specific FivePrime Licensed Territory Patents, and the final decision shall be made by *** Chief Executive Officer (or designee) on all other matters
with respect to FivePrime Licensed Territory Patents. 

   (ii)        The responsible party will notify the other Party of any
decision to cease prosecution and/or maintenance of, or not to continue to pay the expenses of prosecution and/or maintenance of, any such FivePrime Licensed Territory Patents. The responsible Party will provide such notice at least *** days
prior to any filing or payment due date, or any other due date that requires action, in connection with such Patent Right. In such event, the responsible Party shall permit the other Party, at its discretion and expense, to continue prosecution or
maintenance of such FivePrime Licensed Territory Patent. HGS’ prosecution or maintenance of such FivePrime Licensed Territory Patent shall not change the Parties’ respective rights and obligations under this Agreement with respect to such
FivePrime Licensed Territory Patent other than those expressly set forth in this Section 9.2(a)(ii). 

   (b)        Joint Patents 

   (i)        Each Party will be responsible for Prosecution of any Joint
Patents in its territory at its own cost and expense. Each Party will fully cooperate with the other Party in connection with the Prosecution of such Joint Patents in such other Party’s territory. The responsible Party in a particular territory
will consult with the other Party, will keep the other Party reasonably informed of the status of such Joint Patents, and will promptly provide the other Party with drafts of all proposed material filings and correspondences with the patent
authorities with respect to such Joint Patents for such other Party’s review and comment prior to the submission of such proposed filings and correspondences. The responsible Party will confer with the other Party and take into consideration
such other Party’s comments prior to submitting such filings and correspondences, provided that such other Party will provide such comments within *** days of receiving the draft filings and correspondences from the responsible
Party. If such other Party does not provide comments within such period of time, then such other Party shall be deemed to have no comment to such proposed filings or correspondences. In case of disagreement between the Parties with respect to the
Prosecution of such Joint Patents, the final decision shall be made by the responsible Party. 

   (ii)        The responsible Party will notify the other Party of any
decision to cease prosecution and/or maintenance of, or not to continue to pay the expenses of prosecution and/or maintenance of, any Joint Patents. The responsible Party will provide such notice at least *** days prior to any filing or
payment due date, or any other due date that requires action, in connection with such Patent Right. In such event, such other Party shall have the right, but not the obligation, to continue prosecution or maintenance of such Joint Patent at its
expense. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 56 

    (c)        HGS Patents (other
than Joint Patents). 
    (i)        As between the Parties,
HGS shall have the first right (but not the obligation) to prepare, file, register, prosecute and maintain the HGS Patents (other than Joint Patents), at HGS’ cost and expense. For all HGS Patents in the Retained Territory (the “HGS
Retained Territory Patents”), HGS will consult with FivePrime and keep FivePrime reasonably informed of the status of such HGS Retained Territory Patents and will promptly provide FivePrime with material correspondences received from patent
authorities. In addition, HGS will promptly provide FivePrime with drafts of all proposed material filings and correspondences to the patent authorities with respect to such HGS Retained Territory Patents for FivePrime’s review and comment
prior to the submission of such proposed filings and correspondences. HGS will confer with FivePrime and take into consideration FivePrime’s comments prior to submitting such filings and correspondences, provided that FivePrime will
provide such comments within *** days of receiving the draft filings and correspondences from HGS. If FivePrime does not provide comments within such period of time, then FivePrime shall be deemed to have no comment to such proposed filings
or correspondences. In case of disagreement between the Parties with respect to the Prosecution of such HGS Retained Territory Patents, the final decision shall be made by HGS. 

   (ii)        HGS will notify FivePrime of any decision to cease
prosecution and/or maintenance of, or not to continue to pay the expenses of prosecution and/or maintenance of, any such HGS Retained Territory Patents. HGS will provide such notice at least *** days prior to any filing or payment due date,
or any other due date that requires action, in connection with such Patent Right. In such event, HGS shall permit FivePrime, at its discretion and expense, to continue prosecution or maintenance of such HGS Retained Territory Patent.
FivePrime’s prosecution or maintenance of such HGS Retained Territory Patent shall not change the Parties’ respective rights and obligations under this Agreement with respect to such HGS Retained Territory Patent other than as expressly
set forth in this Section 9.2(c)(ii). 
    (iii)        In
the event this Agreement terminates and FivePrime obtains the license under such HGS Patents pursuant to Article 11, then FivePrime shall have the right, but not the obligation, to elect to prosecute and maintain such HGS Patents at FivePrime’s
cost and expense. 
 9.3      Patent Enforcement. 

   (a)        Each Party will notify the other within *** business
days of becoming aware of any infringement by a Third Party of any of the FivePrime Patents, Joint Patents, or HGS Patents through the Development or commercialization of a Product in the Field in the Licensed Territory of which such Party becomes
aware, including any “patent certification” (or its equivalent for biologic products) filed in the United States under 21 U.S.C. §355(b)(2) or 21 U.S.C. §355(j)(2) or similar provisions in other jurisdictions and of any
declaratory judgment, opposition, or similar action alleging the invalidity, unenforceability or non-infringement of any of the FivePrime Patents, Joint Patents, or HGS Patents (collectively “Product Infringement”). 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 57 

    (b)        HGS shall have
the first right to bring and control any legal action in connection with such Product Infringement in the Licensed Territory at its own expense as it reasonably determines appropriate, and FivePrime shall have the right to be represented in any such
action by counsel of its choice. If HGS decides not to bring such legal action, it shall so inform FivePrime promptly and FivePrime shall have the right to bring and control any legal action in connection with such Product Infringement in the
Licensed Territory at its own expense as it reasonably determines appropriate after consultation with HGS. 

   (c)        At the request of the Party bringing the action, the other
Party shall provide reasonable assistance in connection therewith, including by executing reasonably appropriate documents, cooperating in discovery and joining as a party to the action if required. 

   (d)        In connection with any such proceeding, the Party bringing
the action shall not enter into any settlement admitting the invalidity of, or otherwise impairing the other Party’s rights in, the FivePrime Patents, Joint Patents, or HGS Patents without the prior written consent of the other Party.

    (e)        Any recoveries resulting from such an action
relating to a claim of Product Infringement shall be first applied against payment of each Party’s costs and expenses in connection therewith. Any such recoveries in excess of such costs and expenses (the “Remainder”) will be
shared by the Parties as follows: *** percent (***%) of such Remainder shall be retained by (or if received by the other Party, paid to) the Party bringing such action, and *** percent (***%) of such Remainder shall be
paid to the Party not bringing such action. 

   (f)        FivePrime shall have the exclusive right to enforce the
FivePrime Patents for any infringement that is not a Product Infringement. 

9.4        Third Party Patent Proceedings. Each Party will notify the other Party and
confer with such other Party prior to challenging the patent position of a Third Party where that patent position is relevant to a Compound or Product. Such challenges include declaratory judgment actions, inter parties re-examinations, or
interferences or oppositions (collectively “Third Party Patent Proceeding”). At the request of the Party bringing a Third Party Patent Proceeding that is relevant to a Compound or Product, the other Party shall provide reasonable
assistance in connection therewith, including by executing reasonably appropriate documents, cooperating in discovery and joining as a party to the action if required. The Party bringing any such action shall confer with the other Party with respect
to the strategy of such action and shall keep the other Party reasonably informed of the status of such action. In addition, the Party bringing such action shall give the other Party the opportunity to comment on all material court filings in
connection with such action, and shall consider such other Party’s comments in good faith. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 58 

 9.5        Trademarks. HGS shall have the
right to brand the Products using HGS related trademarks and any other trademarks and trade names it determines appropriate for the Products, which may vary by country or within a country (“Product Marks”). HGS shall own all rights
in the Product Marks in the Licensed Territory and shall register and maintain the Product Marks in the countries and regions in the Licensed Territory that it determines reasonably necessary, at HGS’ cost and expense. 

9.6        Patent Extensions 

(a)        The Parties shall cooperate in obtaining patent term restoration (under but
not limited to Drug Price Competition and Patent Term Restoration Act), supplemental protection certificates or their equivalents, and patent term extensions with respect to the FivePrime Patents, Joint Patents, and/or HGS Patents in any country
and/or region where applicable. 
 (b)        The JDC shall determine which
FivePrime Patent(s), Joint Patent(s), or HGS Patent(s) it will apply to extend in the Licensed Territory, and HGS shall file for such extension at HGS’ cost and expense. At HGS’ reasonable request, FivePrime shall provide all reasonable
assistance to HGS in connection with such filing. 
 9.7        Sublicensed Patent
Rights. HGS agrees that, to the extent any FivePrime Patents are also Sublicensed Patent Rights, HGS’ rights to file, prosecute, maintain and enforce such sublicensed Patent Rights under this Article 9 shall be secondary to the rights
retained by The Regents or ICOS, as applicable, and HGS’ rights and obligations under this Article 9 shall be subject to the terms and conditions of the UCSF Agreement or the ICOS Agreement, as applicable. 

ARTICLE 10 

CONFIDENTIALITY; PUBLICATION 
 10.1      Duty of Confidence. Subject to the other provisions of this Article 10: 
 (a)        all Confidential Information disclosed by a Party or its Affiliates under this Agreement will be maintained in confidence and otherwise
safeguarded by the recipient Party and its Affiliates, in the same manner and with the same protection as such recipient Party maintains its own confidential information; 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 59 

 (b)        the recipient Party may only use
any such Confidential Information for the purposes of performing its obligations or exercising its rights under this Agreement; and 
 (c)        the recipient Party may disclose Confidential Information of the other Party to: (i) its Affiliates and sublicensees; and
(ii) employees, directors, agents, contractors, consultants and advisers of the Party and its Affiliates and sublicensees, in each case to the extent reasonably necessary for the purposes of, and for those matters undertaken pursuant to, this
Agreement; provided that such Persons are bound to maintain the confidentiality of the Confidential Information in a manner consistent with the confidentiality provisions of this Agreement. 

10.2      Exceptions. The foregoing obligations as to particular Confidential Information of a
Disclosing Party shall not apply to the extent that the Receiving Party can demonstrate that such Confidential Information: 

(a)        is known by the Receiving Party at the time of its receipt, and not through a
prior disclosure by the Disclosing Party, as documented by the Receiving Party’s business records; 

(b)        is in the public domain before its receipt from the Disclosing Party, or
thereafter enters the public domain through no fault of the Receiving Party; 

(c)        is subsequently disclosed to the Receiving Party by a Third Party who may
lawfully do so and is not under an obligation of confidentiality to the Disclosing Party; or 

(d)        is developed by the Receiving Party independently and without use of or
reference to any Confidential Information received from the Disclosing Party, as documented by the Receiving Party’s business records. 
 Any combination of features or disclosures shall not be deemed to fall within the foregoing exclusions merely because individual features are published or available to the general public or in the
rightful possession of the Receiving Party unless the combination itself and principle of operation are published or available to the general public or in the rightful possession of the Receiving Party. 

10.3      Authorized Disclosures. Notwithstanding the obligations set forth in Sections 10.1
and 10.5, a Party may disclose the other Party’s Confidential Information (including this Agreement and the terms herein) to the extent: 
 (a)        such disclosure: (i) is reasonably necessary for the filing or prosecuting Patent Rights as contemplated by this Agreement; (ii) is
reasonably necessary in connection with Regulatory Filings for Products; (iii) is reasonably necessary for the prosecuting or defending 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 60 

 
litigation as contemplated by this Agreement; or (iv) is made to any Third Party bound by written obligation of confidentiality and non-use similar to those set forth under this Article 10,
to the extent otherwise necessary or appropriate in connection with the exercise of its rights or the performance of its obligations hereunder; 
 (b)        such disclosure is reasonably necessary: (i) to such Party’s directors, attorneys, independent accountants or financial advisors for the
sole purpose of enabling such directors, attorneys, independent accountants or financial advisors to provide advice to the receiving Party, provided that in each such case on the condition that such directors, attorneys, independent
accountants and financial advisors are bound by confidentiality and non-use obligations substantially consistent with those contained in this Agreement; provided, however, that the term of confidentiality for such directors, attorneys,
independent accountants and financial advisors shall be no less than five (5) years; or (ii) to actual or potential investors and/or acquirors solely for the purpose of evaluating an actual or potential investment or acquisition;
provided that in each such case on the condition that such actual or potential investors and/or acquirers are bound by confidentiality and non-use obligations substantially consistent with those contained in the Agreement; provided,
however, that the term of confidentiality for such directors, attorneys, independent accountants and financial advisors shall be no less than five (5) years; 
 (c)        such disclosure is required by judicial or administrative process, provided that in such event such Party shall promptly inform the other
Party of such required disclosure and provide the other Party an opportunity to challenge or limit the disclosure obligations. Confidential Information that is disclosed by judicial or administrative process shall remain otherwise subject to the
confidentiality and non-use provisions of this Article 10, and the Party disclosing Confidential Information pursuant to law or court order shall take all steps reasonably necessary, including seeking of confidential treatment or a protective order
to ensure the continued confidential treatment of such Confidential Information; 

(d)        such disclosure is deemed necessary by FivePrime to be disclosed to The
Regents and/or ICOS to fulfill its obligations under the UCSF Agreement or the ICOS Agreement, respectively, including disclosing the terms of this Agreement to or sharing this Agreement with The Regents and/or ICOS, provided FivePrime shall
first notify HGS (and disclose the reasons for disclosure) in the event it is necessary to share this Agreement with The Regents and/or ICOS; 
 (e)        such disclosure is deemed necessary by HGS to be disclosed to Affiliates, agents, consultants or other Third Parties for any and all purposes HGS
or its Affiliates deem necessary or advisable in the ordinary course of business in furtherance of the Development, Manufacture and/or Commercialization of Compounds and Products and in accordance with this Agreement, on the condition that such
Third Parties agree to be bound by confidentiality and 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 61 

 
non-use obligations that are substantially consistent with the confidentiality and non-use provisions contained in this Agreement; provided, however, that the term of
confidentiality for such Third Parties shall be no less than five (5) years; or 

(f)        such disclosure is deemed necessary by FivePrime to be disclosed to
Affiliates, agents, consultants or other Third Parties for any and all purposes FivePrime or its Affiliates deems necessary or advisable in the conduct of any of the FivePrime-Conducted Trials, Other FivePrime-Conducted Activities or any FivePrime
Development Activities, including disclosing the terms of this Agreement to, and/or share this Agreement with, potential or actual licensee(s) of FivePrime in the Retained Territory, on the condition that such actual or potential licensee(s) agree
to be bound by confidentiality and non-use obligations that are substantially consistent with the confidentiality and non-use provisions contained in this Agreement; provided, however, that the term of confidentiality for such Third
Parties shall be no less than five (5) years. 
 10.4      Scientific Publication.
Publication strategy shall be managed by the JDC, which shall have the right to review and approve any scientific publication, considering HGS’ and FivePrime’s interest in publishing the results of its research in order to obtain
recognition within the scientific community and to advance the state of scientific knowledge, the need to protect Confidential Information and the Parties’ mutual interest in obtaining valid patent protection, protecting reasonable business
interests and trade secret information, and having an integrated approach to developing one or more Products for one or more Indications. Consequently, except for disclosures permitted pursuant to Sections 10.2 and 10.3, either Party or its
Affiliates, or its or their employee(s) or consultant(s) shall deliver to the JDC for review and comment a copy of any proposed publication or presentation that pertains to any Compound or Product, pursuant to a procedure to be established by the
JDC. The JDC shall have the right to require modifications of the publication or presentation: (a) to protect each Parties’ respective Confidential Information; (b) for trade secret reasons or business reasons; and/or (c) to
delay such submission as may be reasonably necessary to seek patent protection for the information disclosed in such proposed submission. 
 10.5      Publicity; Use of Names. HGS and FivePrime have agreed on language of a joint press release announcing this Agreement, which is attached hereto as
Exhibit E, to be issued by the Parties promptly after the mutual execution of the Agreement. Subject to Section 10.3, no other disclosure of the existence or the terms of this Agreement may be made by either Party or its Affiliates
except as provided in this Section 10.5, and no Party shall use the name, trademark, trade name or logo of the other Party, its Affiliates or their respective employees in any publicity, promotion, news release or disclosure relating to this
Agreement or its subject matter, except as provided in this Section 10.5 or with the prior express written permission of the other Party, except as may be required by applicable Law. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 62 

 (a)        A Party may disclose this
Agreement and its terms, and material developments or material information generated under this Agreement, in securities filings with the Securities Exchange Commission (or equivalent foreign agency) to the extent required by applicable Law after
complying with the procedure set forth in this Section 10.5(a). In such event, the Party seeking such disclosure will prepare a draft confidential treatment request and proposed redacted version of this Agreement to request confidential
treatment for this Agreement, and the other Party agrees to promptly (and in any event, no less than *** days after receipt of such confidential treatment request and proposed redactions) give its input in a reasonable manner in order to
allow the Party seeking disclosure to file its request within the time lines proscribed by applicable Law. The Party seeking such disclosure shall exercise Commercially Reasonable Efforts to obtain confidential treatment of the Agreement from the
Securities Exchange Commission (or equivalent foreign agency) as represented by the redacted version reviewed by the other Party. 
 (b)        Further, each Party acknowledges that the other Party may be legally required to make public disclosures (including in filings with the Government
Authorities) of certain material developments or material information generated under this Agreement and agrees that each Party may make such disclosures as required by law, provided that the Party seeking such disclosure first provides the
other Party a copy of the proposed disclosure, and provided further that (except to the extent that the Party seeking disclosure is required to disclose such information to comply with applicable Law) if the other Party demonstrates to the
reasonable satisfaction of the Party seeking disclosure, within *** days of such Party’s providing the copy, that the public disclosure of previously undisclosed information will materially adversely affect the development and/or
commercialization of a Compound or Product being Developed or Commercialized under this Agreement, the Party seeking disclosure will remove from the disclosure such specific previously undisclosed information as the other Party shall reasonably
request to be removed. 
 (c)        Other than the press release set forth in
Exhibit E, the Parties agree that any other news release or other public announcement relating to this Agreement or the performance hereunder that would disclose information other than that already in the public domain, shall first be
reviewed and approved by both Parties (with such approval not to be unreasonably withheld or delayed); provided, however, that notwithstanding the foregoing, FivePrime shall have the right to disclose publicly (including on its
website): (i) the fact that it has entered into this Agreement; (ii) the commencement, completion and key results of the FP-1039 Phase 1 Trial and/or any FP-1039 Endometrial Trial (FP-1039-002); (iii) the receipt of any milestone
payments under this Agreement; (iv) Regulatory Approval of any Product; (v) the first Commercial Sale of any Product; and (vi) royalties received from HGS (without disclosing the royalty rate or Net Sales reported by HGS). For each
such disclosure, unless FivePrime otherwise has the right to make such disclosure under this Article 10, FivePrime shall provide HGS with a draft of such disclosure at least *** business days prior to its intended release for

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 63 

 
HGS’ review and comment, and shall consider HGS’ comments in good faith. If FivePrime does not receive comments from HGS within *** business days, FivePrime shall have the right
to make such disclosure without further delay. In addition, FivePrime shall have the right to, without HGS’ prior written approval, list FP-1039 and any other Compound or Product on its website and in presentations of its product pipeline,
identifying such Compounds and Products with FivePrime’s and HGS’ logos and name to indicate that such Compounds and Products are covered by this Agreement. 
 (d)        The Parties agree that after (i) a disclosure pursuant to Section 10.5(b); or (ii) the issuance of a press release (including the
initial press release) or making of any other public announcement pursuant to Section 10.5(c) either Party may make subsequent public disclosures reiterating information in such disclosure, press release or other announcement without having to
obtain the other Party’s prior consent and approval. 
 (e)        Each
Party agrees that the other Party shall have the right to use such first Party’s name and logo in presentations, the company’s website, collateral materials and corporate overviews to describe the collaboration relationship, as well as in
taglines of press releases issued pursuant to this Section 10.5. 
 ARTICLE 11 

TERM AND TERMINATION 
 11.1      Term. The term of this Agreement will commence upon the Effective Date and continue in full force and effect, on a Product-by-Product basis, until the
expiration of the royalty obligations of HGS with respect to the applicable Product, unless earlier terminated as set forth in Section 11.2 below (the “Term”). 

11.2      Termination. 
 (a)        Termination by HGS for Convenience. At any time, HGS may terminate this Agreement by providing written notice of termination to FivePrime, which
notice includes an effective date of termination at least *** days after the date of the notice. 

(b)        Termination for Material Breach. If either Party believes that the other is in
breach of its material obligations hereunder, then the non-breaching Party may deliver notice of such breach to the other Party. For all breaches other than a failure to make a payment as set forth in this Agreement, the allegedly breaching Party
shall have *** days from such notice to dispute or cure such breach, except that in the event the breach is a result of HGS’ breach of its obligations under the first sentence of Section 4.2(b), HGS shall have *** days from
such notice to dispute such breach or *** days from such notice to cure such breach. For any 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 64 

 
breach arising from a failure to make a payment set forth in this Agreement, the allegedly breaching Party shall have *** days from the receipt of the notice to dispute or cure such
breach. If the Party receiving notice of breach fails to cure, or fails to dispute, that breach within the applicable period set forth above, then the Party originally delivering the notice of breach may terminate this Agreement effective on written
notice of termination to the other Party. If the allegedly breaching Party in good faith disputes such material breach or disputes the failure to cure or remedy such material breach and provides written notice of that dispute to the other Party
within the applicable period set forth above, the matter will be addressed under the dispute resolution provisions in Section 14.6, and the notifying Party may not terminate this Agreement until it has been determined under Section 14.6
that the allegedly breaching Party is in material breach of this Agreement, and such breaching Party further fails to cure such breach within *** days after the conclusion of that dispute resolution procedure (and such termination shall then
be effective upon written notification from the notifying Party to the breaching Party). Notwithstanding this Section 11.2(b), in the event of FivePrime’s uncured material breach of any of its obligations under Section 7.2 or the
Co-Promotion Agreement, HGS shall have the right to terminate FivePrime’s rights under Section 7.2 and the Co-Promotion Agreement, and this Agreement shall otherwise continue in full force and effect as if FivePrime had not initiated any
Co-Promotion Term for any Product under Section 7.2 and the time period during which FivePrime had the right to initiate such Co-Promotion Term has expired. 
 (c)        Termination for Patent Challenge. Except to the extent the following is unenforceable under the laws of a particular jurisdiction,
either Party may terminate this Agreement if the other Party or its Affiliates or sublicensees, individually or in association with any other person or entity, commences a legal action challenging the validity, enforceability or scope of any
FivePrime Patents, Joint Patents, or HGS Patents. 
 (d)        Termination for
Bankruptcy. This Agreement may be terminated at any time during the Term by either Party upon the other Party’s filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a
substantial portion of the assets for the benefit of creditors by the other Party; provided, however, that in the case of any involuntary bankruptcy proceeding such right to terminate shall only become effective if the Party consents
to the involuntary bankruptcy or such proceeding is not dismissed within *** days after the filing thereof. 

11.3      Effect of Termination. 

(a)        Termination by HGS for Convenience; Termination by FivePrime for Breach or Patent
Challenge. Upon termination of this Agreement by HGS pursuant to Section 11.2(a) or by FivePrime pursuant to Section 11.2(b) or (c), the following consequences shall apply to the termination and shall be effective as of the effective
date of such termination: 
  (i)        each Party shall pay all amounts
then due and owing to the other Party as of the termination date; 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 65 

  (ii)        all licenses and other
rights granted to HGS under the FivePrime Technology will terminate; 

 (iii)        no later than *** days after the effective date of such
termination, each Party shall return or cause to be returned to the other Party all Confidential Information in tangible form that is received from the other Party and all copies thereof and all materials substances or compositions delivered or
provided by the other Party; provided, however, that (A) FivePrime may retain any such Confidential Information or materials as reasonably necessary for FivePrime’s continued practice under any license under this Agreement
that remains effective after such termination (including licenses that become effective pursuant to this Section 11.3), and (B) each Party may keep one copy of Confidential Information received from the other Party in its confidential
files for record purposes; 
  (iv)        HGS will transfer and assign to
FivePrime all Regulatory Filings and Regulatory Approvals, and any HGS Know-How contained in such Regulatory Filings and Regulatory Approvals shall be subject to the license grants set forth in Section 11.3(a)(vi). HGS shall use Commercially
Reasonable efforts to cause its Contract Manufacturers to provide FivePrime a right of reference to any DMF for the Products and Compounds contained therein; 
  (v)        HGS shall, at FivePrime’s request, provide reasonable technical assistance and transfer all HGS Know-How relating to the Products and
Compounds to FivePrime or its designee; 
  (vi)        HGS hereby grants
FivePrime an exclusive license, with the right to grant sublicenses, under HGS Technology to develop, make, have made, use, sell, offer for sale, import all Compounds and Products in the form that is being used, developed or commercialized by HGS,
its Affiliates or sublicensees as of the date of such termination (a “Terminated Product”). For clarity, all Patents and Know-How actually practiced by HGS or its Affiliates in the Manufacture, use, Development and/or
Commercialization of Compounds or Products as of the effective date of such termination shall be deemed HGS Technology for the purpose of this Section 11.3(a)(vi). Such license shall be royalty bearing for any Terminated Product sold by
FivePrime, its Affiliates, licensees or sublicensees in accordance with Section 11.3(a)(vii). 

 (vii)        FivePrime shall pay HGS royalties on Net Sales (as such definition is
applies to FivePrime, its Affiliates, licensees and sublicensees, mutatis mutandis) of the Terminated Product in the Licensed Territory, for a period of *** years after the First Commercial Sale of such Terminated Product, at the
following rates (subject to application of 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 66 

 
Sections 8.3(c), 8.4(b), 8.5, 8.6 and 8.8, mutatis mutandis), provided that FivePrime shall not be required to make any payment to HGS under this Section 11.3(a)(vii) in the
event FivePrime terminates this Agreement: (A) pursuant to Section 11.2(b) for HGS’ uncured material breach of its diligence obligations under the second sentence of Section 4.2(b); (B) pursuant to Section 11.2(b) for
HGS’ uncured material breach of its diligence obligations under the first sentence of Section 4.2(b), only if such material breach occurs prior to HGS’ Commencement of a Phase 3 Clinical Trial for the Product for any Indication other
than Mutant Endometrial Cancer; (C) pursuant to Section 11.2(b) for HGS’ uncured material breach of its obligations under Section 7.4 and HGS has not expended best efforts to implement a cure of such material breach (for
clarity, in the event such material breach is not cured after HGS has expended best efforts, FivePrime shall not have the right to terminate pursuant to Section 11.2(b)); or (D) pursuant to Section 11.2(c) for HGS’ challenge of
FivePrime Patents licensed to HGS hereunder: 
  

			
	Stage of Most Advanced Development or Commercialization for a Particular Product at the Time such Product Becomes a Terminated
Product	  	Royalty Rate for such    
Terminated
Product
	 After
FivePrime’s receipt of the upfront payment under Section 8.1, but prior to the Completion of the first Phase 2 Clinical Trial in the Licensed Territory for any Indication other than Mutant Endometrial Cancer

 
	  	***%    
	 After the
Completion of the first Phase 2 Clinical Trial in the Licensed Territory for an Indication other than Mutant Endometrial Cancer, but prior to the Filing of a BLA in the Licensed Territory for any Indication other than Mutant Endometrial
Cancer
  
	  	***%    
	 After the
Filing of a BLA in the Licensed Territory for the first Indication other than Mutant Endometrial Cancer, but prior to the first Regulatory Approval in the Licensed Territory for the first Indication other than Mutant Endometrial Cancer

 
	  	***%    
	 After the first
Regulatory Approval in the Licensed Territory for the first Indication other than Mutant Endometrial Cancer
  
	  	***%    

  (viii)        if HGS is Manufacturing any Product
(or the Compound contained therein) for commercial sale, HGS shall, at FivePrime’s election, supply FivePrime with HGS’ existing inventory of such Compound and/or Product that is compliant with applicable laws and specifications (unless
such inventory is in HGS’ trade dress, in which case this subsection shall not apply) at no cost to FivePrime, ordered pursuant to a single purchase order placed by FivePrime within *** days after the notice of such termination;

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 67 

  (ix)        HGS shall, at
FivePrime’s request and election, use Commercially Reasonably Efforts to facilitate negotiations between FivePrime and HGS’ Third Party providers of clinical research, Manufacturing and/or distribution services for all Products and to
assign key contracts for the Products to FivePrime; 
  (x)        in the
event one or more clinical trials are ongoing or are scheduled to Commence within *** months after the effective date of such termination, HGS shall, at FivePrime’s request, supply to FivePrime Compounds and Products associated with such
clinical trials in amounts not to exceed *** documented requirements for such Compound and Product sufficient for FivePrime’s use until the end of a *** period after the effective date of such termination, at HGS’
Manufacturing Cost, ordered pursuant to a single purchase order placed by FivePrime within *** days after the notice of such termination; and 
  (xi)        if HGS, its Affiliates or sublicensees is conducting one (1) or more human clinical trials for the Product at the time of such
termination, then, at FivePrime’s election on a trial-by-trial basis: (A) HGS shall fully cooperate with FivePrime to transfer the conduct of all such human clinical trials to FivePrime and FivePrime shall assume any and all liability for
such human clinical trials as of the effective date of such termination, provided that HGS shall continue to bear all costs and expenses incurred in connection with the conduct of such clinical trials until the earlier of the completion of
such trial or *** days after the effective date of such termination; or (B) HGS shall, at its expense, orderly wind down the conduct of any such human clinical trial which is not assumed by FivePrime under clause (A). In each case HGS
shall reimburse FivePrime for any non-cancellable and non-refundable out-of-pocket costs FivePrime may incur in connection with the conduct or wind down of all such clinical trials as of the effective date of such termination. 

(b)        Termination by HGS for Breach or Patent Challenge. Upon termination of this
Agreement by HGS pursuant to Section 11.2(b) or 11.2(c), the following consequences shall apply to the termination and shall be effective as of the effective date of such termination: 

 (i)        each Party shall pay all amounts then due and owing to the other Party
as of the termination date; 
  (ii)        all licenses and other rights
granted to FivePrime under the HGS Technology will become non-exclusive; 

 (iii)        the licenses and other rights granted by FivePrime to HGS under the
FivePrime Technology will remain in full force and effect as set forth in Sections 2.1 and 2.2; provided, however, that (A) such licenses shall remain in effect only if HGS has satisfied in full, and continues to satisfy in full,
its payment obligations under Article 8 in accordance with the 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 68 

 
terms of Article 8; and (B) HGS shall have the right to offset against its financial obligations all costs and losses as finally awarded to HGS and all expenses incurred by HGS as a result
of FivePrime’s breach of this Agreement. 
  (iv)        no later than
*** days after the effective date of such termination, each Party shall return or cause to be returned to the other Party all Confidential Information in tangible form received from the other Party and all copies thereof and all materials,
substances or compositions delivered or provided by the other Party; provided, however, that (A) each Party may retain any such Confidential Information or materials as reasonably necessary for its continued practice under any
license under this Agreement that does not terminate upon such termination pursuant to this Section 11.3, and (B) each Party may keep one copy of Confidential Information received from the other Party in its confidential files for record
purposes; and 
  (v)        except as set forth in this
Section 11.3(b) and for the surviving provisions set forth in Section 11.4, the rights and obligations of the Parties hereunder shall terminate, including any rights FivePrime may have with regard to co-promotion pursuant to
Section 7.2. 
 (c)        Termination for Bankruptcy. If this Agreement is
terminated by HGS pursuant to Section 11.2(d) due to the rejection of this Agreement by or on behalf of FivePrime under Section 365(n) of the United States Bankruptcy Code (the “Code”), all licenses granted under or
pursuant to this Agreement are, and will otherwise be deemed to be, for purposes of Section 365(n) of the Code and any similar laws in any other country in the Licensed Territory, licenses of rights to “intellectual property” as
defined under Section 91 of the Code. The Parties agree that HGS, as licensee of such rights under this Agreement, will retain and may fully exercise all of its protections, rights and elections under the Code and any similar laws in any other
country in the Licensed Territory. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against FivePrime under the Code and any similar laws in any other country in the Licensed Territory, HGS will be
entitled to a complete duplicate of (or complete access to, as HGS deems appropriate) any such intellectual property and all embodiments of such intellectual property, and the same, if not already in its possession, will be promptly delivered to it:
(a) upon any such commencement of a bankruptcy proceeding upon its written request therefor, unless FivePrime elects to continue to perform all of its obligations under this Agreement, or (b) if not delivered under (a) above, upon
written request therefor by HGS following the rejection of this Agreement by or on behalf of FivePrime. The foregoing provisions of this Section 11.3(d) are without prejudice to any rights HGS may have arising under the Code or other applicable
law. 
 11.4      Survival. Expiration or termination of this Agreement shall not relieve
the Parties of any obligation accruing prior to such expiration or termination. Without limiting the foregoing, the provisions of Articles 1, 10 and 14, and Sections 2.3, 2.4, 2.5(c) (the last sentence

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 69 

 
only), 5.1(c) (the last two sentences only), 5.2, 5.5, 7.4 (such sections in Article 5 and Article 7 shall survive solely in the event HGS maintains the license granted to it under
Section 2.1 after termination of this Agreement or after the expiration of this Agreement on its terms), 9.1, 9.5, 10.1, 10.2, 10.3, 10.5, 11.3, 11.4, 11.5, 13.1, 13.2, 13.3, 13.4 (Sections 13.1, 13.2, 13.3 and 13.4 shall survive solely with
respect to Claims arising from actions and/or omissions prior to the effective date of such termination or expiration) and 13.5 shall survive the expiration or termination of this Agreement. 

11.5      Termination Not Sole Remedy. Termination is not the sole remedy under this Agreement and,
whether or not termination is effected and notwithstanding anything contained in this Agreement to the contrary, all other remedies will remain available except as agreed to otherwise herein. 

ARTICLE 12 

REPRESENTATIONS AND WARRANTIES 
 12.1      Representations and Warranties of Each Party. Each Party represents and warrants to the other Party as of the Effective Date that: 

(a)        it has the full right, power and authority to enter into this Agreement, to
perform its obligations hereunder; and 
 (b)        this Agreement has been
duly executed by it and is legally binding upon it, enforceable in accordance with its terms, and does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any
material law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it. 

12.2      Representations and Warranties by FivePrime. FivePrime represents and warrants to HGS as
of the Effective Date that: 
 (a)        it has not previously assigned,
transferred, conveyed or otherwise encumbered its right, title and interest in FivePrime Patents or FivePrime Know-How in a manner that is inconsistent with the exclusive license granted to HGS under Section 2.1; 

(b)        it has the right to grant the license and rights herein to HGS and it has not
granted any license, right or interest in, to or under the FivePrime Patent Rights or FivePrime Know-How to any Third Party that is inconsistent with the exclusive license granted to HGS under Section 2.1; 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 70 

 (c)        to its Knowledge, the
development, use, sale and import of FP-1039 in the Licensed Territory in the manner that is and has been conducted by FivePrime, its Affiliates and its Contract Manufacturers do not infringe any valid intellectual property rights owned or possessed
by any Third Party and do not breach any obligation of confidentiality or non-use owed by FivePrime to a Third Party; 

(d)        there are no claims, judgments or settlements against or owed by FivePrime and
to its Knowledge, there are no pending or threatened claims or litigation; in each case relating to FP-1039 or to the FivePrime Patents or FivePrime Know-How in the Licensed Territory; and 

(e)        to its Knowledge, it has provided to HGS all material research results,
pre-clinical and clinical data and any and all documentation in its possession related to the Compound. 

12.3      No Other Warranties. EXCEPT AS EXPRESSLY STATED IN THIS ARTICLE 12, (A) NO
REPRESENTATION, CONDITION OR WARRANTY WHATSOEVER IS MADE OR GIVEN BY OR ON BEHALF OF HGS OR FIVEPRIME; AND (B) ALL OTHER CONDITIONS AND WARRANTIES WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE ARE HEREBY EXPRESSLY EXCLUDED, INCLUDING ANY
CONDITIONS AND WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT. 
 ARTICLE 13

 INDEMNIFICATION; LIABILITY 
 13.1      Indemnification by FivePrime. FivePrime shall indemnify and hold HGS, its Related Parties and their respective officers, directors, agents and employees
(“HGS Indemnitees”) harmless from and against any Claims against them to the extent arising or resulting from: 
 (a)        The Development, Manufacture or Commercialization of Products by or on behalf of FivePrime or any of its Affiliates, sublicensees or
subcontractors, including any FivePrime Development Activities; or 

(b)        any Development, Manufacture or Commercialization of the Compounds and/or
Products by FivePrime or any of its Affiliates, licensees, sublicensees or subcontractors after the termination of this Agreement pursuant to the rights reverted to FivePrime under Section 11.3(a); or 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 71 

 (c)        the conduct of the
FivePrime-Conducted Trials and/or Other FivePrime Activities by FivePrime or any of its Affiliates, licensees or subcontractors outside of the scope of such activities as set forth in the Development Plan or in contravention to any instructions of
HGS or the Development Plan; or 
 (d)        clinical trials conducted by
FivePrime prior to the Effective Date of this Agreement; or 
 (e)        the
negligence or willful misconduct of any of the FivePrime Indemnitees; or 

(f)        the breach of any of the warranties or representations made by FivePrime to
HGS under this Agreement; or 
 (g)        any breach by FivePrime of its
material obligations pursuant to this Agreement; 
 except in each case, to the extent such Claims result from the material
breach by any HGS Indemnitee of any covenant, representation, warranty or other agreement made by HGS in this Agreement or the negligence or willful misconduct of any HGS Indemnitee. 

13.2      Indemnification by HGS. HGS shall indemnify and hold FivePrime, its Affiliates, The
Regents, ICOS, and their respective trustees, officers, directors, agents and employees (“FivePrime Indemnitees”) harmless from and against any Claims arising under or related to this Agreement against them to the extent arising or
resulting from: 
 (a)        the Development, Manufacture or Commercialization
of the Products by or on behalf of HGS or any of its Affiliates, sublicensees or subcontractors, including any HGS Development Activities; or 
 (b)        the negligence or willful misconduct of any of the HGS Indemnitees; or 
 (c)        the breach of any of the warranties or representations made by HGS to FivePrime under this Agreement; or 

(d)        any breach by HGS of its material obligations pursuant to this Agreement;

 except in each case, to the extent such Claims result from the material breach by any FivePrime Indemnitee of any covenant,
representation, warranty or other agreement made by FivePrime in this Agreement or the negligence or willful misconduct of any FivePrime Indemnitee. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 72 

 13.3      Indemnification Procedure. If either Party is
seeking indemnification under Section 13.1 or 13.2 (the “Indemnified Party”), it shall inform the other Party (the “Indemnifying Party”) of the claim giving rise to the obligation to indemnify pursuant to such
section as soon as reasonably practicable after receiving notice of the claim. The Indemnifying Party shall have the right to assume the defense of any such claim for which it is obligated to indemnify the Indemnified Party. The Indemnified Party
shall cooperate with the Indemnifying Party and the Indemnifying Party’s insurer as the Indemnifying Party may reasonably request, and at the Indemnifying Party’s cost and expense. The Indemnified Party shall have the right to participate,
at its own expense and with counsel of its choice, in the defense of any claim or suit that has been assumed by the Indemnifying Party. Neither Party shall have the obligation to indemnify the other Party in connection with any settlement made
without the Indemnifying Party’s written consent, which consent shall not be unreasonably withheld or delayed. If the Parties cannot agree as to the application of Section 13.1 or 13.2 as to any claim, pending resolution of the dispute
pursuant to Section 14.6, the Parties may conduct separate defenses of such claims, with each Party retaining the right to claim indemnification from the other Party in accordance with Section 13.1 or 13.2 upon resolution of the underlying
claim. 
 13.4      Mitigation of Loss. Each Indemnified Party will take and will procure
that its Affiliates take all such reasonable steps and action as are reasonably necessary or as the Indemnifying Party may reasonably require in order to mitigate any Claims (or potential losses or damages) under this Article 13. Nothing in this
Agreement shall or shall be deemed to relieve any Party of any common law or other duty to mitigate any losses incurred by it. 

13.5      Special, Indirect and Other Losses. NEITHER PARTY NOR ANY OF ITS AFFILIATES SHALL BE
LIABLE IN CONTRACT, TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY OR OTHERWISE FOR ANY CONSEQUENTIAL, SPECIAL OR PUNITIVE DAMAGES OR FOR LOSS OF PROFITS SUFFERED BY THE OTHER PARTY, EXCEPT TO THE EXTENT ANY SUCH DAMAGES ARE REQUIRED TO BE PAID TO A
THIRD PARTY AS PART OF A CLAIM FOR WHICH A PARTY PROVIDES INDEMNIFICATION UNDER THIS ARTICLE 13. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 73 

 ARTICLE 14 
 GENERAL PROVISIONS 
 14.1      Force
Majeure. Neither Party shall be held liable to the other Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in performing any obligation under this Agreement to the extent such failure or delay is caused
by or results from causes beyond the reasonable control of the affected Party, potentially including embargoes, war, acts of war (whether war be declared or not), acts of terrorism, insurrections, riots, civil commotions, strikes, lockouts or other
labor disturbances, fire, floods, earthquakes or other acts of God, or acts, omissions or delays in acting by any governmental authority or the other Party or unavailability of materials related to the Manufacture of Compounds or Products. The
affected Party shall notify the other Party in writing of such force majeure circumstances as soon as reasonably practical, and shall promptly undertake and continue diligently all reasonable efforts necessary to cure such force majeure
circumstances or to perform its obligations in spite of the ongoing circumstances. 

14.2      Assignment. This Agreement may not be assigned or otherwise transferred, nor may any right
or obligation hereunder be assigned or transferred, by either Party without the prior written consent of the other Party. Notwithstanding the foregoing, either Party may, without consent of the other Party, assign this Agreement and its rights and
obligations hereunder in whole or in part to an Affiliate of such Party, or in whole to its successor in interest in connection with the sale of all or substantially all of its stock or its assets to which this Agreement relates, or in connection
with a merger, acquisition or similar transaction. Any attempted assignment not in accordance with this Section 14.2 shall be null and void and of no legal effect. Any permitted assignee shall assume all assigned obligations of its assignor
under this Agreement. The terms and conditions of this Agreement shall be binding upon, and shall inure to the benefit of, the Parties and their respected successors and permitted assigns. The Patent Rights and Know-How owned or in-licensed by a
permitted assignee in connection with the sale of all or substantially all of a Party’s stock or assets, or an entity who becomes an Affiliate of a Party by reason of such transaction, in each case as existing on the date of closing of such
transaction, shall be automatically excluded from the rights licensed to the other Party under this Agreement. 

14.3      Severability. If any one or more of the provisions contained in this Agreement is held
invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s)
adversely affects the substantive rights of the Parties. The Parties shall in such an instance use their best efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as
practical, implement the purposes of this Agreement. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 74 

 14.4      Notices. All notices which are required or
permitted hereunder shall be in writing and sufficient if delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally-recognized overnight courier or
sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows: 
 If to FivePrime:

 Five Prime Therapeutics, Inc. 

Two Corporate Drive 
 South San Francisco, CA 94080 
 Attention: Legal Department

 Facsimile: (415) 365-5601 
 with a copy to: 
 Cooley LLP 

3017 Hanover Street 
 Palo Alto, CA 94304 
 Attention: Robert L. Jones, Esq. 

Facsimile: (650) 849-7400 
 If to HGS: 
 Human Genome Sciences, Inc. 

14200 Shady Grove Road 
 Rockville, MD 20850 USA 
 Attention: General Counsel 

Facsimile: (301) 517-8831 
 With a Copy to: Chief Commercial Officer 
 or to such other address(es) as the Party to whom
notice is to be given may have furnished to the other Party in writing in accordance herewith. Any such notice shall be deemed to have been given: (a) when delivered if personally delivered or sent by facsimile on a business day (or if
delivered or sent on a non-business day, then on the next business day); (b) on the business day after dispatch if sent by nationally-recognized overnight courier; or (c) on the *** business day following the date of mailing, if
sent by mail. 
 14.5      Applicable Law. This Agreement shall be governed by and
construed in accordance with the laws of the State of New York and the patent laws of the United States without reference to any rules of conflict of laws. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 75 

 14.6      Dispute Resolution 

(a)        The Parties shall negotiate in good faith and use reasonable efforts to settle
any dispute, controversy or claim arising from or related to this Agreement or the breach thereof. If the Parties do not fully settle, and a Party wishes to pursue the matter, each such dispute, controversy or claim that is not an Excluded Claim
(defined in Section 14.6(f) below) shall be finally resolved by binding arbitration administered by JAMS pursuant to JAMS’ Streamlined Arbitration Rules and Procedures then in effect (the “JAMS Rules”), and judgment on the
arbitration award may be entered in any court having jurisdiction thereof. 

(b)        The arbitration shall be conducted by a panel of three persons experienced in
the pharmaceutical business: within *** days after initiation of arbitration, each Party shall select one person to act as arbitrator and the two Party-selected arbitrators shall select a third arbitrator within *** days of their
appointment. If the arbitrators selected by the Parties are unable or fail to agree upon the third arbitrator, the third arbitrator shall be appointed by JAMS. The place of arbitration shall be San Francisco, California, and all proceedings and
communications shall be in English. 
 (c)        Either Party may apply to the
arbitrators for interim injunctive relief until the arbitration award is rendered or the controversy is otherwise resolved. Either Party also may, without waiving any remedy under this Agreement, seek from any court having jurisdiction any
injunctive or provisional relief necessary to protect the rights or property of that Party pending the arbitration award. The arbitrators shall have no authority to award punitive or any other type of damages not measured by a Party’s
compensatory damages. Each Party shall bear its own costs and expenses and attorneys’ fees and an equal share of the arbitrators’ fees and any administrative fees of arbitration. 

(d)        Except to the extent necessary to confirm an award or as may be required by
law, neither a Party nor an arbitrator may disclose the existence, content, or results of an arbitration without the prior written consent of both Parties. In no event shall an arbitration be initiated after the date when commencement of a legal or
equitable proceeding based on the dispute, controversy or claim would be barred by the applicable New York statute of limitations. 
 (e)        The Parties agree that, in the event of a dispute over the nature or quality of performance under this Agreement, neither Party may terminate this
Agreement until final resolution of the dispute through arbitration or other judicial determination. The Parties further agree that any payments made pursuant to this Agreement pending resolution of the dispute shall be refunded if an arbitrator or
court determines that such payments are not due. 
 (f)        As used in this
Section, the term “Excluded Claim” shall mean a dispute, controversy or claim that concerns (a) the scope, validity, enforceability, inventorship or infringement of a patent, patent application, trademark or copyright; or
(b) any antitrust, anti-monopoly or competition law or regulation, whether or not statutory. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 76 

 14.7      Entire Agreement; Amendments. This Agreement,
together with the Schedules and Exhibits hereto, contains the entire understanding of the Parties with respect to the Collaboration and the licenses granted hereunder. Any other express or implied agreements and understandings, negotiations,
writings and commitments, either oral or written, in respect to the Collaboration and the licenses granted hereunder are superseded by the terms of this Agreement. The Schedules and Exhibits to this Agreement are incorporated herein by reference and
shall be deemed a part of this Agreement. This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by authorized representative(s) of both Parties hereto. The Parties agree that, effective as of the
Effective Date, that certain Mutual Non-Disclosure Agreement between the Parties dated as of March 23, 2010 (“Confidentiality Agreement”) shall be superseded by this Agreement, and that disclosures made prior to the Effective
Date pursuant to the Confidentiality Agreement shall be subject to the confidentiality and non-use provisions of this Agreement. 
 14.8      Headings. The captions to the several Articles, Sections and subsections hereof are not a part of this Agreement, but are merely for convenience to assist in
locating and reading the several Articles and Sections hereof. 
 14.9      Independent
Contractors. It is expressly agreed that FivePrime and HGS shall be independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency. Neither FivePrime nor HGS shall have the
authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior written consent of the other Party. 

14.10      Waiver. The waiver by either Party hereto of any right hereunder, or of any failure of
the other Party to perform, or of any breach by the other Party, shall not be deemed a waiver of any other right hereunder or of any other breach by or failure of such other Party whether of a similar nature or otherwise. 

14.11      Cumulative Remedies. No remedy referred to in this Agreement is intended to be exclusive,
but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law. 
 14.12      Waiver of Rule of Construction. Each Party has had the opportunity to consult with counsel in connection with the review, drafting and negotiation of this
Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 77 

 14.13      Business Day Requirements. In the event that
any notice or other action or omission is required to be taken by a Party under this Agreement on a day that is not a business day then such notice or other action or omission shall be deemed to required to be taken on the next occurring business
day. 
 14.14      Counterparts. This Agreement may be executed in two or more counterparts
by original signature, facsimile or PDF files, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 78 

 IN WITNESS WHEREOF, the Parties intending to be bound have caused this Agreement to be
executed by their duly authorized representatives. 
  

									
	Five Prime Therapeutics, Inc.	 		 	Human Genome Sciences, Inc.
					
	By:	 	/s/ Julia P. Gregory	 		 	By:	 	/s/ H. Thomas Watkins

									
					
	Name:	 	Julia P. Gregory	 		 	Name:	 	H. Thomas Watkins

									
					
	Its:	 	President & CEO	 		 	Its:	 	President and Chief Executive Officer

 SIGNATURE PAGE OF THE
LICENSE AND COLLABORATION AGREEMENT BY AND BETWEEN 
 FIVE PRIME THERAPEUTICS, INC. AND HUMAN GENOME SCIENCES, INC.

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
  
  

 EXHIBIT A 
 FivePrime Patents Existing as of the Effective Date 
 *** 

*** INDICATES THIRTEEN PAGES OF MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED
MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

  
 A-1

 EXHIBIT B 
 UCSF Agreement 
 Incorporated by reference to Exhibit 10.24 to the Registrant’s
Amendment No. 1 to the Registration Statement on Form S-1, File No. 377-00211, filed on July 15, 2013. The Registrant has also requested confidential treatment for certain portions of Exhibit 10.24. Exhibit 10.24 omits the confidential
information subject to this request, and the omitted portions have been filed separately with the SEC. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 B-1 

 EXHIBIT C 
 Initial Development Outline 
 *** 

  
 ***
INDICATES TWO PAGES OF MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT
OF 1933, AS AMENDED. 
 C-1 

 EXHIBIT D 
 Budget of FivePrime-Conducted Trials 
 FP-1039 Endometrial Trial (FP-1039-002) Projected
Budget 
 *** 

FP-1039 Endometrial Trial (FP-1039-002) Projected FivePrime FTEs 
 *** 
 FP-1039 Phase I Study Projected Budget 

*** 
 FP-1039 Phase I
Study Projected FivePrime FTEs 
 *** 
 *** INDICATES FOUR PAGES OF MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

  
 D-1

 EXHIBIT E 
 Press Release 
  
 

 
 HUMAN GENOME SCIENCES AND FIVEPRIME THERAPEUTICS ANNOUNCE 

DEVELOPMENT AND COMMERCIALIZATION AGREEMENT FOR NOVEL ANTI-CANCER DRUG 

	 	•	 	 FP-1039 is a fibroblast growth factor (FGF) ligand trap being studied in early stage clinical trials in a variety of cancers 

	 	•	 	 HGS acquires exclusive rights to develop and commercialize FivePrime’s FP-1039 in the United States, Canada and European Union

	 	•	 	 Five Prime retains minority co-promotion rights in the US and full rights to rest of world territories, including Asia 

ROCKVILLE, Maryland and SOUTH SAN FRANCISCO, California – March 16, 2011. Human Genome Sciences, Inc. (Nasdaq: HGSI) and FivePrime
Therapeutics, Inc. announced today that they have entered into an agreement to develop and commercialize FivePrime’s FP-1039 product for multiple cancers. FP-1039 is a first-in-class biologic discovered by FivePrime that targets multiple
fibroblast growth factor (FGF) ligands. Under the terms of the agreement, HGS has acquired rights to develop and commercialize FP-1039 in the United States, Canada and the EU markets, while FivePrime retains minority co-promotion rights in the U.S.
and full development and commercialization rights in rest of world territories, including Asia. 
 “Today’s announcement underscores
Human Genome Sciences’ commitment to developing novel targeted therapies that address significant unmet medical needs for patients,” said H. Thomas Watkins, President and Chief Executive Officer, HGS. “We are excited to add FP-1039 to
our pipeline and look forward to working with FivePrime to develop and commercialize this innovative biologic product.” 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 E-1 

 Under the terms of the agreement, HGS will pay FivePrime an upfront license fee of $50 million and FivePrime
will be eligible to receive up to $445 million in future development, regulatory and commercial milestone payments. The agreement calls for tiered double-digit percentage royalty payments on net sales. HGS has exclusive rights to develop and
commercialize FP-1039 for all indications in the United States, Canada and the European Union. FivePrime has an option to co-promote FP-1039 and any next-generation products in the United States, and retains full development and commercialization
rights in all other regions of the world outside the US, Canada and the EU, including Asia, Latin America and non-EU nations in Europe, including Russia. At FivePrime’s request, HGS will supply FivePrime with FP-1039 for use in the rest of
world territories. 
 “We are delighted to enter into this collaboration with HGS. It will significantly broaden the clinical plan for
FP-1039, enabling us to address the multiple tumor types in which FP-1039 may have activity,” said Julia P. Gregory, President and Chief Executive Officer of FivePrime. “This strategically important collaboration evidences the rapidly
growing excitement surrounding novel oncology drugs.” 
 “FivePrime’s valuable discovery platforms have enabled us to develop a very
promising therapeutic agent in a signaling pathway that has been historically untapped for drug development. HGS is a great partner for FP-1039 because of their track record of success in developing breakthrough biologics,” stated Lewis T.
Williams, MD PhD, Executive Chairman and Founder of FivePrime. 
 FP-1039 is being evaluated in an ongoing phase 1 clinical study in which it has
been shown to be safe and well tolerated to date. Patients are currently being screened for a phase 2 trial for a form of endometrial cancer. 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 E-2 

 ABOUT FP-1039 
 FP-1039 is a first-in-class ligand trap that binds to and inhibits most members of the FGF (Fibroblast Growth Factor) family. FGF proteins are growth factors that, along with VEGF (Vascular Endothelial
Growth Factor) and EGF (Epidermal Growth Factor), play important roles in the growth and maintenance of many solid tumors. FP-1039 is a soluble fusion protein consisting of the extracellular portion of Fibroblast Growth Factor Receptor 1 (FGFR1)
that is attached to the base of a human antibody. The drug is designed to neutralize the activity of multiple FGF ligands and inhibit their signaling through all FGF receptors. Data indicate that FP-1039 is a very effective inhibitor of the complex
and crucial FGF signaling pathway. Moreover, FP-1039 is expected to exert a dual effect on cancer cells both as a result of direct inhibition of tumor cell growth and through inhibition of tumor-associated angiogenesis — both of which are
FGF-mediated processes. 
 ABOUT HUMAN GENOME SCIENCES 
 Human Genome Sciences exists to place new therapies into the hands of those battling serious disease. For more information about HGS, please visit the Company’s web site at www.hgsi.com. Health
professionals and patients interested in clinical trials of HGS products may inquire via e-mail to medinfo@hgsi.com or by calling HGS at (877) 822-8472. HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc. Other
trademarks referenced are the property of their respective owners. 
 ABOUT FIVEPRIME 

FivePrime Therapeutics, Inc. is a clinical-stage, privately-held, biotechnology company discovering and developing innovative protein and antibody
therapeutics. Using its novel, high-tech discovery platform, FivePrime is building a strong pipeline of oncology, immunology and metabolic disease drug candidates. Its proprietary platform mines FivePrime’s comprehensive library of secreted and
extracellular human proteins

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 E-3 

 
to screen for medically relevant new therapeutic proteins and antibody targets. FivePrime has active collaborations with Pfizer, Inc. in the fields of oncology and diabetes and GlaxoSmithKline
for skeletal muscle disorders. For more information about FivePrime, please visit FivePrime’s web site at www.fiveprime.com. 

HGS’ SAFE HARBOR STATEMENT 
 This
announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on
Human Genome Sciences’ current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially
from these forward-looking statements because of Human Genome Sciences’ unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials and regulatory approvals, Human Genome Sciences’ ability to
develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities, intense competition, the uncertainty of
patent and intellectual property protection, Human Genome Sciences’ dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the
Company’s filings with the SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today’s date. Human Genome Sciences undertakes no obligation to update
or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise. 
  

 

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 E-4 

 ### 

HGS Contacts: 
 Media  

Jerry Parrott 
 Vice President, Corporate
Communications 
 301-315-2777 
 Susannah
Budington 
 Director, Corporate Public Relations 
 301-545-1062 
 Investors  
 Claudine Prowse, Ph.D. 
 Executive Director, Investor Relations 

301-315-1785 
 Peter Vozzo 

Senior Director, Investor Relations 
 301-251-6003

 FivePrime Contacts: 
 Julia P.
Gregory 
 President and CEO 
 415-365-5677

  

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 E-5 

 Debbie Tobin 
 Communications Specialist 
 415-365-5721 
 Debbie.Tobin@fiveprime.com 
  
  

 
  
  

  
 ***
INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED. 
 E-6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}]]